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Chapter 1
General introduction and outline of the thesis

1.1 CIRCULATING TUMOR CELLS
In recent years, many new anti-cancer agents have been developed and introduced into 
clinical care. While these new agents have led to substantial gains in response rates and 
life expectancies, they have also increased the need for tools to select those patients 
benefitting from said therapies. Once patients develop metastatic disease, treatment is aimed 
at improving quality of life and prolonging life expectancy, but is always a trade-off against 
the side-effects that are inevitably associated with anti-tumor therapy, underscoring the need 
to select only those patients who are likely to respond to a particular drug. However, there is 
still an unmet need for such an array of reliable predictive factors, a need that can be met by 
designing studies in which patient subgroups are defined and stratified based on rational, 
biology-driven but feasible tumor characteristics. An increasing number of studies is being 
designed in which, for example, only patients with a specific gain-of-function mutation are 
subjected to a monoclonal antibody therapy aimed at the activated pathway this gene is 
involved in. While substantial progress is being made with this approach
1-2
, patient selection 
has thus far been far from perfect. Even a powerful predictor such as a KRAS mutation for 
EGFR-inhibiting therapy results in a response in just 20% of patients who are deemed 
sensitive based on their KRAS wild-type status
3-4
. One of the reasons for the disappointing 
performance of predictive factors could be the fact that they are most often based on 
primary tumor characteristics, while at the time of metastatic disease, a patients’ prognosis is 
determined by their metastatic tumor load and its biological phenotype. Through processes 
such as clonal selection and the inherent genomic instability of the tumor or as a consequence 
of therapy pressure, metastatic tumor cells can differ substantially and vitally from primary 
tumor cells
5-7
. Analysis of metastatic tissue would thus probably be better indicative of 
the actual tumor load and its underlying biology, and lead to better response prediction. 
Unfortunately, repetitive metastatic biopsies are invasive and painful, understandably limiting 
their use in clinical practice. Circulating tumor cells (CTCs) provide a very promising solution 
for this problem, as they can be obtained and characterized repetitively and non-invasively 
through venipunctures, and thus serve as a surrogate ‘liquid biopsy’ of metastases.
CTCs are cells that circulate in the peripheral blood of cancer patients, originating from either 
primary tumor or metastases. Since their discovery in 1869, CTCs have been regarded as a very 
promising field of research due to the opportunities that lie within the ability to easily and 
repeatedly access tumor cells. Only since recent years, this promise has started to be fulfilled, 
as the detection of CTCs turned out be extremely challenging.
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CTC detection methods
CTCs are extremely low-frequent in the circulation, with a median CTC count of 3 – 5 per 
7.5 mL of blood in metastatic cancer patients
8
. The scarcity of CTCs and the abundance of 
leukocytes amongst which they are present
9
 demand extreme sensitivity and specificity from 
their detection methods. Additionally, tumors, and thus probably also CTCs, are heterogeneous 
within and between patients
6-7
, and the search for the perfect CTC detection marker is by 
no means finished. It is this heterogeneity, caused by the existence of CTC subpopulations 
with distinct biological roles or simply reflecting the heterogeneity that is also present in solid 
tumors, which has hampered the development of an assay that is able to detect all types 
of CTCs in every patient. Moreover, because most assays rely on the expression of epithelial 
markers on CTCs, cells that have undergone epithelial-to-mesenchymal transition (EMT) upon 
entering the bloodstream could remain undetected. The detection of CTCs lacking epithelial 
markers may however be of crucial clinical importance, as EMT is thought to be mandatory 
for haematogenous metastasis and is associated with poor prognosis
10-12
.  Importantly, it is 
currently not known whether all CTCs are equal, or if most are passively-shed ‘by-stander’ 
CTCs accompanied by a few aggressive counterparts that have the ability to grow out into new 
metastatic lesions.
In an effort to obtain the highest and most relevant CTC count, many different CTC detection 
methods have been developed, ranging from flow cytometry-based methods
13-15
 and 
immunocytochemistry
16-18
 to microfluidic chips
19-20
 and quantitative reverse transcriptase PCR 
(qRT-PCR)
21-24
.
CTC enumeration
While advances in CTC detection methods are crucial to increase their clinical value, an 
FDA-approved CTC detection method is already available. Enumeration of CTCs with this 
CellSearch® assay (Veridex™ LLC, Raritan, NJ) has repeatedly been proven to be prognostic in 
an expanding number of tumor types such as metastatic breast
25-28
, colorectal
28-29
, lung
30 
and 
prostate cancer
28,31
. Moreover, CTC change during the first cycle of chemotherapy is a reliable 
predictor of therapy response
25
, performing at least as good as but earlier than conventional 
radiological assessment
32
 or PSA measurement
31,33
 do. In the primary setting, CTCs are even 
less frequent and lower in numbers than in the metastatic setting, but the subgroup of patients 
with detectable CTCs, usually comprising 10 – 20% of patients, does have a considerably worse 
prognosis than those without CTCs
34-35
.
Because of this low CTC frequency in patients with primary cancer and the fact that even in 
metastatic cancer patients, CTCs cannot be detected in 40 – 60% of patients
8
, CTC enumeration 
is far from ready to be employed as a cancer screening tool. With the introduction of more 
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sensitive assays, which could importantly lead to the detection of more CTCs in more patients, 
screening too could become a potential application of CTC enumeration.
CTC characterization
Characterization of CTCs is even more challenging than mere counting, as their low numbers 
and presence among, even after enrichment procedures, a substantial number of leukocytes
9 
complicates techniques such as DNA sequencing and qRT-PCR. Despite these hurdles, DNA 
mutation
36
 and methylation detection
37
, mRNA and miRNA expression
38-39
, FISH analysis
40-42 
and immunocytochemistry (ICC)
43-44
 have all proven to be feasible in these low-frequent cells. 
The potential clinical value of CTC characterization is seemingly endless as technology improves; 
analysis of drug targets such as HER2
45-48
 and estrogen receptor (ER)
45,47,49
 has already revealed 
clinically relevant discrepancies between primary tumor and CTCs, and besides drug targets, 
quantification of gammaH2AX expression on CTCs enables their use as a pharmacodynamic 
marker
50
, while large-scale gene expression analysis of CTCs provides insight into their biology 
and heterogeneity
38-39
.
Is there more to the circulation?
The studies described thus far have focused on the enumeration or characterization of CTCs 
in whole blood, but this is not the only compartment of the circulation from which tumor-
derived information can be obtained. Blood plasma
51
 and serum
52
, but also peritoneal
53
, 
pleural
54-55
 and cerebrospinal fluid
56
 can contain tumor-derived particles, and could provide 
a valuable addition to CTCs in blood. Also, whole tumor cells are not the only source of 
tumor-derived information and the presence and prognostic value of circulating DNA
57
, 
mRNA
51,58-59, 
miRNA
52,60
, fragments
61
 and exosomes
62-63
 stemming from tumor cells has been 
shown in a number of studies. All these different approaches could add to the knowledge we 
are acquiring on the behavior and relevance of tumor cells in the circulation, and eventually 
to the identification of novel predictive factors and models, together contributing to a more 
personalized treatment approach of cancer patients.
1.2 AIMS AND OUTLINE OF THE THESIS
This thesis is aimed at optimizing the quantity and quality of predictive and prognostic 
information that can be obtained from CTCs, through improvement of CTC detection and 
characterization methods and by correlating CTC counts and properties with clinical outcome. 
The value of CTC enumeration in metastatic breast cancer patients is confirmed, and the 
possibilities of CTC characterization within this and other cancer populations are explored.
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Since the first description of CTCs in 1869, many different CTC detection methods, both 
cytometry-based and nucleic acid-based, have been described. Depending on the choice 
of method for enrichment –capturing cells based on morphological properties or on the 
expression of tumor-specific markers–, and on the choice of method for detection –measuring 
mRNA, miRNA, DNA or protein expression–, varying degrees of success have been achieved. 
An overview of these different CTC detection methods is provided in Chapter 2.
The only currently FDA-approved CTC detection method is CellSearch, which captures CTCs 
based on anti-EpCAM enrichment followed by selection based on cytokeratin 8/18/19, DAPI 
and CD45. After having previously established that a subgroup of breast cancer cells lacks 
EpCAM-expression and are thus missed using the conventional CellSearch method
64
, we 
describe the use of an alternative enrichment marker, CD146, in Chapter 3. The addition of 
CD146 to EpCAM enables detection of all breast cancer subtypes, and CD146-positive CTCs 
were identified in breast cancer patients.
Despite marked improvements in breast cancer detection by adding CD146 to the enrichment 
step in the CellSearch assay, some cytokeratin-negative cells were still missed. Attempting to 
further improve the CellSearch assay, we tested various CTC selection markers as an alternative 
to cytokeratin 8/18/19 in Chapter 4. CD49f was identified as being broadly expressed among 
all breast cancer subtypes, and the addition of CD49f to cytokeratin 8/18/19 led to improved 
detection of cytokeratin-negative breast cancer cells.
In addition to CTC enumeration, CTC characterization enables the assessment of prognostic 
and predictive factors, which are probably better reflective of tumor load and its biology 
at the time of metastatic disease than characteristics obtained from a primary tumor that 
was resected years before, and, importantly, before administration of systemic treatment. In 
Chapter 5, we show that a CTC-specific gene expression panel consisting of 55 mRNAs and 
10 miRNAs can be reliably measured in CTCs of metastatic breast cancer patients. This panel 
is able to discriminate between healthy donors (HDs) and three patient subgroups, and the 
patient subgroups were characterized by differential expression of growth factor receptor-, 
estrogen receptor- and proliferation-associated genes. In addition, we describe clinically 
relevant discrepancies between CTC and primary tumor ER and HER2 expression.
After showing the feasibility of the measurement of our CTC-specific gene expression panel, 
we proceeded to establish its clinical relevance as a prognostic factor in metastatic breast 
cancer patients. In Chapter 6, we show that a 16-gene CTC gene expression profile identifies 
poor prognosis patients among those with <5 counted CTCs, while a separate 9-gene CTC 
profile further discriminates patients with ≥5 CTCs, identifying those patients with treatment 
switch or death within 9 months after start of 1
st
 line systemic therapy versus those with a 
more favorable outcome. These CTC profiles provide additional prognostic information on top 
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of a CTC count, and thus allow for better patient selection and stratification.
Chapter 7 describes the generation of a CTC-specific gene expression profile in metastatic 
colorectal cancer patients, whose CTCs were isolated before resection of their liver metastases. 
In this patient group too, like in metastatic breast cancer, we were able to identify a panel of 
CTC-specific mRNAs and miRNAs capable of discriminating HDs from patients with ≥3 CTCs. 
In patients without detectable CTCs according to the CellSearch technique, a subgroup was 
identified whose molecular profile was clearly distinct from HDs, and expression of various 
epithelial markers suggested the presence of circulating tumor load in their blood.
Besides mRNA and miRNA expression, mutation analysis on CTCs also provides great 
opportunities for the improvement of personalized cancer treatments. In recent years, KRAS 
and BRAF mutations have been established as crucial predictive factors in colorectal cancer 
patients treated with EGFR-inhibitors. As with gene expression, mutation analysis of CTCs at the 
time of metastatic disease will probably lead to a more reliable identification of those patients 
susceptible to EGFR-inhibiting treatment than analysis of the primary tumor. In Chapter 8, 
we describe the KRAS and BRAF mutation analysis of matched CTCs, primary tumors and liver 
metastases of 42 colorectal cancer patients, and show that clinically relevant discrepancies are 
present between these tumor compartments.
MiRNAs are an important new topic in cancer research, as these small RNA fragments are 
directly involved in regulating a large array of mRNAs. MiRNAs too can be measured in CTCs 
or, presumably because of their profound stability compared to MiRNAs, exosome-bound or 
cell-free in the circulation. In Chapter 9, we review the diagnostic applications of cell-free 
and CTC-associated miRNAs in various tumor types, and provide our opinion on the technical 
specifications and validations needed to establish these tests as reliable prognostic and 
predictive factors.
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Chapter 2
Circulating tumor cells (CTCs): Detection methods 
and their clinical relevance in breast cancer 
Bianca Mostert, Stefan Sleijfer, John A. Foekens, Jan W. Gratama
Cancer Treatment Reviews 2009; 35: 463–474

ABSTRACT
The enumeration of circulating tumor cells has long been regarded as an attractive diagnostic 
tool, as circulating tumor cells are thought to reflect aggressiveness of the tumor and may as-
sist in therapeutic decisions in patients with solid malignancies. 
However, implementation of this assay into clinical routine has been cumbersome, as a vali-
dated test was not available until recently. Circulating tumor cells are rare events which can be 
detected specifically only by using a combination of surface and intracellular markers, and only 
recently a number of technical advances have made their reliable detection possible. Most of 
these new techniques rely on a combination of an enrichment and a detection step.
This review addresses the assays that have been described so far in the literature, including 
the enrichment and detection steps and the markers used in these assays.  We have focused 
on breast cancer as most clinical studies on CTC detection so far have been done in these 
patients.
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INTRODUCTION
The outcome of breast cancer largely depends on the development of metastases in the 
course of the disease. Given this vital importance of metastases, means to detect and monitor 
their existence are continuously sought for. The detection of circulating tumor cells (CTCs) 
is one field of research focusing on a new method to detect metastatic disease earlier, less 
invasive and more reliably than currently available conventional methods, such as clinical 
presentation, radiographic evaluation and serum tumor markers do. CTCs are defined as 
tumor cells circulating in the peripheral blood of patients, shed from either the primary tumor 
or its metastases. Numerous efforts have been made to reliably detect and quantify CTCs in 
peripheral blood, but development of a suitable assay has proven to be difficult. Unfortunately, 
there is not one specific feature that universally distinguishes CTCs from blood cells. Ideally, 
a specific marker would be identified, which is expressed in every cell of every breast cancer 
type. In reality, different histological and molecular types of tumors express different arrays of 
markers, and marked heterogeneity of expression exists even within one histological distinct 
tumor type. Another challenge regarding sensitivity of assays is the fact that CTCs are rare 
events, with numbers as low as one CTC in 10
6
- 10
7
 leukocytes
65
. In spite of these challenging 
characteristics, the importance of detecting and enumerating CTCs in breast cancer has been 
established in several clinical studies, showing a correlation with decreased progression-
free survival (PFS) and overall survival (OS)
66-67
. In addition to detection and enumeration, 
molecular characterization of CTCs provides a second much-anticipated application in 
oncology. Currently, we are dependent on the primary tumor for molecular characteristics in 
order to determine the type of therapy the patient will benefit from most. However, tumor 
genotype and/or phenotype may change in the course of treatment as indicated by therapy 
resistance. CTCs might function as a real-time biopsy of tumor load, and enable oncologists to 
make better-informed choices regarding therapy.
In addition to CTCs, disseminated tumor cells (DTCs), i.e., isolated tumor cells in bone marrow, 
are thought to reflect the metastatic potential of tumors. DTCs have also been correlated 
with prognosis
68-69
, but for their detection an invasive diagnostic procedure, bone marrow 
aspiration, is necessary. This requirement makes their implementation in the clinic more 
troublesome. By contrast, CTCs have the advantage of being readily available in peripheral 
blood and given this, together with mounting evidence supporting their clinical feasibility as 
reviewed here, the detection of CTCs is anticipated to gain clinical relevance shortly. For a 
comprehensive review on DTCs and their complementary role to CTCs, we refer to the recent 
review by Riethdorf et al.
70
.
Here we will discuss the principals and technical aspects of the different techniques available 
for detecting CTCs, in addition to the most frequently used markers in these techniques. 
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Furthermore, we will discuss clinical studies showing the utility of CTC detection in breast 
cancer patients with these techniques.  Reviews focusing on the detection techniques of both 
DTCs and CTCs, as well as biological relevance, have been published recently
71-72
.
DETECTION OF CIRCULATING TUMOR CELLS
In general, methods for CTC detection can be divided into cytometric (i.e., whole-cell based) 
and nucleic-acid based techniques. Both techniques usually include an enrichment step and 
a detection step.
As CTCs are rare events occurring at rates as low as 1 cell per 10
6
- 10
7
 leukocytes, enrichment is 
generally needed to increase sensitivity to an acceptable level. One type of enrichment relies 
upon the selection of target cells with tumor-specific markers (immunoseparation). Other 
methods for enrichment are based solely on morphologic criteria, such as cell size or density. 
Sensitivity and specificity is an issue with both techniques, due to heterogeneity of tumors 
in size, density and marker expression. Consequently, while enrichment is thought to be 
required, some tumor cell loss is likely to occur irrespective of the enrichment technique used. 
The extent of cell loss should be determined with recovery experiments for each technique to 
validate the results
73-74
.
After enrichment, nucleic-acid based techniques like reverse transcriptase (RT)-PCR or 
cytometric methods are applied to detect CTCs through putative tumor-specific markers. 
Here we will discuss the most commonly used enrichment and detection techniques. 
Some techniques have combined their enrichment and detection steps and these will be 
presented separately. While a number of studies have compared the performance of different 
assays
16-17,75
, not all techniques have been compared directly to each other. In an attempt to 
clarify the hierarchy in the various techniques, we have depicted their major advantages and 
disadvantages in Tables 1 and 2.
INCREASING ASSAY SENSITICITY: ENRICHMENT TECHNIQUES
As mentioned before, enrichment can be based on morphologic cell characteristics, such as 
size or density, or on immunoseparation, using magnetic beads, ferrofluids or rosettes.
Morphology-based enrichment
ISET (Isolation by Size of Epithelial Tumor cells) isolates tumor cells individually by filtration 
based on their larger size (>8 μm) compared to leukocytes
76
. The Nucleopore assay (Whatman 
International Ltd, England) is based on the same assumption
77
. However, no validation 
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studies have been executed confirming that CTCs are indeed never smaller than 8 μm, leaving 
questions about the sensitivity of this method.
Density gradient-based techniques are techniques separating mononuclear cells based on 
their lower density compared to other blood compartments. Mononuclear cells and tumor 
cells are separated from blood cells and granulocytes using a density gradient of 1,077 g/mL. 
Similarly, Oncoquick (Greiner Bio One, Frickenhausen, Germany) is based on density gradient 
separation, but adds a porous barrier, which prevents the gradient-separated cells to be 
contaminated with the whole blood.
Immunomagnetic separation
The simplest separation can be done with immunomagnetically labeled monoclonal antibodies 
and a basic handhold magnet. Negative selection of a blood sample can be done with magnetic 
beads loaded with an anti-CD45 antibody, a pan-leukocyte marker, or against CD61 thereby 
removing megakaryocytes and platelets
78
.
MACS® (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), or Magnetic Activated Cell 
Sorting system, is a dedicated instrument that captures cells by immunomagnetic labeling 
with microbeads. It does so by membrane or intracellular staining, the latter requiring a 
permeabilization and fixation step. Magnetic beads are available linked to anti-epithelial 
antibodies for positive selection through EpCAM, for example. EpCAM, or tumor-associated 
calcium signal transducer 1 (CD326), is a cell surface molecule involved in cell-to-cell adhesion 
and is highly expressed in most epithelial carcinomas
79
. Magnetic beads targeting the tumor-
specific cell antigen epidermal growth factor receptor 2 (HER2) are also available. 
The AdnaTest (AdnaGen AG, Laggenhagen, Germany) combines two epithelial and tumor 
associated antigens. Two antibodies against MUC1 and one antibody against EpCAM are 
conjugated to magnetic beads. As neither MUC1 nor EpCAM are present on all circulating 
tumor cells
80
, cells expressing MUC1 and/or EpCAM should be isolated with this double-
antibody method.
RARE™ (StemCell Technologies, Vancouver), i.e., RosetteSep-Applied imaging Rare Event, is a 
technique that combines a density gradient separation with an antibody-mediated enrichment 
step. Enrichment is done through negative selection, as CD45
+
 cells are cross-linked to multiple 
red blood cells by bispecific tetrameric antibody complexes, forming rosettes. As the density 
of these unwanted cells then increases, the CD45-positive cells accumulate in the lower 
compartment after density gradient centrifugation. CD45-negative mononuclear cells are 
isolated between the separation medium and plasma
81
. A more extensive negative selection 
can be done with the same technique, by using a kit containing antibodies directed against 
CD2, CD16, CD19, CD36, CD38, CD45, CD66b and glycophorin A.  
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DETECTION TECHNIQUES
Cytometric methods
The presence of tumor cells in the bone marrow was first identified using conventional 
imaging techniques
82
. Building on this, detecting tumor cells in the circulation was attempted 
using simple hematoxylin and eosin staining
83
. This exhaustive method consisted of visually 
identifying large numbers of gradient-separated cells and comparing them with primary tumor 
cells morphologically. Nowadays, as previously mentioned, detection of CTCs occurs on a 
cytometric or a nucleic-acid basis. 
Cytometric methods isolate and enumerate individual cells based on their antigen expression, 
using for example monoclonal antibodies directed against epithelium-specific antigens. 
The advantage of cytometric methods over nucleic-acid based methods is the possibility to 
further characterize the cells, as the target cells are not lysed in the procedure. This allows 
subsequent morphological identification and molecular characterization of CTCs. The major 
draw-back is the current lack of a tumor specific antibody. The commonly used Cytokeratin 
(CK) antibodies bind specifically and non-specifically to macrophages, plasma cells and 
nucleated hematopoietic cell precursors
84-85
. The same holds true for Mucin-1 (which binds 
nonspecifically to erythroid progenitors)
86
. This problem can be reduced significantly by 
counterstaining with CD45, a pan-leukocyte marker. Breast cancer specific markers have been 
used (i.e., HER2, anti-Mammaglobin), but as these are not present on all breast cancer tumors 
or on every cell of a particular tumor, false negatives are likely to occur. Advances in terms 
of sensitivity and specificity have been made using multimarker assays, which can overcome 
detection problems due to tumor heterogeneity
64
. 
To overcome the problem of high numbers of immunofluorescently labeled mononuclear 
cells having to be analyzed to identify rare CTCs, FAST was developed. This Fiber-optic Array 
Scanning Technology locates immunofluorescently labeled cells on glass substrates at rates 
500 times higher than conventional automated digital microscopy. The key innovation is a light 
collection system that has a very large field of view (50 mm), which is large enough to enable 
continuous scanning without the need to analyze the sample in multiple steps. Because larger 
volumes of peripheral blood can be analyzed than using conventional microscopy in the same 
time, purification or enrichment steps are avoided, which reduces the risk of cell loss. In cell 
line spiking experiments, an average sensitivity of 98% was reached in colorectal and breast 
cancer after whole blood lysis
87-88
.
Attempting to improve scanning of fluorescent cells, the Laser Scanning Cytometer (LSC) 
(Compucyte Corporation, Cambridge, MA) was developed. Following whole blood lysis and 
staining with anti-human epithelial antibody (HEA) in combination with CD45, this cytometer 
analyses fluorescence after the cells are contoured using forward scatter as a threshold 
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parameter. The cytometer determines background fluorescence dynamically to calculate 
peak and integral fluorescence on a per-cell basis. This calculation results in improved 
correction for background fluorescence variation. It is also possible to relocate the cells 
within the positive population, allowing for visual verification through the microscope
14,89
. In 
a recent study, three different combinations of techniques were compared; immunomagnetic 
separation and LSC vs. cell filtration and LSC vs. a multimarker quantitative RT-PCR assay. 
qRT-PCR was found to be the most sensitive. Samples from patients with metastatic breast 
cancer were significantly more likely to be positive for one or more of three markers (CK19, 
mammaglobin, and PIP (prolactin inducible protein) using RT-PCR than to be positive in 
LSC
75
.
ACIS®
85
 (Automated Cellular Imaging System) (DAKO, Glostrup, Denmark) and ARIOL®
90 
(Applied Imaging Corp., San Jose, CA) are automated scanning microscopes enabling faster 
examination of slides. After initial automated scanning and analysis of slides in a manner 
that can be configured to the assay used, the investigator reviews the presented images and 
classifies them morphologically. Numerous other automated scanning systems have been 
used in the immunocytochemical detection of rare events
91-93
.
Nucleic-acid based methods
CTCs may be identified through the detection of (epi)genetic alterations that are specific for 
cancer cells. Alterations in DNA such as mutations in proto-oncogenes or tumor suppressor 
genes, microsatellite instability and sequences of oncogenic viruses may be detected. 
Circulating free total DNA in the blood of cancer patients was detected for the first time 
in 1977 using a radioimmunoassay
94
. In later studies, circulating mitochondrial DNA
95
 and 
amplification of MYC-N (a neuroblastoma-derived MYC oncogene) DNA
96-97
 in neuroblastoma 
patients was detected in greater amounts in patients with cancer than in healthy individuals. 
Implementing DNA-based CTC detection in clinical practice is difficult however. DNA changes 
occur in merely dysplastic lesions as well as in full-blown neoplasm. Furthermore, there is 
uncertainty about the half-life of circulating cells and nucleic acids, which means that the 
presence of circulating free DNA may reflect merely the presence of nucleic acids, not tumor 
cells. As a result, the detection of free total DNA has not been implemented into clinical 
practice.
Detection of mRNA of factors that are overexpressed or mutated in breast cancer using 
RT-PCR is a more widely used alternative. As RNA disappears quickly from the blood after 
cell death, detection of RNA is likely due to the presence of a whole tumor cell, not cell 
fragments or free RNA. In RT-PCR, after cDNA synthesis, the gene of interest is amplified 
using oligonucleotide primers specific for this gene of interest. The sensitivity of RT-PCR 
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was higher than immunocytochemistry in several studies
16-17,98
. However, RT-PCR is prone 
to false-positivity, as sample contamination, expression of target genes in normal cells, and 
pseudo genes (genes without protein-coding abilities) can all occur. The problem of false-
positivity was demonstrated very clearly in work on activated peripheral blood mononuclear 
cells (PBMCs)
99
. A multimarker RT-PCR assay was performed on healthy donors, stimulated 
PBMCs and unstimulated PBMCs from patients with immune thrombocytopenic purpura (ITP). 
While all markers (SCCA (secondary structure conserved A), EGFR (epidermal growth factor 
receptor), hMAM (mammaglobin), SBEM (small breast epithelial mucin) and CA-9 (carbonic 
anhydrase 9)) were negative in healthy donors, 4 out of 5 (SCCA, EGFR, hMAM, SBEM) 
were positive in stimulated PBMCs and 3 of 5 (SCCA, EGFR, SBEM) were positive in patients 
suffering from ITP. In another study, it was revealed that CK19 and CEA (carcinoembryonic 
antigen) expression is present in lymphatics following cytokine stimulation, as well as in 50% 
of bone marrow samples of patients with chronic inflammatory disease
100
. As cancer can 
induce inflammatory responses
101
, these inducible signals may be the cause of false-positive 
outcomes in CTC detection. Another possible source of false-positivity is the presence of 
free RNA or genomic DNA, which can be eliminated by adding a gradient separation step or 
genomic DNA elimination by DNAse, respectively
102
.
In general, nucleic-acid based methods combine their higher sensitivity with a lower 
specificity, as background noise due to expression of markers in normal cells is hard to 
distinguish from a true positive signal. Quantitative RT-PCR provides a way of visualizing 
low and high expression of a chosen marker, increasing discrimination between mRNA 
expression of normal cells and tumor cells. Like in cytometric methods, in RT-PCR as well 
the absence of a true tissue-specific marker has been an issue with regard to specificity. RT-
PCR outperformed immunocytochemistry in sensitivity (49.6 vs. 42% positive samples in 133 
patients) in a study on CK19 detection. However, no data were provided on results in healthy 
donors
17
. The importance of the latter was underlined by the findings of another study 
comparing CK19 detection by immunocytochemistry vs. RT-PCR vs. Nucleic Acid Sequence-
Based Amplification (NASBA). While RT-PCR was more sensitive than immunocytochemistry 
and NASBA, all three methods showed false-positive results in healthy donors
16
, prompting 
the authors to deem CK19 an unsuitable marker. As these studies show, single-marker assays 
reach sufficient sensitivity but lack in specificity. Given the heterogeneity of breast cancer, the 
consistent presence of a specific tumor marker or fusion gene such as in Ewing tumors
103-104 
seems unlikely. Instead, the use of multiple marker assays, combining several breast cancer-
specific markers as well as leukocyte-specific markers, might at least in part resolve the issue 
of specificity.
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COMBINED ENRICHMENT AND DETECTION TECHNIQUES
CellSearch® (Veridex™, Warren, PA) is a semi-automated technology by which whole blood 
is enriched for CTCs by adding ferrofluids loaded with antibodies directed towards EpCAM. 
Currently, CellSearch is the only FDA-approved assay for CTC detection. CTCs in the enriched 
population are stained with CK and DAPI using fluorescent antibodies, while hematopoietic 
cells are counterstained with CD45. The CK
+
/DAPI
+
/CD45- cells are then enumerated with an 
automated fluorescence microscope. The semi-automated character of this system enables 
samples to be analyzed rapidly and reproducibly. When CellSearch was compared directly 
to Oncoquick followed by labeling with CKs, EpCAM and DAPI, both methods reached 100% 
specificity in 15 healthy donors, but CellSearch detected more samples with >1 CTC in a group 
of 61 heterogeneous carcinoma patients (14 vs. 33 positive samples). The mean number of 
CTCs per sample was also higher using the CellSearch technique
105
.
A technologically advanced and novel method to isolate CTCs is the ‘CTC-chip’. This chip 
consists of 78,000 microposts, each coated with EpCAM antibodies. As whole blood is 
pumped across the chip under controlled flow conditions, EpCAM-positive cells bind to the 
microposts, which are then detected by a camera based on their morphology, viability and 
tumor markers. This system uses CKs and DAPI for positive selection together with CD45 for 
negative selection
20,106
. The micropost system should prevent trapping of EpCAM positive 
cells among leukocytes. According to the developers, sensitivity was remarkably high with this 
method, as CTCs were detected in every patient, including those with localized disease
20
. 
Another new approach is the epithelial immunospot (EPISPOT) assay, an immunological 
assay based on the enzyme-linked immunosorbent assay (ELISPOT). The assay is preceded 
by immunomagnetic depletion of CD45
+
-cells and enrichment for CXCR4
+
-cells (a chemokine 
receptor involved in the homing of metastatic tumor cells
107
). EPISPOT detects specific proteins 
released by breast cancer CTCs, such as cathepsin-D (a cysteine protease) or Mucin-1, thus 
counting only viable, protein-excreting cells
108-109
. In theory, viable cells have more clinical 
relevance than apoptotic cells as they should still be capable of forming metastases. In a first 
study on breast cancer CTC detection, this assay was performed using Mucin-1 and CK19 as 
markers, showing high sensitivity and specificity
108
.
In conclusion, no enrichment or detection method for CTCs has yet proven to be the golden 
standard, and continuing efforts are made to improve the reliability of these methods.
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MARKERS
The effectiveness of tumor cell enrichment and detection depends upon the choice of 
markers, tools to identify and characterize CTCs. Many different markers have been explored 
in the field of CTCs. To date, no one marker has proven to be ideal for the detection of 
breast cancer CTCs. This is not unexpected given the heterogeneity of the disease and 
the rarity of CTCs. In breast cancer, a wide array of markers has been studied, especially 
with nucleic-acid based techniques. In Table 3, we present an overview of markers for 
enrichment and detection of breast cancer CTCs in cytometric techniques. Table 4 depicts 
the methods of enrichment and the markers for detection of breast cancer CTCs in nucleic-
acid based techniques. The heterogeneity of experiments in studies to date does not allow 
drawing conclusions on superiority of one marker. Study populations, sample handling and 
preparation and use of markers differ so strongly that any comparison would be misleading. 
However, all these markers do represent a specific quality of tumor cells, and can therefore 
offer essential information. As a consequence, the combination of multiple markers seems 
promising when this results in an increment in specificity and sensitivity.
CLINICAL APPLICATIONS OF CTC DETECTION
The presence of occult metastases cannot be deduced from the finding of CTCs alone, 
as CTCs must pass through several stages before forming a metastatic colony. Cells must 
extravasate from the circulation into target organs and subsequently proliferate whilst evading 
immunological response and overcoming metabolic difficulties. It has been estimated that 
only one in 10,000 CTCs is able to form a metastasis
110
. 
Despite all this, the clinical usefulness of CTC detection has been demonstrated in metastatic 
breast cancer
66,111
, metastatic colorectal
29,112
 and metastatic prostate cancer
31
. In addition, 
CTCs have been studied in pancreatic
113
, gastric
114-117
, bladder
118-121
 and lung cancer
14,122-123
, 
among others, with variable results. Of all tumor types, breast cancer is the tumor type 
in which CTCs have most strongly proven their value, and in which the largest variety of 
techniques has been applied.
Notably, while reaching technically good results with respect to sensitivity and specificity, 
no studies in large patient series have been conducted using RARE, Histopaque, Percoll, 
ISET, Nucleopore or MACS as enrichment techniques. Furthermore, with regard to detection 
techniques, EPISPOT and FAST have not been correlated to clinical outcome. In contrast, 
CTC detection using other techniques such as CellSearch or PCR-based techniques has been 
extensively studied in large series of patients. For this review we have chosen to discuss only 
major CellSearch- and RT-PCR-based studies.
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CTC DETECTION IN LOCALIZED BREAST CANCER
Neoadjuvant setting
For patients presenting with locally advanced breast cancer, i.e., tumors presenting with 
extensive regional lymph node involvement, skin involvement or a large size (>5 cm), 
resection of the primary tumor is frequently either not possible or only at the cost of an 
amputation of the breast. Systemic therapy given prior to management of the primary 
tumor, also known as neoadjuvant therapy, aims to reduce tumor size thereby rendering 
the residual tumor amendable for a breast-conserving resection. In addition, neoadjuvant 
systemic therapy aims to eradicate micrometastases, which may otherwise have resulted 
in incurable, overt metastatic disease later on. Until now, the value of CTC detection in the 
neoadjuvant setting has not been extensively studied. Recently, CTCs were detected before 
and/or after neoadjuvant chemotherapy with CellSearch in 118 patients included in a phase 
II trial
34
. In 23% of the patients, one or more CTC per 7.5 mL blood was detected before the 
administration of neoadjuvant chemotherapy, while 17% had >1 CTC per 7,5 mL blood after 
neoadjuvant chemotherapy. The persistence of CTCs during neoadjuvant chemotherapy was 
not correlated with treatment response, but the presence of CTCs either at baseline or after 
neoadjuvant chemotherapy was an independent prognostic factor for distant metastasis-
free survival
34
. In another study, CTCs were monitored by Laser Scanning Cytometer (LSC) 
before each of 3 therapy cycles in 30 patients
124
. CTCs were detected in all patients prior 
to the start of therapy, but the decrease in number of CTCs for different patients varied up 
to several hundred-fold. A strong correlation was however shown between a reduction in 
the number of CTCs and a favorable pathological response at surgery
124
. This correlation 
suggests that CTCs may serve as an early marker to assess response to neoadjuvant therapy. 
However, the remarkable high CTC detection rate in these primary breast cancer patients, as 
well as in another 30 patients treated in the adjuvant setting using the same technique as 
discussed below, has been questioned
125
. It was suggested that further characterization is 
needed to confirm that the cells assigned as CTC using this technique are tumor cells indeed. 
The authors explained their findings by stating that the lack of enrichment in their method 
accounts for less cell loss and, consequently, the high CTC counts
125
.
Adjuvant setting
Adjuvant chemotherapy refers to systemic therapy after primary surgery for early stage breast 
cancer patients who are considered to have a high risk for metastatic disease developing 
from micrometastases that are already present at initial presentation. The intent of adjuvant 
therapy is to cure patients by eradicating these micrometastases. Currently, it is not possible 
to adequately identify patients who do not harbor micrometastases and therefore should 
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be spared from adjuvant therapy and the accompanying toxicities. On the other end of the 
spectrum, 20 - 30% of patients treated with adjuvant therapy will develop overt metastasis, 
in spite of the adjuvant therapy
126
. Detecting this population not cured by the administered 
adjuvant therapy could open the door for additional treatments with new drugs. Several 
studies have recently been conducted to establish whether or not CTC detection and 
enumeration may guide treatment in this setting. 
In a study of 91 clinically non-metastatic primary breast cancer patients, CTCs were quantified 
by LSC before adjuvant therapy, before each new cycle and at the end of the chemotherapy
127
. 
There were 3 distinct patterns of response: 28 patients showed a decrease in cell number of 
10-fold or more, 30 patients showed changes less than 10-fold in cell number and 33 patients 
had an increase of more than 10-fold. The pattern of CTC counts during therapy correlated 
significantly with relapse, and in multivariate analysis, an increasing CTC count of 10-fold or 
more at the end of therapy was associated with shorter relapse-free survival
127
. If confirmed, 
this group of patients may be candidate for additional therapy. As in another study of the 
same group as discussed before
124
, the remarkably high rate of CTC positivity in the current 
study
127
 has been subject of discussion
125
. 
The prognostic relevance of the detection of CTCs with RT-PCR has recently been 
demonstrated in 444 early-stage breast cancer patients
128
. After a median follow-up of 53.5 
months, patients with CK19 mRNA-positive CTCs experienced significantly reduced disease-
free survival (DFS) and OS compared to those without CTCs. In multivariate analysis as well, 
the detection of CTCs was associated with decreased DFS and OS
128
. It should be noted, as 
discussed before, that using only CK19 as a marker does raise concerns about specificity
16
.
As HER2 has become an important target for therapy since the introduction of trastuzumab 
(Herceptin®), the determination of HER2 expression on CTCs has caught the interest of 
research groups. Apostolaki et al. showed that the detection of HER2 mRNA-positive cells 
with RT-PCR after the administration of adjuvant chemotherapy was correlated with shorter 
disease-free interval (DFI) in 214 stage I and stage II breast cancer patients
21
. However, this 
prognostic value of HER2 on CTCs could not be reproduced in a more recent multimarker 
qRT-PCR based study
59
. Simultaneously studying mammaglobin A (MGB1), HER2 and CK19 
in 175 patients with stage I-II breast cancer after primary surgery and before adjuvant 
therapy, marked heterogeneity was seen in the CTC phenotypes inter- and intra-individually. 
In multivariate analysis, CK19 mRNA+ and MGB1 mRNA+ cells were independent adverse 
prognostic factors, whereas HER2 mRNA+ cells were not
59
. This apparent difference in 
significance of HER2 might be due to the fact that the presence of HER2 mRNA+ cells after 
adjuvant therapy, which was only determined in the first study, could reflect resistance to 
chemotherapy and therefore be stronger associated with prognosis.
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In a single-marker assay, using CK7 as a marker for qRT-PCR, CTCs were detected in 37 of 206 
primary breast cancer patients
129
. Ninety-eight patients were followed up 24 months after 
primary surgery. Of those, the CK7-negative group showed significantly longer DFS than the 
CK7-positives. This difference was even more profound in 61 lymph node-negative patients 
observed over 24 months after surgery. This suggests that CK7+ CTCs are a prognostic marker 
for early recurrence after primary surgery
129
.
Employing the CellSearch technique, a large trial is currently being conducted to assess 
the value of CTCs in the adjuvant setting
130
. This SUCCESS trial has enrolled 1767 primary 
breast cancer patients. Preliminary results show detection of >1 CTCs per 7.5 mL blood 
with CellSearch in 10% of 1500 patients before the start of systemic therapy. Of those, 
10% remained positive after chemotherapy. Persistence of CTCs after chemotherapy was 
associated with decreased PFS and OS. As follow-up of this trial is ongoing, the prognostic 
value of these promising data cannot yet be determined.
Oncoquick was combined with immunocytochemical staining with anti-cytokeratin, CD45 and 
Ki-67, the latter being a proliferation marker, to detect CTCs in 60 primary and 63 metastatic 
breast cancer patients
131
 CTCs were detected in 8.3% of primary and 39.7% of metastatic 
breast cancer patients, but this didn’t correlate with prognosis or tumor characteristics. 
Remarkably, in a subset of 47 randomly chosen patients, none of the 9 CTC-positive patients 
expressed Ki-67 on their CTCs, suggesting that CTCs are at the very least rarely proliferative.
Studying 341 primary breast cancer patients included within 3 years after primary surgery, 
CTCs could be detected by immunocytochemical staining with anti-cytokeratin following 
enrichment with Ficoll and immunomagnetic CD45-depletion in 10% of the patients
132
. While 
the presence of CTCs was correlated with DFS and breast cancer specific survival in the whole 
group of patients, when 23 patients who had had a breast cancer-related event prior to the 
collection of peripheral blood were excluded, CTC detection no longer correlated with DFS.
CTC DETECTION IN METASTATIC BREAST CANCER
In metastatic disease, the intention of treatment is essentially palliative, striving to optimize 
quality rather than duration of life. Assessing prognosis in patients with metastatic breast 
cancer with CTCs can be helpful in the individualized management of these patients. In a 
multicenter, prospective study conducted by Cristofanilli et al
25
, CTC count was assessed 
using CellSearch in 177 progressive metastatic breast cancer patients who were to start a 
new line of systemic therapy. CTCs were enumerated before the start of new treatment and 
at first follow-up visit. Patients with a level of CTCs before the start of treatment of ≥5 cells 
per 7.5 mL blood had a shorter median PFS (2.7 vs. 7.0 months) and shorter OS (10.1 vs. 
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>18 months). Maybe even more interestingly, patients with initially elevated CTC levels at 
baseline that had declined below 5 cells per 7.5 mL blood at first follow-up after the first 
administration of therapy had a PFS and OS similar to the patients with low levels of CTCs 
at baseline and follow up. These results indicate the potential role of CTCs as a prognostic 
marker, and as a marker establishing at an early stage whether a patient benefits from anti-
tumor therapy
133
. Recently, the patients in this cohort whose CTC levels were determined 
at the time of newly diagnosed recurrent or de novo metastatic disease, and therefore 
being treatment-naïve, were analyzed retrospectively
134
. Also in these patients, it could be 
confirmed that a CTC level of >5 was an independent prognostic factor for death (HR 3.64), 
and median OS was 28.3 vs. 15 months in patients with CTCs <5 vs.>5.
Even more so than in localized disease, in metastatic breast cancer the clinician should carefully 
evaluate the effects of chemotherapy taking into account its side-effects. It is important to 
assess response or lack thereof as early as possible in order to avoid exposure of the patient 
to unnecessary toxicity. The current methods to evaluate this response, namely clinical 
presentation and radiographic imaging, are suboptimal, as they are often only helpful late in 
the disease process. Ideally, CTCs could predict response to therapy after one or two cycles 
of therapy, and do so more reliable than traditional parameters. Budd et al
32
 compared the 
prognostic value of the presence of >5 CTCs per 7.5 mL blood with radiologic response on OS 
in 138 metastatic breast cancer patients in the same cohort as Cristofanilli et al
25
. Radiologic 
evaluation was conducted 10 weeks after initiation of therapy, CTC counts were determined 
with the CellSearch system 4 weeks after initiation of therapy. CTC determination showed 
lower inter-reader variability than radiologic evaluation (0.7% vs. 15.2%, respectively). In 
patients who were non-progressive according to radiological evaluation, the median OS was 
significantly shorter for patients with ≥5 CTCs than for patients with <5 CTCs per 7.5 mL 
blood (15.3 versus 26.9 months). In patients with radiological progressive disease, a similar 
significant difference in median OS was objectified in patients with ≥5 CTCs versus patients 
with <5 CTCs per 7.5 mL blood (6.4 versus 19.9 months)
32
. This study strongly suggests that 
CTCs are a good tool to evaluate tumor response to therapy, and in fact better than radiologic 
evaluation. 
The study of multiple rather than single markers to increase sensitivity of CTC detection 
assays, studying multiple markers seems promising. Combining CK19, p1B, PS2 and EGP2, 
CTCs were detected by qRT-PCR in 94 metastatic breast cancer patients. After combining 
the four expression levels into a single discriminant value, a positive value correlated with a 
significantly worse PFS and OS
111
.
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DISCUSSION
Circulating tumor cells are being recognized as a promising diagnostic tool in oncology, 
and thus many efforts have been made to detect them reliably. In breast cancer, several 
techniques (both cytometric and nucleic-acid based) have been explored in different settings 
yielding interesting results. However, in addition to independent confirmation of these 
results, several issues remain to be resolved. 
Studies have shown remarkably varying CTC counts, ranging from <5 to thousands per mL 
in the same patient category. Whether these differences are caused by cancer biology or 
varying sensitivity of the techniques used, awaits clarification. Limited studies have been 
performed comparing the sensitivity and specificity of the different detection techniques. 
The ultimate goal is to set up an assay that generates inter-individually interpretable results 
for each individual patient, underlining the necessity for consensus on the exact technique 
for enrichment and detection that should be applied and on the markers that should be used. 
Given the heterogeneity between breast cancer subtypes, it is anticipated that assays cannot 
rely on a single, universally expressed and specific marker. Therefore, efforts should be made 
to develop a marker set, as multiple markers probably do more justice to the heterogeneity 
of breast cancer. EpCAM seems to insufficiently detect some molecular subtypes of breast 
cancer
64 
prompting the need for a combination of cellular markers by which all breast cancer 
subtypes can be detected.
Despite these challenges, enumeration of CTCs has shown to bear prognostic information, 
and may inform oncologists about response to systemic therapy shortly after its start. 
Building on this, it would be of great benefit if the increase or decrease in CTC count after 
the first cycle of systemic treatment would be a better guideline for continuation or switch of 
therapy than conventional (radiologic) evaluation after 2-3 cycles. Currently, a study is being 
conducted by the Southwest Oncology Group, measuring CTCs at baseline and after the first 
cycle of chemotherapy. Patients with >5 CTCs per 7.5 mL blood at baseline who remain at 
>5 CTCs per 7.5 mL blood after completing one course of chemotherapy are randomized to 
either continue their current chemotherapy or to switch to a different regimen. The results of 
this trial (www.clinicaltrials.gov search for NCT003820128
135
) could prove a big step forward 
in the clinical field. 
Another interesting possibility in the CTC field is their molecular characterization. Klein et al. 
have applied comparative genomic hybridization and discovered remarkable heterogeneity 
between individual tumor cells in patients treated in the adjuvant setting over time as well as 
between patients
136
. In these patients, only a few TP53 mutations were revealed. In patients 
treated in the metastatic setting, genetic heterogeneity over time was less marked, but TP53 
mutations were encountered more frequently
136
. Smirnov et al. were the first to generate 
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global gene expression profiles of CTCs from 3 cancer patients, resulting in 35 cancer- and 
CTC-specific genes
39
. The expression of these genes was subsequently confirmed by qRT-
PCR in 74 metastatic breast cancer patients and 50 healthy donors, ultimately generating 
16 genes (such as AGR2 and FABP1), which may be useful to distinguish individuals without 
cancer from cancer patients, as well as distinguishing breast cancer from colon cancer and 
prostate cancer patients
39
. 
Molecular characterization of primary tumor tissue by gene expression profiling has shown 
to yield prognostic and predictive models in breast cancer
137-139
. The level of expression of 
various genes is determined, which results in a number of differentially expressed genes, 
which can classify patients into a poor-prognosis and good-prognosis group. Gene expression 
profiles have also shown a correlation with response to therapy. However it is likely that in 
the metastatic setting, molecular characterization of CTCs better represents tumor genetics 
than of primary tumors. Studies have shown that expression of clinically relevant markers 
such as ER, PR and HER2 can differ between the primary tumor and its metastases
80,140
. For 
HER2, nearly one-third of patients whose primary tumor was HER2 negative, had amplified 
HER2 on CTCs
80
. Furthermore, tumor characteristics may change over time under pressure 
of therapy. In a preliminary report, 27% of patients with HER2-negative primary tumors 
acquired HER2 overexpression during the course of chemotherapy
41
. Among 23 patients 
obtaining less than a pathologic complete response on neoadjuvant chemotherapy with 
concomitant trastuzumab, 7 (30.4%) had HER2-negative residual tumors at surgery
141
. It is 
likely that when the metastatic tumor cells gain or lose such important markers, treatment 
should change accordingly. Prospective studies should clarify whether it is indeed of benefit, 
for example, to start trastuzumab therapy when the CTCs of a prior HER2-negative primary 
tumor do express HER2. A predictive and prognostic gene expression model for CTCs could 
be of great help to the oncologist in making treatment decisions as the disease progresses. 
In addition, comparison of molecular profiles of primary tumors to CTCs may provide better 
insight into those mechanisms involved in dissemination. Tumor cells are thought to lose 
and/or gain specific gene expression as they evolve to enter the circulation and proliferate in 
a target organ. Identifying these changes in gene expression for each point in the evolution 
toward overt metastasis could improve our understanding of the metastatic cascade. 
In conclusion, several assays enabling the detection and enumeration of circulating tumor 
cells in breast cancer have been introduced during the past 10 years. With some of these, 
already promising results with potential clinical relevance have been obtained. If confirmed, 
this may pave the way for the introduction of such assays in daily clinical care.  However, 
much is still uncertain in this field and in particular consensus is required on the most 
optimal assays for CTC detection. In addition to enumeration, characterization of CTCs forms 
 38 Chapter 2 
an interesting possibility to clarify the metastatic cascade and to improve prognostic and 
predictive models enabling more individualized treatment of breast cancer patients.
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Figure 1: see section ‘Color figures’
Figure 2: see section ‘Color figures’

Chapter 3
Detection of circulating tumor cells in breast cancer may 
improve through enrichment with anti-CD146
Bianca Mostert, Jaco Kraan, Joan Bolt-de Vries, 
Petra van der Spoel, Anieta M. Sieuwerts, Mieke Schutte, 
Annemieke M. Timmermans, Renée Foekens, John W.M. Martens, 
Jan W. Gratama, John A. Foekens, Stefan Sleijfer
Breast Cancer Research and Treatment 2010; 127(1): 33–41

ABSTRACT
Most assays to detect circulating tumor cells (CTCs) rely on EpCAM expression on tumor cells. 
Recently, our group reported that in contrast to other molecular breast cancer subtypes, 
“normal-like” cell lines lack EpCAM expression and are thus missed when CTCs are captured 
with EpCAM-based technology
64
. Here, the use of CD146 is introduced to detect EpCAM-
negative CTCs, thereby improving CTC detection.
CD146 and EpCAM expression were assessed in our panel of 41 breast cancer cell lines. 
Cells from 14 cell lines, 9 of which normal-like, were spiked into healthy donor blood. Using 
CellSearch® technology, 7.5 mL whole blood was enriched for CTCs by adding ferrofluids loaded 
with antibodies against EpCAM and/or CD146 followed by staining for Cytokeratin and DAPI. 
Hematopoietic cells and circulating endothelial cells (CECs) were counterstained with CD45 
and CD34, respectively. A similar approach was applied for blood samples of 20 advanced 
breast cancer patients.
Eight of 9 normal-like breast cancer cell lines lacked EpCAM expression but did express CD146. 
Five of these 8 could be adequately recovered by anti-CD146 ferrofluids. Of 20 advanced breast 
cancer patients whose CTCs were enumerated with anti-EpCAM and anti-CD146 ferrofluids, 9 
had CD146+ CTCs. 
Cells from breast cancer cell lines that lack EpCAM expression frequently express CD146 and 
can be recovered by anti-CD146 ferrofluids. CD146+ CTCs are present in the peripheral blood 
of breast cancer patients with advanced disease. Combined use of anti-CD146 and anti-EpCAM 
is likely to improve CTC detection in breast cancer patients.
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INTRODUCTION
The enumeration of circulating tumor cells (CTCs) in the peripheral blood of cancer patients 
is a promising tool to detect and monitor cancer earlier and less invasively than conventional 
methods
218-219
. In recent years, several assays to detect CTCs have been introduced
219
. CTCs 
measured with the FDA-approved CellSearch technique (Veridex™, Raritan, NJ) have prognostic 
value in metastatic breast cancer
25-26
 and changes in CTC counts during systemic therapy can 
serve as early marker for response
25-26,35,67
.
Like most CTC detection assays in breast cancer, the CellSearch technique relies on EpCAM 
(epithelial cell adhesion molecule, CD326) expression on tumor cells. However, despite its 
robustness and proven clinical relevance, CellSearch identifies CTCs in only 60% of metastatic 
breast cancer patients
25
. There are two possible explanations for this; CTCs are simply not 
present, or they cannot be detected by this assay. 
In breast cancer, five different molecular subtypes have been identified
220
. Recently, our group 
reported that in contrast to the other molecular subtypes, most normal-like breast cancer 
cell lines lack EpCAM expression and are missed using CellSearch technology
64
. Normal-like 
breast cancer accounted for 7.8% of all breast cancers in 344 breast cancer samples
221
 thus 
forming a substantial breast cancer subgroup. In accordance with our preclinical findings
222
, 
Spizzo et al., showed that 10.3% of 1715 invasive breast cancer patient samples lacked EpCAM 
expression
223
. 
Using the lack of EpCAM expression on a subset of breast cancer cells as a model for EpCAM-
negative CTCs, we embarked on a search for additional markers, ultimately aiming to improve 
CTC detection in all breast cancer patients, irrespective of the molecular subtype of their 
primary tumor. As a first attempt, CD146 was our marker of choice, based on our gene 
expression data
64
, availability of anti-CD146 ferrofluids, and a recent study by Zabouo et al
224,
 
who showed that CD146 is expressed in a subset of primary breast cancers and is correlated 
with poor prognosis.
METHODS
Breast cancer cell lines
In order to identify an additional marker expressed on EpCAM-negative breast cancer cells, we 
used our well-defined panel of 41 human breast cancer cell lines 
225-226
. The intrinsic subtype 
of these cell lines has been determined by gene expression profiling previously
64
.
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CD146 mRNA expression levels
The transcript levels of the 41 cell lines were determined with Affymetrix GeneChip Exon 1.0 
ST Arrays (Affymetrix UK Ltd., Wooburn Green, UK) as described previously
226
. Additionally, 
expression of CD146 was determined by real-time reverse transcriptase PCR. RNA was isolated 
from breast cancer cell lines with the RNeasy (Micro) kit (Qiagen, Valencia, CA). cDNA was 
prepared with the Superscript II RNase H-kit (Invitrogen, Carlsbad, CA). The resulting cDNA 
preparations were analyzed by real-time PCR in a 20 μL reaction volume in a MX3000P
TM 
Real-Time PCR System (Agilent/Stratagene, Amsterdam, The Netherlands), using TaqMan™ 
Gene Expression Assays in combination with TaqMan Universal PCR Master Mix No AmpErase 
UNG (Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. Levels 
of hydroxymethylbilane (HMBS), hypoxanthine phosphoribosyltransferase 1 (HPRT1) and 
glucuronidase, beta (GUSB) were used to control sample loading and RNA quality.
CD146 protein expression levels
Cells from cultured human breast cancer cell lines were incubated with fluorochrome-
conjugated monoclonal antibodies and presence of antigens was assessed as described 
before
64
. In brief, cells were incubated with CD34 conjugated with FITC (clone 8G12; BD 
Biosciences, San Jose, CA), CD146 conjugated with PE (clone P1H12; BD Biosciences) and anti-
EpCAM conjugated with FITC (clone EBA-1; BD Biosciences). Cells were then analyzed on a 
FACSCanto flow cytometer (BD Biosciences). Unstained cells were used as a negative control.
Tissue microarrays (TMAs) were prepared in duplicate from blocks of 37 formalin-fixed, 
paraffin-embedded (FFPE) breast cancer cell line cells that were cultured to near confluence 
in complete growth medium, and from blocks of 206 FFPE primary breast cancer specimens. 
These blocks and 23 FFPE normal-like primary breast cancer specimens were sectioned at 4 
µm, mounted on StarFrost slides (Waldemar Knittel–GmbH, Braunschweig, Germany), dried, 
deparaffinized in xylene and rehydrated in graded solutions of ethanol and distilled water. 
Specimens were pretreated with retrieval buffer (DAKO, Glostrup, Denmark) at pH 6.0 for 
CD146 and pH 9.0 for CD34 for 40 min at 95-99°C in a water bath, cooled to room temperature 
for 20 min and rinsed in phosphate-buffered NaCL solution (PBS). This was followed by a 10-
min blocking step with a 0.3% peroxide PBS solution and a 30-min blocking step with a 5% 
bovine serum albumin PBS solution. Slides were stained with monoclonal antibodies against 
CD146 (Abcam, Cambridge, UK, N1238) and CD34 (Neomarkers, Fremont, CA, clone QBE) and 
counterstained with the peroxidase-conjugated Envision technique (DAKO EnVision™+ System, 
HRP). Each core was scored by a well-trained technician and positive staining was recorded as 
100%, 50 - 99%, 25 - 50%, 10 - 25%, 0 - 10% or 0% number of positive cells.
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Enumeration of epithelial cells spiked in whole blood
Blood samples containing EDTA (7.5 mL aliquots of blood) from a single healthy male donor 
were obtained from CellSave Preservative Tubes (Veridex). To each sample, a predefined 
amount (50 - 500) of cultured human breast cancer cells was added. To determine the actual 
viable cell number, a 100-μL aliquot of the cultured cells was incubated with 10 μL of 7AAD 
(Sigma-Aldrich, St. Louis, MO) and 100 μL of fluorescent beads (Beckman-Coulter, Miami, 
FL). After 15 min incubation at room temperature, 2 mL PBS was added, and samples were 
analyzed on a FACSCalibur flow cytometer (BD Biosciences). At least 10,000 beads were 
acquired to estimate the number of 7AAD-negative (viable) cells. The efficiency of retrieving 
the tumor cells was controlled by counting the number of viable cells that were drawn in 
triplicate by light microscopy after serial dilution. 
To establish the number of recovered CTCs following spiking into blood from a healthy donor, 
samples were processed on the CellTracks AutoPrep analyzer (Veridex) with the CellSearch 
Epithelial Cell kit (Veridex). Briefly, ferrofluids coated with antibodies directed towards 
EpCAM were added to a blood sample, and CTCs bound to anti-EpCAM coupled ferrofluid 
were isolated from whole blood by magnets. Unbound cells and the remaining plasma were 
aspirated, followed by staining of the isolated cells with the nuclear dye 4’,6-diamidino-
2-phenylindole (DAPI), anti-cytokeratin 8, 18 and 19 antibodies labeled with PE and CD45 
antibodies labeled with APC. After incubation, CTCs were separated magnetically once 
more and unbound staining reagents removed. Finally, the cells were resuspended in a 
MagNest Cell Presentation Device (Veridex). In this device, labeled cells are oriented by two 
magnets for analysis in the CellSpotter Analyzer (Veridex) after which the number of CTCs are 
enumerated according to the manufacturer’s instructions.
For the detection of cells expressing CD146, anti-CD146 ferrofluid from the CellSearch 
Circulating Endothelial Cell kit (Veridex) was used in a volume of 150 µL per sample plus 
an excess volume of 300 µL. The sample was enriched for CD146-positive cells and further 
characterized by staining for the presence or absence of DAPI, cytokeratin 8, 18 or 19 and CD45 
as provided in the CellSearch Epithelial Cell kit. As CD146 enriches for circulating endothelial 
cells (CECs)
227
, and CECs can express cytokeratin 18
228
, a marker to exclude the cytokeratin 
18-expressing subset of CECs was needed. As CD34 is a pan-endothelial marker
229
, CD34 
conjugated with FITC (clone 8G12; BD Biosciences) was added to the CellSearch Epithelial 
Cell kit, in a volume of 150 µL per sample plus an excess volume of 300 µL. The number of 
CTCs was determined on the CellSpotter Analyzer (Veridex) according to the manufacturer’s 
instructions. CD146+ CTCs were defined as DAPI+/CK+/CD45-/CD34-. 
For combined anti-EpCAM and anti-CD146 enrichment, anti-EpCAM ferrofluids from the 
CellSearch Circulating Epithelial Cell kit and anti-CD146 ferrofluids from the CellSearch 
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Circulating Endothelial Cell kit were combined in even parts to a total volume of 150 µL 
per sample plus an excess volume of 300 µL. The number of CTCs in samples enriched for 
CD146-expressing and EpCAM-expressing events was determined and defined as mentioned 
above. 
The pivotal differences between the classic CellSearch CTC enumeration assay and the new 
combined anti-EpCAM/anti-CD146 assay are highlighted in Figure 1.
Blood samples
Blood samples were obtained from a laboratory volunteer and patients with metastatic 
breast cancer seen at the outpatient clinic. For each patient, 22.5 mL of blood was drawn into 
CellSave tubes and CTCs were enumerated after enrichment using anti-EpCAM, anti-CD146 
and mixed anti-EpCAM/anti-CD146 ferrofluids, using 7.5 mL of blood for each enrichment 
method.
Additionally, 10 healthy female donors (age 23 - 56) were tested for CD146+ events by 
enumerating CTCs in 7.5 mL blood after enrichment with anti-CD146 ferrofluids.
This study was approved by the Erasmus MC Institutional Review Board (METC protocol 
2006-248), and all donors and patients gave their written informed consent.
RESULTS
Breast cancer cell lines
As previously reported, our cell line panel consists of 10 normal-like, 5 basal-like, 5 erbb2 
and 21 luminal breast cancers as determined by gene expression profiling according to the 
intrinsic subtypes of Perou and Sorlie
64,226
. As the MDA-MB-435 normal-like cell line has been 
the subject of debate in literature recently with doubts about its origin
230-232
, we excluded 
this cell line from our experiments.
Candidate markers
We have previously shown that 8 out of these 9 cell lines lack EpCAM-expression
64
. Using 
these normal-like cell lines as a model for non-EpCAM expressing breast cancer, several 
candidate markers for the assessment of EpCAM-negative CTCs were identified by comparing 
gene expression data between molecular subtypes. Candidate markers required membrane 
expression of the proteins on the EpCAM-negative breast cancer cells and absence on 
hematopoietic cells, or, if present, hematopoietic cells expressing the marker should be easily 
excluded using additional markers. Several markers fulfilled these criteria, amongst which 
CAV1
64
, MUC1
64
 and MCAM (CD146). Given the availability of ferrofluids coated with CD146 
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antibodies
233
, and the possibility to exclude interference of expression by hematopoietic 
cells (by CD45-counterstaining) and CECs (by CD34-counterstaining), we chose to further 
explore this marker.
CD146 and EpCAM expression
Based on Affymetrix micro-array and qRT-PCR data, 7 out of the 9 normal-like cell lines 
expressed high levels of CD146 mRNA. In addition, one basal-like cell line, SUM149PT, 
expressed CD146, resulting in a total of 8 cell lines expressing CD146 mRNA (Table 1).
As previously reported
64
, we confirmed that cells from only 1 of the 9 normal-like cell lines 
(MDA-MB-157) expressed EpCAM (Table 1 and Figure 2a). Evaluation of CD146 expression by 
flow cytometry showed that 8 of the 9 normal-like cell lines had CD146 membrane expression 
at a level likely to be detected using CellSearch technology (i.e., a signal to noise ratio >5) 
(Table 1 and Figure 2a). Remarkably, cells from an early passage of the MDA-MB-157 cell 
line were CD146–positive, while cells from a later passage showed a CD146-positive and a 
CD146-negative population. In addition to these normal-like cell lines, two of 5 basal-like cell 
lines (SUM149 and SUM229) expressed both CD146 and EpCAM (Table 1 and Figure 2b). 
To obtain an overview of CD146 expression across all different breast cancer subtypes, CD146 
expression was determined by immunohistochemistry on a TMA of 37 breast cancer cell 
lines. A total of 17 cell lines stained positive for CD146, among which 8 were normal-likes, 2 
basal-like, 4 luminal and 3 erbb2 cell lines. Most cell lines staining positive for CD146 showed 
a heterogeneous expression pattern (Figure 3a).
CD146 staining was also performed in a set of 23 normal-like primary breast tumors, 7 of 
which stained positive for CD146 on epithelial cells (Figure 3b).
CD34 to distinguish CTCs from CECs
The expression of CD146 on activated T-lymphocytes
234
 and CECs
235
 might interfere with 
the detection of CD146-positive CTCs. While leukocytes can be excluded with CD45, which 
is already incorporated in the standard CellSearch Circulating Epithelial Cell kit, we assessed 
whether CECs could be excluded with CD34, a pan-endothelial marker
227,229
. CD34 proved 
to be a suitable marker to distinguish CTCs from CECs, as none of the normal-like cell lines 
expressed CD34 as determined by flow cytometry (Table 1). In addition, CD34 staining was 
completely negative on a TMA containing 37 breast cancer cell lines (data not shown). CD34 
staining on 206 primary breast tumors showed less than 10% CD34-positivity in only one 
tumor specimen, all other tumors were entirely CD34 negative.
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EpCAM-negative breast cancer cells detected with anti-CD146 ferrofluids 
To test whether EpCAM-negative breast cancer cells could be detected in healthy donor 
blood using CellSearch with anti-CD146 ferrofluids, a fixed number of cells from normal-
like and basal-like cell lines was spiked into 7.5 mL healthy donor blood of the same donor 
(Figure 4b). As a control, a fixed number of luminal cells (CAMA-1) was spiked into 7.5 mL 
healthy donor blood (Figure 4b, bottom bar).
As previously reported
64
, cells from 7 out of 9 normal-like cell lines could not be recovered 
with anti-EpCAM ferrofluids while cells from 1 of the other 2 normal-like cell lines (MDA-
MB-231, Figure 4b) were partially detected (11%). Cells from the remaining cell line, MDA-
MB-157, could be adequately recovered with anti-EpCAM ferrofluids, consistent with its 
EpCAM-expression. Of the 8 cell lines insufficiently recovered with anti-EpCAM, 5 could 
be detected with anti-CD146 (45 - 88% recovery). Additionally, the EpCAM-expressing cell 
line MDA-MB-157 was partially detected by anti-CD146 (11% recovery). After enrichment 
with mixed anti-EpCAM/anti-CD146 ferrofluids, cells from 6/9 normal-like cell lines were 
recovered at rates of 46 to 100%. Despite CD146 expression, cells from 3 normal-like cell 
lines could not be recovered (Figure 4b).
Cells of the luminal cell line CAMA-1 were detected with a recovery approaching 100% 
using anti-EpCAM ferrofluids. Enrichment with anti-CD146 ferrofluids alone did not result 
in recovery of CAMA-1 cells. The combined use of anti-CD146 and anti-EpCAM ferrofluids 
still enabled detection of all spiked CAMA-1 cells (Figure 4b), suggesting that mixing both 
ferrofluids does not greatly compromise enrichment. In accordance, 2 basal-like cell lines 
expressing EpCAM and CD146 could be detected with both anti-EpCAM and anti-CD146 
ferrofluids as well as with a mixture of both (Figure 4b). 
CD146+ cells in healthy donors
In all blood samples from 10 healthy female donors and a healthy male donor enriched with 
anti-CD146 ferrofluids, either in mixture or alone, a small number of CD146+/CK+/DAPI+/
CD45-/CD34+ cells was identified (median 1, range 0 - 7), most likely accounting for a subset 
of CECs from the healthy donors
236
. In none of the healthy donors, CD146-expressing tumor 
cells, i.e., CD146+/CK+/DAPI+/CD34- cells, could be identified (data not shown). 
CD146+ CTCs in breast cancer patients
To assess whether CD146-expressing CTCs do occur in breast cancer, CTCs were enumerated 
in 20 advanced breast cancer patients using anti-EpCAM, anti-CD146 and mixed ferrofluids. 
Of these 20 patients, 9 had CD146+ CTCs (Table 2). As expected, given the heterogeneity of 
breast cancer and the fact that some breast cancer cell lines express both EpCAM and CD146, 
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8 of these 9 CD146+ patients also had EpCAM+ CTCs. Enrichment with mixed ferrofluids 
yielded a higher CTC number compared to EpCAM enrichment alone in 8 patients (Table 2, 
patients 1, 2, 7, 9, 12. 13, 14 and 20). In six patients (Table 2, patients 4, 5, 15, 17, 18 and 19), 
the combined enrichment for CD146 and EpCAM resulted in a lower recovery of CTCs. In this 
small series of patients, CD146+ CTCs were present in patients with both hormone receptor 
positive and hormone receptor negative primary tumors.
DISCUSSION
CTC detection with the CellSearch assay has proven its value as a prognostic marker in 
metastatic breast cancer
25-26
. Additionally, a change in CTC numbers at first follow-up of 
therapy is associated with outcome
32,34-35,237
. Nevertheless, CTCs can be detected in only 60% 
of the metastatic breast cancer patients, suggesting that there is room for improvement in 
the CellSearch assay. As enrichment for EpCAM is the limiting first step in this and many other 
CTC enumeration assays, EpCAM expression on tumor cells is pivotal. However, evidence is 
accumulating that EpCAM is not a perfect marker for breast cancer CTCs
64,221-222
.
In this study we demonstrated that CD146 is frequently present on EpCAM-negative breast 
cancer cell lines. CD146 is ubiquitously expressed on endothelial cells
238
 and melanoma 
cells
239
. A correlation with poor prognosis has recently been found in breast cancer; of 635 
primary breast tumors, 7% were CD146-positive, and CD146 expression was associated with 
poor prognosis
224
. Our finding that CD146 is present on EpCAM-negative breast cancer cell 
lines renders it a putative marker to detect EpCAM-negative CTCs. Expression of CD146 by 
other cells in blood such as CECs could hinder detection of CTCs. We found that the exclusion 
of CK+/DAPI+/CD45-/CD34+ events after anti-CD146 enrichment resulted in CTC-negative 
test results in healthy donors. Hematopoietic cells expressing CD146, such as activated 
T-lymphocytes
240
 and NK-cells
241
, can be identified according to their bright expression of 
CD45. 
Using the definition of CD146+/CK+/DAPI+/CD45-/CD34- for CD146-positive CTCs we were 
able to detect cells from five out of eight normal-like cell lines when spiked in healthy blood. 
For the remaining three cell lines, for which detection is limited despite CD146 expression, 
the assay may need further improvement, for instance by adding an additional enrichment 
or positive selection marker, such as different cytokeratins.
In the clinical setting, both EpCAM-positive and EpCAM-negative tumor cells are likely to 
be present in the blood of patients, given the heterogeneity in terms of EpCAM expression 
within primary tumors
222
. As a consequence, one can imagine EpCAM-negative CTCs in 
patients with a primary tumor that is predominantly comprised of EpCAM-positive cells and 
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vice versa. Although we mostly observed CD146 expression in breast cancer cell lines with 
a normal-like subtype, the added value of CD146 is probably not limited to patients with 
normal-like primary tumors. CD146+ CTCs can be present in other patients too, as shown by 
the detection of CD146+ CTCs in patients with hormone receptor positive primary tumors, 
due to tumor heterogeneity or clonal selection during progression. Improved CTC detection 
in breast cancer using combined anti-CD146 and anti-EpCAM enrichment may be of value 
irrespective of the molecular subtype of the primary tumor.
To determine whether CD146-expressing CTCs are present in breast cancer patients, CTCs 
were captured with anti-EpCAM, anti-CD146 alone and a mixture of ferrofluids in twenty 
patients with advanced disease. Besides EpCAM-positive CTCs, CD146-positive CTCs were 
detected in 9 patients. In contrast, no CD146-expressing CTCs could be detected in healthy 
female controls. Although in a small series of patients, in line with the assumption that the 
combination of anti-EpCAM and anti-CD146 enrichment might improve CTC detection, a 
higher CTC count was found in 8 out of 20 patients when combining anti-EpCAM and anti-
CD146 ferrofluids. However, a lower recovery was found in 6 patients using this approach. 
Whether this is due to technical reasons, such as suboptimal concentrations of the ferrofluids, 
should be evaluated before implementation into clinical studies. Importantly, the application 
of CD146 as an additional marker to detect CTCs is not restricted to the CellSearch assay 
alone, but may be useful for all assays depending on EpCAM-expression on the target cells.
Although based on a relatively small series of patients, the EpCAM-positive CTCs seem to 
outnumber the CD146-expressing CTCs. Nonetheless, even if CD146+ CTCs occur in only a 
small subset of patients, and may be of limited clinical relevance, minimizing false negative 
results is crucial for diagnostic purposes. Studies are being initiated to determine the exact 
incidence of CD146-positive CTCs in breast cancer patients and to reveal their clinical 
relevance.
In conclusion, we have shown that the majority of EpCAM-negative breast cancer cell lines can 
be detected using anti-CD146 ferrofluids. Furthermore, CD146-positive CTCs are present in 
breast cancer patients. It must be stressed that the clinical relevance of CD146-positive CTCs 
remains to be established, and whether the prognostic value of CD146+ CTCs is equivalent to 
that of EpCAM+ CTCs will be determined in a large clinical study. Nevertheless, the detection 
of CTCs, although already well established in metastatic breast cancer, can become even 
more relevant when detecting EpCAM-positive as well as CD146-positive CTCs.
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Table	  2	   	   	   	   	   	   	   	  
CTC	  counts	  with	  anti-­‐EpCAM,	  anti-­‐CD146	  and	  mixed	  anti-­‐EpCAM/CD146	  ferrofluids	  for	  10	  
advanced	  breast	  cancer	  patients,	  and	  their	  primary	  tumor	  characteristics	  
	   Primary	  tumor	  characteristics	   	   CTC	  count	  
Patient	  
number	  
ERa	   PRb	   Her2	   	  
EpCAM+	   CD146+	  
EpCAM/	  
CD146+	  
	   	   	   	   	   	   	   	  1	   +	   +	   -­‐	   	   15	   1	   17	  
2	   +	   -­‐	   +	   	   19	   1	   25	  
3	   +	   -­‐	   -­‐	   	   0	   4	   1	  
4	   +	   +	   -­‐	   	   38	   5	   20	  
5	   +	   +	   -­‐	   	   47	   2	   30	  
6	   +	   +	   NA	   	   2	   1	   1	  
7	   -­‐	   +	   -­‐	   	   28	   5	   40	  
8	   +	   NA	   +	   	   0	   0	   0	  
9	   +	   -­‐	   -­‐	   	   54	   0	   75	  
10	   +	   +	   -­‐	   	   0	   0	   0	  
11	   +	   +	   -­‐	   	   0	   0	   0	  
12	   +	   +	   -­‐	   	   0	   0	   1	  
13	   +	   +	   -­‐	   	   0	   0	   1	  
14	   +	   +	   -­‐	   	   1	   0	   2	  
15	   +	   +	   NA	   	   2	   0	   1	  
16	   -­‐	   -­‐	   NA	   	   0	   0	   0	  
17	   +	   +	   -­‐	   	   19	   0	   11	  
18	   +	   +	   -­‐	   	   155	   24	   148	  
19	   +	   +	   -­‐	   	   107	   3	   94	  
20	   +	   +	   -­‐	   	   0	   0	   1	  
	   	   	   	   	   	   	   	  
aER;	  estrogen	  receptor,	  bPR;	  progesterone	  receptor,	  NA;	  not	  available	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Figure 1
Setup of the CellSearch CTC enumeration assay (left column) versus the new anti-EpCAM/anti-CD146 
assay (right column). Description of the makers used in each assay for enrichment, positive selection 
and negative selection, and the cell type associated with these selection criteria. CK; cytokeratin
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7.5 mL whole blood
anti-EpCam ferrofluid anti-EpCAM + 
anti-CD146 ferrofluid
enrichment
CK 8/18/19+
DAPI+
CK 8/18/19+ 
DAPI+
positive 
selection
negative 
selection
cell type
CD45+ CD45-
leukocyte CTC
CD45+ CD34+ CD45- 
CD34-
leukocyte CEC CTC
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Figure 2
EpCAM and CD146 membrane 
expression as assessed by 
flowcytometry. Black histograms 
show unstained cells, grey 
histograms show expression on 
EpCAM-stained cells (left panel) and 
CD146 stained cells (right panel) of 
normal-like a and basal-like b cell 
lines. X-axis; fluorescence intensity; 
Y-axis; number of counted cells
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a.      b. 
Figure 3: see section ‘Color figures’
Figure 4
EpCAM and CD146 membrane expression in normal-like n, basal b and luminal l cell lines a, and recovery 
of these cell lines b. a Open bar EpCAM membrane expression, closed bar CD146 membrane expression, 
s/n; signal-to-noise ratio, s/n >5 considered detectable expression. b Open bar recovery with anti-EpCAM 
ferrofluids, closed bar recovery with anti-CD146 ferrofluids, hatched bar recovery with anti-EpCAM/anti-
CD146 ferrofluids
0 20 40 60 80 100 
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CD49f-based selection of circulating tumor cells 
(CTCs) improves detection across breast cancer 
intrinsic subtypes
Bianca Mostert, Jaco Kraan, Anieta M. Sieuwerts, 
Petra van der Spoel, Joan Bolt-de Vries, 
Wendy J.C. Prager-van der Smissen, Marcel Smid, 
Annemieke M. Timmermans, John W.M. Martens, 
Jan W. Gratama, John A. Foekens, Stefan Sleijfer
Cancer Lett 2011; 319(1): 49-55

ABSTRACT
Circulating tumor cells (CTCs) can be enumerated using CellSearch, but not all breast cancer 
subtypes, specifically those with epithelial-mesenchymal transition (EMT) characteristics, 
sufficiently express the enrichment (EpCAM) and selection (CK8/18/19) markers used in 
this method. While CD146 can detect EpCAM-negative CTCs, we here evaluated the value of 
various cytokeratins and CD49f to detect CK8/18/19-negative CTCs. The tested cytokeratins 
provided no substantial benefit, but adding CD49f to CK8/18/19 as a selection marker resulted 
in improved recovery of normal-like cell lines.
Combined staining of CK8/18/19 and CD49f after CD146/EpCAM enrichment is likely to further 
improve CTC detection in breast cancer.
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INTRODUCTION
In recent years, numerous assays for the detection of circulating tumor cells (CTCs) have been 
described
219
. One of these is the CellSearch® technique (Veridex™ LCC, Raritan, NJ), the only 
FDA-approved method to detect CTCs based on their prognostic value in metastatic breast
25,
 
colorectal
29
 and prostate cancer
31
. The CellSearch technique consists of an EpCAM-based 
immunomagnetic enrichment step, followed by selection of CTCs based on cytokeratin (CK) 
8/18/19 and 4,6-diamidino-2-phenylindole (DAPI) nuclear expression, and absence of the 
pan-leukocyte marker CD45. While CTCs according to this definition are present in 60% of 
metastatic breast cancer patients
8
, we have recently shown that breast cancer cell lines of the 
normal-like type - one of the five intrinsic subtypes of breast cancer
242
 - lack EpCAM expression. 
Consequently, CTCs of this subtype are missed when using the standard CellSearch method
64
. 
The normal-like subtype has been the subject of heavy debates regarding its characteristics, 
and has recently also been described as Claudin-low, characterized by low expression of the 
epithelial markers CD24 and EpCAM, and high expression of CD44 and CD49f
243
. Epithelial 
markers have been shown to be down regulated in circulating and disseminated tumor cells 
in the context of EMT, a process which tumor cells are thought to undergo upon entering the 
blood stream
11,244
. Evidence of EMT in CTCs, showing stem cell-like features rendering them 
resistant to chemotherapy, has recently been reported
245-249
. This loss of epithelial markers has 
been associated with the process of metastasis and poor prognosis
10-12
, and tumors harboring 
more mesenchymal features frequently exhibit drug resistance. The detection of CTCs lacking 
epithelial markers may therefore be of crucial clinical importance.
Following up on the subtype-specific expression of EpCAM in vitro
64
, we identified CD146 to 
be highly expressed on normal-like breast cancer cell lines, and showed that the combined 
enrichment of CTCs with anti-EpCAM and anti-CD146 ferrofluids improves breast cancer cell 
detection
250
. Additionally, CD146-positive CTCs were identified in the blood of metastatic 
breast cancer patients
250
, and we are currently undertaking a clinical study in primary breast 
cancer patients in whom both EpCAM and CD146-positive CTCs are enumerated to establish 
the clinical relevance of these cells. Despite high CD146 expression in most cell lines with EMT 
features, a subset of cell lines was still not optimally recovered after combined CD146/EpCAM 
enrichment followed by selection based on CK8/18/19 expression
250
. We hypothesized this 
insufficient recovery to be due to lack of CK8/18/19 expression, which is a prerequisite for 
identification of CTCs in CellSearch, but also in other CTC detection methods
59,131
. CK expression 
is known to be heterogeneous among breast cancer subtypes; basal-likes commonly express 
CK5, 6, 14 and 17, luminals CK8, 18 and 19, and normal-likes often have low expression of all 
CKs
220,251-252
. 
In addition to examining the added value of selecting cancer cells with a broader array of 
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CKs, we tested CD49f (ITGA6; integrin, alpha 6) as an alternative selection marker. CD49f is an 
integral cell-surface protein involved in cell adhesion which has also been described as a stem 
cell marker in breast cancer
253-256
, making it a candidate to select EMT-like breast cancer cells 
with stem cell-like features.
In this study, we set out to identify a new additional marker to be used after capturing of 
breast cancer cells with combined anti-CD146/anti-EpCAM ferrofluids, in order to detect those 
cancer cells that lack CK8/18/19 expression.
MATERIALS & METHODS
Breast cancer cell lines
Expression of putative markers was assessed on the 34 cell lines of our well-defined human 
breast cancer cell line panel
225,257
. These cell lines have been analyzed for their global gene 
expression to reveal their intrinsic subtype as described previously
258
. The normal-like cell line 
MDA-MB-435s has been the subject of debate on its origin
231
, some researchers suggesting that 
it is in fact a melanoma cell line. Recently however, compelling evidence has been presented 
on its breast cancer origin
232,259
, justifying its presence in our cell line panel.
CD49f and CK mRNA expression levels
Cell line CK and CD49f transcript levels were determined with Affymetrix GeneChip Human 
Exon 1.0 ST Arrays (Affymetrix UK Ltd., Wooburn Green, UK) and confirmed by qRT-PCR. 
Total RNA was isolated using the Qiagen RNeasy kit and quality was assessed using the 
Agilent Bioanalyser, requiring RNA integrity >7.0. All further processing of the samples was 
performed according to the Affymetrix GeneChip Whole Transcript (WT) Sense Target Labeling 
Assay as described before
258
. Briefly, Affymetrix GeneChip Human Exon 1.0 ST Arrays were 
used to determine the expression levels of virtually all exons present in the human genome 
(1.4 million probe sets covering >1 million exon clusters). For this study, we used expression 
data of the core probe sets of the transcript clusters as mentioned in Supplementary Table 1 
that are supported by putative full-length mRNA from e.g. the RefSeq database (Geo dataset 
accession number GSE9385). Signal processing was performed as described before, followed 
by an additional normalization on the average of the core probes of three reference genes, 
HBMS, HPRT1 and GUSB. 
CD49f and CK protein expression levels
Cells from cultured human breast cancer cell lines were incubated with fluorochrome-
conjugated monoclonal antibodies as described before
64
. In brief, cells were incubated with 
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CD49f conjugated with PE (clone GoH3, BD Pharmingen, San Jose, CA), CK5 (Clone XM26 
[Monosan, Uden, Netherlands]), CK7 (clone OV-TL 12/30 [Millipore, Billerica, MA]), CK14 
(clone LL002 [Monosan]), panCK conjugated with PE (clone C-11 [Abcam, Cambridge, UK]) 
and a mixture as provided by the manufacturer of CK8/18 (clone C11) and CK19 (clone A53-B/
A2) conjugated with PE (Veridex). For CK5, CK7 and CK14, a goat anti-mouse Ig labeled with PE 
was added as a second step. CK staining was preceded by a fixation and permeabilization step, 
using the fixation and permeabilization reagents as provided in the CellSearch Epithelial Cell 
kit. Cells were then analyzed on a FACSCanto flow cytometer (BD Biosciences). Unstained cells 
were used as a negative control. 
Tissue microarrays (TMAs) were prepared in duplicate from blocks of formalin-fixed, paraffin-
embedded (FFPE) breast cancer cell line cells that were cultured to near confluence, as described 
before
226
. These blocks were sectioned at 4 μm, mounted on StarFrost slides (Waldemar 
Knittel–GmbH, Braunschweig, Germany), dried, deparaffinized in xylene, and rehydrated in 
graded solutions of ethanol and distilled water. Specimens were pre-treated with retrieval 
buffer (DAKO, Glostrup, Denmark) at pH 6.0  (S1699) for CD49f, CK5, CK14 and pH 9 (S2367) 
for CK8/18 and CK19 for 40 min at 95–99°C in a water bath, cooled to room temperature 
for 20 min and rinsed in phosphate buffered NaCl solution (PBS). This was followed by a 10-
min blocking step with a 0.3% peroxide PBS solution and a 30-min blocking step with a 5% 
bovine serum albumin PBS solution. Slides were stained with monoclonal antibodies against 
CK5 (1:100, clone XM26 [Monosan, Uden, Netherlands]), CK8/18 (1:100, clone 5D3 [Thermo 
Fisher Scientific, Waltham, MA]), CK14 (1:20, clone LL002 [Monosan]), CK19 (1:50, clone 
RCK108 [DAKO]) and CD49f (1:500, clone GoH3 [Abcam]) and stained with the peroxidase-
conjugated Envision technique (DAKO EnVision™ System, HRP). Nuclei were counterstained 
with Haematoxylin. Each core was scored as 50 – 100% (++++), 25 – 50% (+++), 10 – 25% (++), 
0 – 10% (+), or 0% (-) of positive cells.
Enumeration of cell line cells spiked in whole blood
Blood samples containing EDTA (7.5 mL aliquots of blood) from healthy donors were obtained 
from CellSave Preservative Tubes (Veridex). A predefined number of 500 cultured human breast 
cancer cells was added to each sample. In order to determine the actual viable cell number, a 
100 μL aliquot of the cultured cells was incubated with 10 μL of 7-Aminoactinomycin D (7AAD) 
(Sigma-Aldrich, St. Louis, MO) and 100 μL of fluorescent beads (Beckman-Coulter, Miami, 
FL). After 15 min incubation at room temperature, 2 mL PBS was added, and samples were 
analyzed on a FACSCalibur flow cytometer (BD Biosciences) or a FACSCanto flow cytometer (BD 
Biosciences). At least 10,000 beads were acquired to estimate the number of 7AAD-negative 
(viable) cells. The efficiency of retrieving tumor cells was controlled by counting the exact 
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number of viable cells that were drawn in triplicate by light microscopy after serial dilution. 
In order to establish the number of recovered breast cancer cells following spiking into blood 
from a healthy donor, samples were processed on the CellTracks AutoPrep analyzer (Veridex) 
with the CellSearch Epithelial Cell kit (Veridex), modified as described previously
250
. Briefly, for 
combined CD146 and EpCAM enrichment, EpCAM ferrofluids from the CellSearch Circulating 
Epithelial Cell kit and CD146 ferrofluids from the CellSearch Circulating Endothelial Cell kit were 
combined in even parts to a total volume of 150 μL per sample plus a standard excess volume 
of 300 μL. Ferrofluids coated with antibodies directed toward CD146 and EpCAM were added 
to the blood sample, and cancer cells bound to CD146/EpCAM coupled ferrofluid were isolated 
from whole blood by magnets. Unbound cells and remaining plasma were aspirated, followed 
by staining of the isolated cells with the nuclear dye DAPI, CK8, 18, and 19 antibodies labeled 
with PE and CD45 antibodies labeled with APC. As CD146 enriches for circulating endothelial 
cells (CECs)
227
, and CECs can express CK18
236
, a marker to exclude the CK18-expressing subset 
of CECs was needed. As CD34 is a pan-endothelial marker
229
, CD34 conjugated with FITC (clone 
8G12; BD Biosciences) was added to the CellSearch Epithelial Cell kit, in a volume of 150 μL per 
sample plus a standard excess volume of 300 μL. After incubation, cancer cells were separated 
magnetically once more in order to remove unbound staining reagents. Finally, the cells were 
resuspended in a MagNest Cell Presentation Device (Veridex), after which the number of 
cancer cells is enumerated according to the manufacturer’s instructions.
For the detection of cells expressing CD49f, equal parts of staining reagent containing anti-
CK8/18/19 conjugated to PE and CD45 conjugated to APC, and CD49f conjugated to PE were 
combined to a total volume of 150 μL per sample plus a standard excess volume of 300 μL. 
The sample was enriched for CD146 and/or EpCAM-positive cells and further characterized by 
staining for the presence or absence of DAPI, CK8/18/19 and CD45 as provided in the CellSearch 
Epithelial Cell kit and CD49f and CD34 as described above. Cancer cells were defined as DAPI+, 
CK8/18/19+/CD49f+, CD45-, CD34-. 
Blood samples
Blood samples for spiking experiments were obtained from laboratory volunteers. Additionally, 
six healthy donors (age 28 – 58) were tested for the presence of CD146/EpCAM+, CD49f+ 
events in 7.5 mL blood. This study was approved by the Erasmus MC Institutional Review Board 
(METC protocol 2007-333), and all healthy donors gave their written informed consent.
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RESULTS
CK8/18/19 expression
mRNA expression of KRT8 (CK8), KRT18 (CK18) and KRT19 (CK19) was determined in all 
34 cell lines in our well-defined breast cancer cell line panel using exon array (Table 1 and 
Supplementary Table 1). Generally, KRT8, KRT18 and KRT19 mRNA was expressed at the 
highest level in luminal cell lines, while the normal-like cell lines showed the lowest expression 
level of particularly KRT19.
Additionally, CK8/18/19 protein expression was determined by flowcytometry and 
immunohistochemistry (Table 1 and Figure 1). For flowcytometry, the standard mixture of 
CK8/18 and CK19 antibodies as provided as part of the CellSearch Epithelial Cell kit was used, 
whereas a separate anti-CK19 monoclonal antibody and a mixture of anti-CK8/18 monoclonal 
antibodies were used for immunohistochemistry. According to flowcytometry, normal- and 
basal-like cell lines showed weak to no expression of CK8/19/19 protein. Immunohistochemistry 
showed that, similar to mRNA expression data, the majority of normal-like cell lines particularly 
lacked CK19 protein expression and expressed variable CK8/18 levels.
CK5, 7 and 14 expression
According to literature and based on mRNA expression levels (Supplementary Table 1), CK5 
(KRT5), 7 (KRT7) and 14 (KRT14) are putative alternative CKs for cancer cells lacking CK8/18/19 
protein expression. However, the CK5, 7 and 14 protein expression assessed by flowcytometry 
and by immunohistochemistry was largely negative among normal- and basal-like cell lines 
(Table 1 and Supplementary Figure 1). 
PanCK expression and spiking experiments
PanCK is a monoclonal antibody targeted against CKs 4, 5, 6, 8, 10, 13 and 18. This combination 
of CKs provides coverage of all subtypes when looking at mRNA expression levels; normal- 
and basal-like cell lines express KRT5 (CK5), KRT6 (CK6) and KRT10 (CK10) and luminal and 
erbb2 cell lines express KRT8 (CK8) and KRT18 (CK18) (Supplementary Table 1). PanCK protein 
expression was indeed positive in five out of nine normal-like and all basal-like cell lines. 
Four cell lines, the normal-like MDA-MB-436, SUM159PT and MDA-MB-231 and the basal-
like SUM149PT, which all lacked CK8/18/19 protein expression, stained positive for panCK 
(Table 1 and Figure 1). Of these four CK8/18/19-negative cell lines, three (MDA-MB-436, 
SUM159PT and MDA-MB-231) were previously not completely detected with CK8/18/19 as a 
selection marker in the CellSearch assay
250
. 
We proceeded to directly compare the recovery of various cell lines using CK8/18/19 versus 
panCK as a selection marker (Figure 2, left and middle panel). Recovery results of tested 
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normal-like and control (MDA-MB-468) cell lines are depicted in Figure 3. Cell lines were 
selected based on their previous low recovery with CK8/18/19 as a selection marker after 
CD146/EpCAM enrichment
250
. No improvement in recovery rates was seen in any of the cell 
lines; BT549 and Hs578T were still almost completely undetected (0.4 vs. 0 and 0.6 vs. 1.2%, 
respectively), while SUM1315 and SUM159 remained at low detection rates of about 20% 
(18.6 vs. 15.6% and 18 vs. 17.6%, respectively). The positive control, cell line MDA-MB-468, 
was fully recovered with both CK8/18/19 and panCK. Because of the observed lack of benefit 
from panCK staining, not all CK8/18/19-negative cell lines were tested for their recovery with 
panCK.
CD49f expression and spiking experiments
We next evaluated the value of CD49f, as an alternative to CK8/18/19. According to our 
Affymetrix data, CD49f (ITGA6) is highly expressed in the normal- and basal-like subtypes 
(Supplementary Table 1). Flowcytometry confirmed a high protein CD49f expression in all 
basal- and normal-like cell lines (Figure 1 and Table 1)., CD49f was expressed on all cell lines 
with varying staining intensity among subtypes and cell lines using immunohistochemistry 
(Table 1 and Supplementary Table 1). Discrepancies can be seen between flowcytometric 
and immunohistochemical CD49f expression (Table 1), especially in terms of intensity of 
staining. However, all cell lines classified as positive by flowcytometry were also positive by 
immunohistochemistry. The discrepancies can probably be explained by differences in staining 
techniques, for instance by the use of fixative in the immunohistochemistry procedure.
We then selected the cell lines that were not at all or suboptimally detected when selected 
based on CK8/18/19 after combined CD146/EpCAM enrichment
250
. All these seven cell 
lines belong to the normal-like subtype and showed moderate to strong CD49f and CD146 
expression (Figure 4 panel b). When using combined CD49f and CK8/18/19 selection after 
combined CD146/EpCAM enrichment in the modified CellSearch assay (Figure 2, middle and 
right panel), BT549, SUM1315, SUM102 and MDA-MB-435, which were only partially detected 
with CK8/18/19, showed substantial gain in recovery (i.e., 0.4 vs. 26.8% of 500 spiked cell 
line cells with CK8/18/19 vs. CD49f/CK8/18/19, 0.2 vs. 79.6%, 17 vs. 72.4% and 0.4 vs. 72.4%, 
respectively) (Figure 4 panel a). No improvement in recovery was seen in the cell lines Hs578T 
(0 vs. 1.8%), MDA-MB-436 (17.2 vs. 17.2%) and MDA-MB-231 (54.6 vs. 45.6%). The luminal 
cell line CAMA1 was included as a positive control, and was completely recovered with both 
marker combinations.
To ensure the specificity of this new modification of the CellSearch assay, we tested six 
healthy donors (age 28 – 58) for the presence of CK8/18/19/CD49f+, CD45-, CD34- events 
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after combined EpCAM/CD146 enrichment. Importantly, occasional false positive events 
were detected (median 1.5, range 0 - 4). Because we also observed numerous CD49f positive, 
CD34 negative events with a very weak CD45 expression (CD45
dim
), we suspected these CD45 
negative events to be granulocytes with a CD45 expression too low to be detected in the 
CellSearch system. We proceeded to evaluate two healthy donor blood samples with the more 
sensitive Imagestream technique, which combines the scanning sensitivity of conventional 
flowcytometry with the capability to produce high-resolution images (Amnis, Seattle, WA)
260-
261
 and compared these results with those obtained using the CellSearch scanning technique. 
Indeed, no false positive (CK/CD49f positive, CD45/CD34 negative) events were seen using 
Imagestream, while the same two samples did both show one such false positive event 
when scanned and analyzed using CellSearch. To confirm the existence of a CD49f+/CD45
dim 
population in healthy donor blood, we stained healthy donor peripheral blood mononuclear 
cells (PBMCs) with CD49f, CD45 and two granulocyte markers (CD13 and CD66). Indeed, a 
clear cell population of CD49f+/CD45
dim
 granulocytes was confirmed to be both CD13 and 
CD66 positive, in line with our hypothesis that these false-positive events are in fact CD45
dim
 
granulocytes (data not shown).
DISCUSSION
CTCs have proven their value as a prognostic factor in metastatic breast cancer. However, 
CellSearch, the only currently available FDA-approved method, detects CTCs in only 60% of 
metastatic breast cancer patients
25
. In the other 40%, CTCs are either not present at the time 
of blood draw, or CTCs remain undetected. Previously, we have shown that a subset of breast 
cancer cells lacks EpCAM expression and is therefore missed using the CellSearch assay
64
. These 
EpCAM-negative cells could be of pivotal importance in the dissemination process of breast 
cancer, possibly representing tumor cells that have undergone EMT. The presence of EMT-
features has been associated with poor prognosis
10-12
 and chemotherapy resistance
245-246
. To 
detect these EpCAM-negative cells, we identified CD146 as an alternative enrichment marker, 
and have shown that CD146+ CTCs can be detected in metastatic breast cancer patients
250
.
In spite of this improvement, not all breast cancer cell lines could be detected by this modified 
CellSearch approach, despite apparent sufficient CD146 expression. These cell lines, both 
normal- and basal-like, are characterized by low CK8/18/19 expression, which is needed for 
the pivotal selection step in the CellSearch assay after CTC enrichment. Thus, we set out to 
identify an alternative marker to be used in combination with CK8/18/19 that would lead 
to the detection of all breast cancer subtypes. Because of the known heterogeneity in CK 
expression among breast cancer subtypes
220,251-252
, we postulated that a broader array of 
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CKs could improve CTC detection. However, no single CK showed sufficient expression across 
normal- and basal-like subtypes. PanCK could theoretically cover all breast cancer subtypes and 
was indeed expressed on all basal-like and half of normal-like cell lines, suggesting an added 
recovery benefit when adding panCK as a selection marker. However, four normal-like cell lines 
still remained partially or completely undetected with combined panCK and CK8/18/19. This 
lack of observed benefit might be due to suboptimal fixation and permeabilization procedures 
in the CellSearch kit for this purpose. Indeed, we observed a stronger panCK staining on cell 
lines when fixed using formaldehyde and permeabilized using saponin than when using the 
fixation and permeabilization reagents as provided in the CellSearch Epithelial cell kit (data 
not shown). 
CD49f or alpha-6-integrin is a cell-surface protein implicated as a promoter of metastasis
262 
and increased tumorigenicity
263-264
. In prostate cancer, CD49f has recently been described as 
the driver of a androgen receptor-regulated survival pathway that is independent of PI3K
265
. In 
hepatocellular carcinoma CD49f has been associated with EMT
266
, and CD49f is regarded as a 
stem cell marker for prostate and bladder cancer
267
. It is also regarded as a stem cell marker in 
breast cancer
253-256
. On a cell line level however, CD49f expression is universal among normal- 
and basal-like subtypes, but is less pronounced in luminal and erbb2 cell lines. This expression 
pattern may reflect the stem cell-like phenotype of the two former breast cancer subtypes
268
. 
CD49f staining indeed enabled the detection of four cell lines which otherwise would have 
been partially or completely undetected. The recovery of three additional cell lines did not 
improve with combined CD49f and CK8/18/19 staining. This incomplete recovery can be 
caused by a number of reasons; insufficient CD146 or CD49f expression to enable detection or 
modification of antigen availability by for instance the fixation and permeabilization step used 
in the CellSearch method.
With any new marker for rare event detection, specificity is a key issue, so we assessed healthy 
donors for the presence of false positive CD49f+/CD45- cells. Using the CellTracks scanning 
microscope, up to four CD45- events per 7.5 mL of whole blood were seen. Analyzing these 
samples with the more sensitive Imagestream technology, no such CD45-negative events were 
seen, pointing to a difference in ability to detect weak CD45 signals between these techniques. 
Additionally, flowcytometry confirmed our hypothesis that these false-positive events are 
CD49f+/CD45
dim
 granulocytes. When implementing CD49f into clinical practice, it should be 
assured that the sensitivity of CD45 staining is high enough to prevent the detection of false 
positives in healthy donors, for instance by using a more sensitive fluorescence detection 
method. Alternatively, an additional marker to exclude granulocytes, such as CD13 could 
be added to the extra channel in CellSearch. CTCs would then have to be negative for CD45 
to exclude leukocytes, negative for CD34 to exclude CECs and negative for CD13 to exclude 
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granulocytes.
After having improved breast cancer CTC detection with the use of CD146 as an additional 
enrichment marker, we have now shown that further benefit can be obtained by adding CD49f 
as a selection marker. Specifically the detection of those cell lines showing EMT-features 
was improved by adding CD49f, possibly enhancing the detection of CTCs involved in EMT-
associated processes such as drug resistance and metastasis. While still no complete coverage 
of all CTC subtypes can be expected, a higher sensitivity of CTC detection is likely to improve 
the clinical value of this assay in breast cancer patients.
74 Chapter 4
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Figure 1
CK8/18/19 and panCK cytoplasmatic and CD49f membrane expression as assessed by flow cytometry. 
Black histograms show unstained cells, grey histograms show expression of CK8/18/19 (left panel), panCK 
(middle panel) and CD49f (right panel) stained cells of normal-like (n) and basal-like (b) cell lines. X-axis; 
fluorescence intensity; Y-axis; number of counted cells
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Figure 3
Recovery of basal-like (b) (MDA-MB-468, used here as a positive control) and normal-like (n) cell lines 
with CK8/18/19 (black bar) and panCK (grey bar) after combined CD146 and EpCAM enrichment (a). 
EpCAM and CD146 membrane expression and CK8/18/19 and panCK cytoplasmatic expression in basal-
like (b) and normal-like (n) cell lines (b). Black histograms show unstained cells, grey histograms show 
expression on EpCAM (first panel), CD146 (second panel), CK8/18/19 (third panel) and panCK (fourth 
panel) stained cells of normal-like (n) and basal-like (b) cell lines. X-axis; fluorescence intensity; Y-axis; 
number of counted cells
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Figure 4
Recovery of luminal (l) (CAMA1, used here as a positive control) and normal-like (n) cell lines with 
CK8/18/19 (black bar) and CD49f (grey bar) after combined CD146 and EpCAM enrichment (a). EpCAM, 
CD146 and CD49f membrane expression and panCK cytoplasmatic expression in luminal (l) and normal-
like (n) cell lines (b). Black histograms show unstained cells, grey histograms show expression of EpCAM 
(first panel), CD146 (second panel), CK8/18/19 (third panel) and CD49f (fourth panel) stained cells of lumi-
nal (l) and normal-like (n) cell lines. X-axis; fluorescence intensity; Y-axis; number of counted cells
Supplementary data:
https://docs.google.com/open?id=0B9Etqm_r7T2mNnN5STlLajcyZFU
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ABSTRACT
Purpose
Molecular characterization of circulating tumor cells (CTC) holds great promise. Unfortunately, 
routinely isolated CTC fractions currently still contain contaminating leukocytes, which makes 
CTC-specific molecular characterization extremely challenging. In this study, we determined 
mRNA and microRNA (miRNA) expression of potentially CTC-specific genes that are considered 
to be clinically relevant in breast cancer.
Experimental Design
CTCs were isolated with the epithelial cell adhesion molecule–based CellSearch® Profile Kit. 
Selected genes were measured by real-time reverse transcriptase PCR in CTCs of 50 metastatic 
breast cancer patients collected before starting first-line systemic therapy in blood from 53 
healthy blood donors (HBDs) and in primary tumors of 8 of the patients. The molecular profiles 
were associated with CTC counts and clinical parameters and compared with the profiles 
generated from the corresponding primary tumors.
Results
We identified 55 mRNAs and 10 miRNAs more abundantly expressed in samples from 32 
patients with at least 5 CTCs in 7.5 mL of blood compared with samples from 9 patients 
without detectable CTCs and HBDs. Clustering analysis resulted in 4 different patient clusters 
characterized by 5 distinct gene clusters. Twice the number of patients from cluster 2 to 4 had 
developed both visceral and non-visceral metastases. Comparing transcript levels in CTCs with 
those measured in corresponding primary tumors showed clinically relevant discrepancies in 
estrogen receptor and HER2 levels.
Conclusions
Our study shows that molecular profiling of low numbers of CTCs in a high background of 
leukocytes is feasible and shows promise for further studies on the clinical relevance of 
molecular characterization of CTCs.
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INTRODUCTION
Molecular characterization of primary tumors has already greatly contributed to the 
personalized treatment of cancer patients. High-throughput techniques have yielded the 
knowledge of mutations or epigenomic changes in certain genes and prognostic and predictive 
models on the basis of mRNA and microRNA (miRNA) expression profiles
269-274
. Combined 
with classical tumor characteristics, these models are increasingly used to guide individualized 
treatment of patients, thereby aiming to avoid over- or undertreatment. However, most of 
these prognostic and predictive models have been developed based on primary tumor tissue, 
whereas metastases, rather than the primary tumor, determine the clinical outcome of cancer 
patients. It has been shown that metastases, which may develop several years after occurrence 
of the primary tumor and after prior systemic therapy in the adjuvant or neoadjuvant setting, 
can differ greatly from primary tumor tissue in terms of genetic characteristics
6,275-280
. It is 
therefore anticipated that molecular characterization of metastases will improve the currently 
available prognostic and predictive models. Taking biopsies from metastases in patients, 
however, is an invasive and often painful procedure, and frequently impossible due to the lack 
of accessible lesions. 
Circulating tumor cells (CTC) are found in the peripheral blood of patients and are shed from 
either the primary tumor or its metastases. A recently developed technology to quantify the 
number of CTCs in whole blood (WB) is the CellSearch CTC Test (Veridex™ LLC, Raritan). So far, 
this is the only test that has been approved by the U.S. Food and Drug Administration (FDA
281
) 
for the detection and enumeration of CTCs in metastatic prostate
282
, colorectal
283
, and breast
25
 
cancer as an independent prognostic factor. After enrichment using magnetic beads coated 
with anti-epithelial cell adhesion molecule (EpCAM) antibodies, isolated cells are stained 
with fluorescently labeled monoclonal antibodies specific for epithelial cells (CK8/18/19), 
leukocytes (CD45), and their nuclei with a nuclear staining dye [4’, 6 diamidino 2 phenylindole 
(DAPI)], and subsequently enumerated by a semi-automated fluorescence microscope. 
In addition to enumeration, CTCs can also be isolated for molecular characterization. This may 
enable insight into the molecular biology of metastasis, the association of their molecular 
profiles with treatment outcomes, and reveal the presence of potential drugable targets. 
However, although EpCAM-based enrichment eliminates a large proportion of leukocytes 
(approximately 4-log depletion), there are still considerable quantities of contaminating 
leukocytes (DAPI+/CD45+) present after this enrichment
9
. This contamination, together 
with the low frequency of CTCs, forms a challenge when aiming to characterize CTCs by very 
sensitive molecular methods such as PCR. 
Despite these challenges, we have recently shown the feasibility of determining mRNA 
expression of epithelial-specific genes in CTC-enriched samples
9
. In addition to mRNA, another 
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class of RNAs that increasingly attracts attention is the group of miRNAs. Each miRNA targets, 
on average, 200 mRNA transcripts by which miRNAs execute widespread control
284
. As might 
be expected based on these activities, altered expression of specific miRNA genes has already 
been shown to contribute to the initiation and progression of cancer
285-287
. Therefore, miRNA-
based cancer gene therapy offers the theoretical appeal of targeting multiple gene networks 
that are controlled by a single aberrantly expressed miRNA
288
, making the profiling of miRNAs 
in cancer even more appealing, especially in the context of CTCs. 
Here, we describe the optimization of a method to perform both miRNA and mRNA expression 
analysis for multiple genes by real-time reverse transcriptase PCR (RT-PCR) on as little as 5 CTCs 
isolated from 7.5 mL of blood, which is considered the clinically relevant cut-off in patients 
with metastatic breast cancer
32,237,289
, in an environment containing excess quantities of up 
to 1,000
9
 contaminating leukocytes. As shown in this study for patients with metastatic breast 
cancer, this robust and novel method allows the simultaneous determination of 65 epithelial 
tumor cell–specific miRNA and mRNA expression levels in CTCs enriched by CellSearch, and the 
exploration of their clinical relevance on the basis of the identification of 4 different patient 
clusters with distinct characteristics.
TRANSLATIONAL RELEVANCE
Metastases, which may develop several years after occurrence of the primary tumor and after 
prior (neo)adjuvant therapy, can differ greatly from primary tumor tissue in terms of genetic 
characteristics. Taking biopsies from metastases in patients, however, is an invasive procedure 
and frequently impossible due to the lack of accessible lesions. Circulating tumor cells (CTC) 
are tumor cells shed from either the primary tumor or its metastases that circulate in the 
peripheral blood of patients and can thus be regarded as “liquid biopsies” of metastasizing cells. 
In this study, we show for the first time the feasibility of extensive molecular characterization 
of CTCs at both the mRNA and microRNA level in a high background of leukocytes and show 
its applicability in a cohort of 50 metastatic breast cancer patients. It is anticipated that such 
an extensive molecular characterization of CTCs will improve the currently available prognostic 
and predictive models on the basis of primary tissue.
MATERIALS AND METHODS
Ethics statement
This study was approved by the Erasmus MC and local Institutional Review Boards (METC 
2006-248), and all donors and patients gave their written informed consent.
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Breast tumor tissues and blood samples 
From 61 patients with metastatic breast cancer, 2 x 7.5 mL blood samples were prospectively 
taken for CTC enumeration and isolation (for details see next) prior to initiation of systemic 
therapy for metastatic disease. From these 61 samples, 11 (18%) were excluded because of 
insufficient RNA quality and/or quantity (for details see next), rendering a total number of 50 
patients eligible for further analysis. Metastatic breast cancer patients had been included at 
the start of systemic therapy between February 2008 and December 2009 in 4 hospitals (9 
patients in the Erasmus Medical Center, Rotterdam, The Netherlands, 10 in the Ikazia Hospital, 
Rotterdam, The Netherlands, and 10 in the Maasstad Hospital, Rotterdam, The Netherlands, 
and 21 patients in the Oncology Center GZA St-Augustinus, Antwerpen, Belgium). For 8 of 32 
patients with at least 5 CTCs, primary tumor tissue containing at least 50% invasive epithelial 
tumor cells was available for RNA isolation [5 fresh frozen (FF) and 3 formalin-fixed paraffin-
embedded (FFPE)]. These 8 specimens were used for comparison of transcript levels between 
CTCs and corresponding primary tumors. Detailed clinicopathological information for these 50 
patients and the 8 matching primary tissues is given in Table 1 and in Supplementary Table 1 
after dichotomization of patients at the breast cancer clinically relevant level of 5 CTCs
32,237,289
. 
Fifty-three healthy blood donor (HBD) blood samples were drawn form laboratory volunteers 
and blood donors of the Sanquin Blood Bank South-west Region.
Enumeration of CTCs
Prior to the administration of first-line systemic therapy, 7.5 mL of blood from HBDs and 
metastatic breast cancer patients was drawn in CellSave tubes (Veridex). For CTC enumeration, 
samples were processed on the CellTracks AutoPrep System (Veridex) by using the CellSearch 
Epithelial Cell Kit (Veridex) and CTC counts were determined on the CellTracks Analyzer 
(Veridex) according to the manufacturer’s instructions and as described previously
64,250
. 
miRNA and mRNA isolation from CTCs, FF, and FFPE
For gene expression studies, in parallel with the enumeration studies, 7.5 mL blood of the 
same healthy donors and patients was drawn in EDTA tubes and enriched for CTCs on the 
CellTracks AutoPrep System using the CellSearch Profile Kit (Veridex). The cells in the enriched 
CTC fractions were lysed by adding 250 µL of Qiagen AllPrep DNA/RNA Micro Kit Lysis Buffer 
(RLT+ lysis buffer) (Qiagen BV, Venlo, The Netherlands) and stored immediately at -80°C until 
RNA isolation was performed with the AllPrep DNA/RNA Micro Kit (Qiagen) according to the 
manufacturer’s instructions. In brief, by using a gradient of ethanol (Absolute Ethyl Alcohol 
(EtOH) Merck, Darmstadt, Germany) the larger RNAs (>200 nt) were first captured in a RNeasy 
Mini spin column in the presence of 35% EtOH and eluted separately from the small RNA 
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molecules (≤200 nt) present in the flow through. These >200 nt aliquots were treated with 
DNAse I according the manufacturer’s instruction. Next, the ≤200 nt molecules present in the 
flow through were captured in a new RNeasy Mini spin column in the presence of a final 
concentration of 60% EtOH and thus eluted separately from the >200 nt molecules. Using this 
approach consisting of two sequential filtrations with different ethanol concentrations, a 12 µL 
RNA fraction highly enriched in RNA species ≤200 nt and a 14 µL RNA fraction enriched in RNA 
species >200 nt could be obtained from the same sample. 
Total RNA was isolated from FF tissue with RNA-Bee as described before
290
 and from FFPE 
tissue with the column-based High Pure RNA Paraffin Kit (Roche Applied Science, Almere, The 
Netherlands) according to the manufacturer’s instructions.
Stem-loop cDNA synthesis, pre-amplification, and real-time PCR (quantitative RT-PCR) 
The generation of pre-amplified cDNA from total RNA from the FF and FFPE tissues and the 
>200 nucleotide (nt) RNA fractions and subsequent TaqMan-based quantitative RT-PCR (qRT-
PCR) analysis, and the validation procedures to ensure homogeneous amplification, were 
performed as described before
9
. 
To analyze miRNAs, a multiplex stem-loop cDNA approach was used essentially as described 
before
286
. In brief, up to 50 different RT primers (250 nmol/L each) were pooled, concentrated 
for 60 minutes in a speed vacuum centrifuge at 50°C, and resuspended in nuclease-free ddH2O 
(double distilled water) to a final concentration of 50 nmol/L each. The use of a specific primer 
with a hairpin structure during cDNA synthesis and mature miRNA-specific detection probes 
precluded the detection of precursor miRNAs. A total of 25 to 50 ng of total RNA sample 
aliquots were reverse-transcribed in a final volume of 20 mL with a final concentration of 
12.5 nmol/L for each RT primer using the TaqMan miRNA for reverse transcription kit [Applied 
Biosystems (ABI)] according to the manufacturer’s instructions and as described before
286
. 
For the miRNA quantification in the CTC samples, 3 mL ≤ 200 nt RNA aliquots were reverse-
transcribed in a final volume of 7.5 mL with a final concentration of 12.5 nmol/L for each RT 
primer (ABI), 0.65 mmol/L of each dNTP (ABI), 3 mmol/L magnesium chloride (Invitrogen), 0.3 
U/mL RNase inhibitor (ABI), 15 U/mL RevertAidH Minus enzyme (Fermentas), and 1x RT buffer 
(Fermentas). Cycling conditions were according to the “Megaplex RT reaction for TaqMan 
miRNA array” protocol from ABI, i.e., 40 cycles of 16°C for 2 minutes, 42°C for 1 minute, and 
50°C for 1 second, followed by a final incubation at 85°C for 5 minutes and a cooldown to 
4°C. Prior to PCR, half of the resulting multiplex cDNA was linearly pre-amplified in 15 cycles 
according to the manufacturer’s instructions (TaqMan PreAmp from ABI) and as described 
previously for our multiplex gene expression studies
290
. Before performing real-time PCRs for 
each of the miRNAs separately, RT samples were diluted in nuclease-free ddH2O and analyzed 
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by real time.
PCR was performed in a 20-mL reaction volume in an Mx3000P RealTime PCR System 
(Stratagene) using the individual TaqMan miRNA primer and probe assays in combination with 
TaqMan Universal PCR Master Mix No AmpErase UNG (ABI) with cycling conditions according 
to the manufacturer’s instructions.
To verify that the multiplex RT approach did not affect the quantification of specific miRNAs, 
all miRNA data were validated in a uniplex RT reaction. A pool consisting of RNA of different 
human breast tissues was included in each cDNA synthesis and pre-amplification run, and 
the resulting data were used to normalize for variation between experiments. In addition, all 
cDNA synthesis runs incorporated a minus RT reaction, which proved to be negative for all 
assays in this study. PCR efficiency, linearity, and the upper and lower detection limits of each 
of the individual miRNA assays were validated with a standard curve prepared of RNA from a 
pool of breast tumors. Negative controls included samples without RT and samples in which 
total RNA and cDNA was replaced with ddH2O. Quantitative values were obtained from the 
threshold cycle (Ct) at which the increase in TaqMan probe fluorescent signal associated with 
an exponential increase of PCR products reached the fixed threshold value of 0.08, which was 
in all cases at least 10-fold higher than the background signal.
First selection of potentially CTC-specific mRNA and miRNA transcripts
The specifics of the used TaqMan assays are given in Supplementary Table 2a for the miRNAs 
and Supplementary Table 2b for the mRNAs. For the identification phase of potentially CTC-
specific miRNA transcripts, the TaqMan Human MicroRNA Assay Set (Sanger miRBase v10; 
ABI), consisting of 446 unique assays to quantify 436 miRNAs and 10 controls (small nucleolar 
RNAs; SNORs/RNUs), was used to screen a pool of 150 primary breast cancer RNAs. Of these 
446 miRNAs, 253 were expressed in these breast cancer samples and approximately 200 had 
an expression level of more than 10% of the expression of the reference miRNA set (see next). 
Next, these levels were compared with those measured in a pool of 6 CellSearch-enriched 
preparations from HBDs for potentially differentially expressed miRNAs. These prescreen 
analyses selected 39 miRNAs with both notable expression in breast tumors and at least a 10-
fold higher expression in breast tumors relative to CellSearch enriched HBDs. Four additional 
miRNAs were included for other reasons, i.e., hsa-miR-452 to compare with hsa-miR-452# 
and hsa-miR-379 because of the observed difference between estrogen receptor (ER)-positive 
and ER-negative samples in the prescreen, RNU6B as being a potential reference miRNA, and 
hsa-miR-210, which has shown clinically relevance in breast cancer (
286,291
; Supplementary 
Table 2a).
For the mRNA transcripts, clinically relevant and potentially CTC-specific genes were selected 
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in silico on the basis of literature data and their reported low expression in white blood cells 
and higher expression in breast tumor tissues, according to the SAGE Genie Database of the 
Cancer Genome Anatomy Project (http://cgap.nci.nih.gov/SAGE/AnatomicViewer). These 
prescreen analyses were performed as described in detail before
9
 and resulted in 90 mRNA 
transcripts, including 3 reference genes and 2 reference leukocyte markers that could be 
measured reliably by qRT-PCR and which were potentially higher expressed in breast tumor 
cells relative to leukocytes (Supplementary Table 2b).
Reference genes, data normalization, and quality control
Unless stated otherwise, levels of HMBS, HPRT1, and GUSB were used to control sample 
loading and >200 nt RNA quality, as described previously
290
. Bone marrow stromal cell antigen 
1 (BST1) and protein tyrosine phosphatise receptor type C (PTPRC coding for CD45) were the 
control genes for leukocyte background and keratin 19 (KRT19) was the control gene for CTC 
quantification
290
. 
Although appropriate reference molecules for miRNAs are still unknown for clinical breast 
cancer cells with a background of leukocytes, previous studies have shown that normalization 
on mean or median expression of all miRNAs measured in a sample can adequately reduce 
technical variation
292
. Therefore, miRNA data of each individual sample were normalized on 
the median level of all miRNAs measured in that particular sample.
After verification of equal PCR efficiency for all assays, the relative expression levels were 
quantified by using the delta Ct method, which is the difference between the median Ct of the 
appropriate control genes and the Ct of the target gene. Only samples that were at the median 
Ct of all miRNAs and the median Ct of HMBS, HPRT1, and GUSB able to generate a signal within 
an arbitrarily chosen cut-off set at 26 Ct were considered of sufficient quality and quantity to 
enter the study. By the use of this threshold, 11 of our initial 61 patient CTC samples (18%) 
were excluded from further analysis.
Finally, all transcript data of the 50 CTC samples, 53 HBD controls, and 8 primary tumors were 
normalized to the Ct of the appropriate reference set, after which, for each individual assay, 
the median Ct measured in CellSearch-enriched HBDs (n = 31 for the mRNAs and n = 8 for the 
miRNAs) was used as a cut-off Ct for the CTC samples. All genes with Ct values exceeding this 
cut-off Ct were considered to be undetectable.
Statistical analysis
Statistical analysis was done by SPSS 15.0 and Datan Framework GenEx Pro package version 
5.2.5.20 software for real-time PCR expression profiling. Grubbs’ test was used to define 
outlier data points (1.1%) that were replaced with the median value of all samples for the 
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gene in question. The strengths of the associations between continuous variables were 
tested with the nonparametric Spearman rank correlation test (rs). Gene expression levels 
in the various fractions were compared with the nonparametric Wilcoxon’s test to test the 
null hypothesis and the Mann–Whitney U test to identify genes with significantly different 
expression levels between groups. A false discovery rate (FDR) control of 10% was applied 
to correct for multiple testing
293
. Cluster analysis (http://rana.lbl.gov/eisen/
294
) was used to 
cluster the samples on the basis of the gene expression values and TreeView (http://rana.lbl.
gov/eisen
294
) was used to visualize the results. DAVID (Database for Annotation, Visualization, 
and Integrated Discovery, david.abcc.ncifcrf.gov
295-296
) was used to functionally annotate genes 
and identify the over-represented functions, with P values corrected for multiple testing via 
the Benjamini-Hochberg’s procedure. All human genes were used to compare frequencies of 
functions. Unless stated otherwise, all statistical tests were 2-sided with P < 0.05 considered 
as statistically significant.
RESULTS
Quality control measures taken to ensure reliable measurement of CTC-specific gene 
transcripts
The first purpose of this study was to establish a sensitive method to perform both mRNA and 
miRNA expression analysis of transcripts specific for CTCs, in samples often containing only a 
few CTCs in an environment of excess quantities of contaminating leukocytes.
To select the gene transcripts, we used the approach described in detail in the Materials and 
Methods section, resulting in 43 putative breast CTC–specific miRNAs, 85 putative breast 
CTC–specific mRNAs, and 5 control mRNAs. Our first challenge was to find a method that 
would enable us to measure both mRNAs and miRNAs in RNA isolated from as little as 5 
CTCs (approximately 50 pg total RNA), which is considered the clinically relevant cut point 
in patients with metastatic breast cancer
32,237,289
 in a reliable and quantitative manner. In 
this respect, as already described and tested for the mRNA assays
9
, any individual miRNA 
expression assay showing as a non-homogeneously amplified outlier in our tests should be 
treated with caution because the data may not be truly representative for the original sample. 
Therefore, our assay had to have a high sensitivity combined with a minimum number of 
non-homogeneously amplified miRNA and mRNA assays. To achieve this, we combined the 
already sensitive multiplex stem-loop cDNA approach with the TaqMan-based linear pre-
amplification method, both from ABI. To validate the sensitivity and linear and homogeneous 
nature of this combined technique, we performed comparative tests between serially diluted 
non-amplified and multiplexed pre-amplified cDNA from total RNA of pooled primary breast 
92 Chapter 5
tumors, as described before
9
. The homogeneity of amplification was set at a cut-off of 2 Ct, 
i.e., for an assay to be considered homogeneously amplified, the number of cycles that were 
required after pre-amplification should be within a 2 Ct range of the number of cycles that 
were required for the non-amplified material. After adjusting for the median 15.5 Ct gain due 
to the pre-amplification procedure, data of 11 miRNA assays were outside this range (Table 2, 
lower). After testing the 43 miRNAs in a multiplex cDNA PCR reaction in our patient cohort of 
50 CTC samples, data of 2 additional miRNAs (hsa-miR-10b and RNU43) had to be discarded 
because they generated very poor amplification curves. Finally, the PCR efficiency of 2 of the 
remaining 30 assays was outside our set range of 75% to 125% (hsa-miR-135b, 135%, and 
hsa-miR-452#, 73%) and these miRNAs were therefore also excluded from our final analyses 
(Table 2, column 6). A summary of the results of these quality control experiments, which left 
us with 28 potentially breast CTC–specific miRNAs that could be measured reliably after our 
multiplexed cDNA followed by the pre-amplification procedure, is listed in Table 2. 
Finally, when implementing an assay into clinical diagnostics, it is important that data can be 
compared in-between qRT-PCR sessions. For our mRNA measurements, we have previously 
shown that the data are reproducible using the pre-amplification procedure from ABI9. To 
certify that the miRNA data generated with these assays and the multiplex pre-amplification 
procedure were also reproducible between different qRT-PCR sessions, a control RNA sample 
consisting of 300 pg total RNA of a pool of breast tumors was included in each session. The 
relative expressions (average delta Ct ± 95% CI) of the 28 miRNAs measured in this control 
sample in 28 independently performed multiplexed pre-amplified qRT-PCR sessions (Figure 1) 
with a median coefficient of variation (CV) at the absolute Ct level of 6%, ranging from 3% for 
hsa-miR-200a# to 15% for hsa-miR-184, illustrate the robustness of our method. 
mRNAs and miRNAs differentially expressed between CTC preparations and leukocytes
The miRNA analyses showed that of the 446 miRNAs investigated, 28 miRNA transcripts could 
be measured reliably and linearly in a multiplex pre-amplification reaction with an anticipated 
more than 10-fold (median 160-fold) higher expression in CTCs relative to blood-derived 
leukocytes (Table 2 and Supplementary Table 2a). Of these 28 small RNAs, only 1 miRNA 
(hsa-miR-183) was higher expressed in the 32 samples that contained at least 5 CTCs than 
the 9 samples without detectable CTCs after the CellSearch procedure. At an FDR of 10%, 
9 additional miRNA transcripts were more abundantly expressed in the preparations that 
contained at least 5 CTCs relative to WB preparations of HBDs prior to (n = 14) or after (n = 8) 
CellSearch enrichment (Table 3a).
For the mRNA transcripts, we used the approach described in detail before
9
. Of the thus in 
silico selected 85 putatively CTC-specific and/or for breast cancer clinically relevant genes 
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(Supplementary Table 2b), 55 were at an FDR of 10% significantly higher expressed in the 
32 samples of patients with at least 5 CTCs than 31 CellSearch-enriched HBD samples. A 
gene expression call rate of 55 of 85 (65%) is within the limits of what can be expected for 
a profiling study
297
. In addition to these 55 mRNA transcripts, another 6 mRNA transcripts 
were more abundantly present in the 32 samples that contained at least 5 CTCs relative to 
the 14 WB samples from HBDs prior to CellSearch enrichment. Of the 55 mRNA transcripts, 
14 were also more abundantly expressed in the 32 samples with at least 5 CTCs relative to 
the 9 enriched metastatic breast cancer blood samples without detectable CTCs. Finally, only 
6 genes, including the 2 leukocyte control genes PTPRC (CD45) and BST1, were found to be 
significantly higher expressed in the 31 CellSearch-enriched HBD samples than the 32 patient 
samples with at least 5 CTCs (Table 3b).
Unsupervised hierarchical clustering to identify clusters of patients according to gene 
expression patterns
Next, unsupervised 2-dimensional average linkage hierarchical cluster analysis
294
 was done 
to compare the gene expression profiles of our 50 patients. For this, we used the 65 genes 
(55 mRNA and 10 miRNA transcripts) that were at a 10% FDR more abundantly expressed in 
CellSearch-enriched fractions of the 32 patients with at least 5 CTCs (Table 3 and Figure 2). This 
analysis resulted in a clustering of 4 groups of patients with a clear discrimination between 
patient cluster 1 and patient clusters 2 to 4. The median number of counted CTCs for cluster 1 
was 1 (range: 0 – 173) CTC; for cluster 2, 14 (0 – 138) CTCs; for cluster 3, 41 (0 – 2, 262) CTCs; 
and for cluster 4, 74 (0 – 886) CTCs (Figure 2).
About the gene clustering, 5 gene clusters with a correlation more than 0.2 could be identified. 
In the largest 18-gene cluster (gene cluster 1), “signaling” was the most significant common 
category for 12 genes (MUCL1, FGFR4, FGFR3, ERBB4, CXCL14, PLOD2, PIP, TFF3, FKBP10, 
IGFBP2, TIMP3, and PLAU) as identified by DAVID
295-296
 analysis (3.9-fold enriched, P = 0.0014). 
In addition to these signaling genes, this gene cluster contains some potentially interesting 
drug targets such as ERBB4, FGFR3, and FGFR4.
The second-gene cluster (gene cluster 2, correlation 0.40) is characterized by luminal genes, 
such as CCND1
226
, ESR1, KRT18
226
, and MUC1, of which MUC1 has previously been used by 
others for the detection of CTCs in breast cancer
80,109,298-300
. At an enrichment of 8.0-fold, 
Benjamini P = 0.008, “mutagenesis site,” i.e., genes with mutational hot spots, was the most 
significant category identified by DAVID for 6 genes (MUC1, CCND1, KRT18, ESR1, CEP55, and 
FEN1) in this 7-gene cluster.
One distinct gene cluster (gene cluster 3, correlation 0.35) was responsible for the association 
with the absence of CTCs, i.e., patient cluster 1. This 14-gene cluster holds in addition to the 
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previously identified CTC-specific genes KRT19, AGR2, S100A16, and KRT7, and as could be 
expected TACSTD1, the gene encoding EpCAM, the antigen that was used to enrich for CTCs, 
also the miRNAs hsa-miR- 452 and hsa-miR-34a. 
Notably, the miRNA-cluster (gene cluster 4, correlation 0.20) containing hsa-miR-183, hsa-
miR-184, hsa-miR-379, and hsa-miR-424 shows an expression pattern that seems to be 
inversely related to the “mutagenesis” gene cluster 2—which includes ESR1-, the gene that 
encodes for the ER. This suggests that these miRNAs might be negatively regulated by ER or, 
vice versa, that these miRNAs negatively regulate ER.
Although no specific category was identified by DAVID as significantly enriched in the last cluster 
(gene cluster 5, correlation 0.20), this cluster seems to be dominated by genes associated with 
cell-cycle progression and proliferation such as DUSP4 (MKP2
301
), KIF11, KPNA2, and MKI67. 
Interestingly, a putative stem cell marker (ITGA6
255
) is also included in this last cluster.
To ascertain that the signals we generated were indeed tumor CTC-specific, we also performed 
a clustering analysis with inclusion of the 14 whole blood HBDs (WB-HBD) from which we had 
data from both the mRNAs and miRNAs (Supplementary Figure 1). These HBDs (marked in 
green below the cluster) indeed clustered closely together. Also, the patients from patient 
cluster 1 (Figure 2, and marked in red below the cluster diagram in Supplementary Figure 
1), which were characterized by the lack of expression of epithelial marker genes, remained 
clustered together, next to the HBD cluster.
To further validate that our identified 65-gene expression profile is able to clearly discriminate 
between signals derived from leukocytes that remain after CellSearch enrichment and signals 
derived from epithelial cells, we performed a proof-of-principle spiking experiment. For this, 
gene expression profiles of cells from 4 different breast cancer cell lines were compared with 
those of HBD samples of 5 different healthy volunteers and an HBD sample of a healthy volunteer 
in which the RNAs of the 4 different tumor cell lines were spiked in a final quantity equivalent 
to approximately 1 CTC (approximately 10 pg) per 1.5 mL blood. As can be appreciated from 
Supplementary Figure 2, a clear distinction can be seen between mixed and unmixed HBD 
and cell line samples. More importantly, no clear distinction can be seen between the final 
expression data by using RNA of the cell lines and the cell lines mixed with RNA from HBD.
These data point to a lack of contribution of the leukocytes to the overall gene expression 
results and confirm that our molecular CTC profile is indeed able to discriminate between 
signals from leukocytes and epithelial-specific signals from CTCs.
Associations of the CTC molecular profile with primary tumor characteristics
For the association of the molecular profile with primary tumor characteristics, we continued 
with the 36 patients in patient clusters 2 to 4. These patients displayed a molecular CTC profile 
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with very distinct patterns from the 14 patients in patient cluster 1, which were characterized 
by the lack of expression of epithelial marker genes. Detailed clinicopathological information 
of our patient cohort, subdivided in 2 groups (patient cluster 1 versus clusters 2 to 4) on the 
basis of our molecular CTC–specific profile, is given in Table 1. There were no differences 
between both groups in terms of nodal status, tumor size, histological tumor type, grade, 
ER, PR, and HER2 status. The only significant association with clinical information was that 
the patients of clusters 2 to 4 displayed a 2-fold higher rate of having both visceral and non-
visceral metastases, as opposed to only visceral or non-visceral metastasis for the patients of 
cluster 1.
Almost identical results were obtained when the associations of primary tumor and patient 
characteristics were studied on the basis of CTC count subdivided in 2 groups (patients with 
less than 5 CTCs versus patients with at least 5 CTCs; Supplementary Table 1).
Associations of gene transcripts measured in CTCs with current drug targets
Although we could not measure PGR transcripts reliably in the CTCs due to the relatively 
high PGR levels present in the contaminating leukocytes, we could measure ESR1 and ERBB2 
mRNA transcript levels, the genes for ER and HER2, respectively, in the CellSearch-enriched 
CTCs. ESR1 and ERBB2 expression levels measured in the 36 patients from clusters 2 to 4 with 
expression of epithelial marker genes and compared with ER and HER2 status of the primary 
tumor as assessed by routine pathological immunohistochemical procedures (with additional 
FISH for the HER2++ cases), respectively, are shown in Figure 3. 
Comparison of gene profiles measured in the CTCs and corresponding primary tumors of 
metastatic breast cancer patients
We could retrieve 8 primary tumor tissues (3 x FFPE and 5 x FF) of our cohort of patients with 
at least 5 CTCs at the time of metastatic disease (median: 174, range 7 – 2,262 CTCs). We 
measured the 65 genes of our mRNA and miRNA panel in these tissues after adjusting levels 
measured in FFPE to those measured in FF. 
From the unsupervised average linkage correlation clustering (Figure 4), it became clear that 
most CTC samples clustered well with the corresponding primary tumor tissue (T) and that the 
clustering was not dependent on the origin of the primary tissue (FF or FFPE).
DISCUSSION
In this study, we describe a robust method to simultaneously determine the expression of 
65 epithelial tumor cell–specific miRNA and mRNA expression levels in CTCs enriched by 
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CellSearch. The rationale of our study using the CellSearch technique as a starting point 
was to develop a simple PCR-based molecular characterization that can be performed on 
material obtained in a clinical setting. Because the CellSearch method is currently the only 
FDA-approved semi-automated method to capture CTCs, taking CellSearch-enriched CTCs as a 
starting point for our method will enable its implementation in clinical studies and broadens 
its application possibilities. However, although the EpCAM-based enrichment employed by 
the CellSearch technique eliminates a large proportion of leukocytes (approximately 4-log 
depletion), there are still considerable quantities of leukocytes present after this enrichment
9
. 
This remaining leukocyte contamination, together with the low frequency of CTCs, forms a 
challenge when aiming to characterize CTCs by the expression of multiple genes. Despite these 
challenges, our data indicate that we have succeeded to measure true epithelial tumor cell–
specific genes in CTCs with our CTC-specific 65-gene panel, and managed to avoid generation 
of a predominant leukocyte–derived signal. First, by only selecting genes highly expressed 
in breast cancer samples and not, or at a much lower level, in blood from HBDs. Second, by 
validating the true epithelial-specific expression with clustering analyses, which showed that 
based on the expression of the 65 genes of our molecular profile, the HBDs and breast cancer 
patients without detectable CTCs clustered closely together and could be clearly separated 
from the breast cancer patients with detectable CTC numbers (Figure 2 and Supplementary 
Figure 1). In addition, after using our 65-gene profile, most CTC samples clustered well with 
the corresponding primary tumor tissue (Figure 4). Finally, as a proof of principle, we showed 
that profiling with our 65- gene panel before and after spiking RNA of HBDs with RNA from 4 
different cell lines in a final quantity equivalent to approximately 1 CTC per 1.5 mL blood clearly 
separated the mixed and unmixed cells (Supplementary Figure 2). These data confirmed that 
our molecular 65-gene profile is indeed able to discriminate between signals from leukocytes 
and epithelial-specific signals from CTCs.
On the basis of the expression levels of this 65-gene profile, we could identify 4 different patient 
clusters characterized by 5 distinct gene clusters (Figure 2). One distinct 14- gene cluster (gene 
cluster 3) was responsible for the association with the absence of CTCs. To further appreciate 
the strength of our 65-gene profile in relation to CTC count, it should be noted that the CTC 
counts were derived from 1 of the 2 aliquots of 7.5 mL blood samples that were processed 
with the CellSearch Epithelial Kit, whereas the other aliquot used for the molecular profiling 
was processed with the CellSearch Profiling Kit. This inevitably introduced stochastic variation 
between the tumor cell content in the 2 aliquots, which is more profound in the lower range 
of CTC counts. Discussion has also started about the actual number of isolated CTCs differing 
between the enumeration and profiling kit
302
. The given cell counts could therefore only 
be used as a rough estimate for our molecular profile. Nevertheless, with 14 of 55 mRNAs 
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(25.4%) and only 1 (hsa-miR-183) of 28 miRNAs (3.6%) higher expressed in the 32 samples 
that contained at least 5 counted CTCs compared with the 9 samples without detectable CTCs 
after the CellSearch enrichment procedure with the Epithelial Kit, it seems to be easier to 
discriminate between CTC-specific and leukocyte-derived mRNAs than between CTC-specific 
and leukocyte-derived miRNAs. Possibly, the detected miRNA transcripts were derived from 
cell fragments present in the blood of cancer patients without detectable intact CTCs. The 
fact that we could measure them might be associated with the remarkable stability of miRNA 
transcripts in blood
303
. Indeed, the detection of an additional 9 of 28 (32.1%) miRNAs that were 
higher expressed in breast cancer patients without detectable CTCs than in WB preparations 
of HBDs prior to (n = 14) or after (n = 8) CellSearch enrichment, compared with an additional 
6 of 55 (10.9%) for mRNAs, further supports this thought. For these reasons, we felt confident 
to continue our analyses with those samples that did contain CTCs according to our molecular 
profile (patient clusters 2 to 4 in Figure 2), irrespective of the CTC count in the blood sample 
that was processed in parallel with the CellSearch Epithelial Kit. 
To show the potential clinical utility of measuring these 65 marker genes in CTCs, we had a 
further look in the data we generated with our molecular profiling on the levels of 2 well-
known genes in breast cancer, ER and HER2 (Figure 3). For 1 of the patients whose primary 
tumor was assessed to be ER negative, a clearly positive ESR1 signal was detected in the 
CTCs (CTC087 in Figure 2) obtained at the time of metastatic disease 7 years after surgical 
removal of the primary tumor. However, and perhaps even more disturbing, in 11 of 30 
patients (37%) whose primary tumor was ER-positive, no detectable ESR1 transcript levels 
were measured in the CTCs obtained 1 to 149 months after primary surgery. Thus, although 
according to the primary tumor characteristics, these patients would have an indication for 
anti-hormonal treatment, no benefit might be expected from this therapy on the basis of these 
CTC characteristics. However, due to the limited number of 4 of these 11 patients that were 
actually treated with anti-hormonal treatment, no conclusion can be drawn yet on the efficacy 
of hormonal treatment in these patients with ESR1-negative CTCs and ER-positive primary 
tumors. Of note in this respect is that half the patients with relatively high CTC-associated 
ESR1 levels expressed relatively low levels of TFF1 (Figure 2). TFF1 is a gene under the control 
of ER. Perhaps, assessment of simultaneous TFF1 expression in CTCs might be able to identify 
a subset of patients with ER-positive CTCs with functionally active ER, who are more likely to 
respond to hormonal treatment
304
.
Similarly, the CTCs of at least 4 patients with HER2-negative primary tumors showed to be 
positive at the time of metastatic disease, whereas in 2 patients with an HER2-positive primary 
tumor, no detectable ERBB2 mRNA could be measured in their CTCs. For those 4 patients 
with ERBB2-positive CTCs, anti-HER2 therapy is not indicated on the basis of primary tumor 
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characteristics, whereas this treatment could nonetheless be beneficial based on their CTC 
characteristics.
No clinically relevant cut point has yet been established for ER and HER2 measured by qRT-
PCR in CTCs. Nevertheless, such discrepancies between the levels of ER and HER2 measured 
in the primary tumor and metastases and CTCs have been described before at both the mRNA 
and the protein level
80,302,305-308
, indicating that the findings with our multigene measuring 
technique may indeed be relevant, not only for ER and HER2 but also for the other markers 
included in our panel.
After clustering CTCs and primary tumors based on the expression of all 65 genes, the only 
obvious discrepancy we observed between the CTCs and the corresponding primary tumors of 
8 different patients concerned patient 2. With 2,262 CTCs, this was the patient with the highest 
number of CTCs, and thus with an expected negligible effect of the presence of contaminating 
leukocytes in the expression analysis. The primary tumor of this patient was originally assessed 
as lobular, low-grade, pT2, ER-positive, PR-positive, and HER2-negative. Such a lobular tumor, 
with scattered epithelial cell clusters, and associated contaminating RNA from many stromal 
cells
309
, may have contributed to this poor correlation with the expression profile of the high 
number of CTCs.
Although the high degree of homology in the gene expression profiles of CTCs and corresponding 
primary tumors was reassuring, discrepancies in expression of individual genes, such as for 
ESR1 in patients 5, 6, and 8 (Figure 4), were detected. Another example in this respect is patient 
8, from whom the CTCs expressed much higher levels of markers associated with cell-cycle 
progression and proliferation such as DTL, KIF11, KPNA2, KIF11, and MKI67 than the primary 
tumor (Figure 4). Such differences between the primary tumor and CTCs isolated at the time of 
metastatic disease might prove clinically relevant and thus deserve further research.
In summary, by excluding genes with a relatively higher expression in leukocytes, our CTC-
specific 65-gene set, consisting of 55 mRNAs and 10 miRNAs, is able to generate a huge 
amount of highly relevant CTC-specific data, even in the presence of a leukocyte background 
signal derived of leukocytes cocaptured with CTCs when using the CellSearch procedure.
Although assessed in a relatively small series, we found discrepancies in several important 
factors such as ER, HER2, and other genes between primary tumor tissue and CTCs. This is not 
surprising given the time elapsing between primary tumor resection and CTC collection, which 
occurred at the diagnosis of metastatic disease, and the fact that several patients received 
prior adjuvant systemic therapy. The discrepancies in molecular characteristics between 
primary tumor tissue and CTCs clearly stress the importance of further studies on molecular 
characterization of CTCs.
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Figure 2: see section ‘Color figures’
Figure 3 
Association between gene expression in CTCs of metastatic breast cancer patients and expression of 
their corresponding protein in the primary tumor. Gene transcript levels were analyzed with real-time 
RT-PCR and normalized as described in the Materials and Methods section from CellSearch-enriched 
fractions of 36 breast cancer patients with molecularly identifiable CTCs. Gene expression levels were 
compared with expression of their corresponding protein in the primary tumor using the nonparametric 
Mann–Whitney U test to identify genes with significantly different expression levels between groups.
114 Chapter 5
Figure 4: see section ‘Color figures’
Supplementary data:
https://docs.google.com/open?id=0B9Etqm_r7T2mNnN5STlLajcyZFU
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ABSTRACT
Purpose
A circulating tumor cell (CTC) count is an established prognostic factor in metastatic breast 
cancer. Besides enumeration, CTC characterization promises to further improve outcome 
prediction and treatment guidance. After having previously shown the feasibility of measuring 
the expression of a panel of 96 clinically relevant genes in CTCs in a leukocyte background, we 
determined the prognostic value of CTC gene expression profiling in metastatic breast cancer.
Patients and methods
CTCs were isolated and enumerated from blood of 130 metastatic breast cancer patients who 
were about to start first-line systemic, endocrine or chemotherapeutic, therapy. Of these, 
103 were evaluable for mRNA gene expression levels as measured by quantitative RT-PCR 
in relation to time to treatment switch (TTS). Separate prognostic CTC gene profiles were 
generated by leave-one-out cross validation for all patients and for patients with ≥5 CTCs per 
7.5 mL blood, and cut-offs were chosen to ensure optimal prediction of patients in need of an 
early therapy switch.
Results
In the total cohort, of whom 56% received chemotherapeutic and 44% endocrine therapy, 
baseline CTC count (>5 versus <5 CTCs/7.5mL blood) predicted for TTS (Hazard Raio (HR) 2.92 
[95% Confidence Interval Cl) 1.71 - 4.95] P <0.0001). A 16-gene CTC profile for all patients 
and a separate 9-gene CTC profile applicable for patients with ≥5 CTCs were generated, which 
identified those patients with  TTS or death within 9 months versus those with a more favorable 
outcome. Test performance for both profiles was favorable; the 16-gene profile had 90% 
sensitivity, 38% specificity, 50% positive predictive value (PPV) and 85% negative predictive 
value (NPV), and the 9-gene profile performed slightly better with 92% sensitivity, 52% 
specificity, 66% PPV and 87% NPV. In multivariate Cox regression analysis the 16-gene profile 
was only factor independently associated with TTS (HR 3.15 [95%Cl 1.35 - 7.33] P 0.008)
Conclusion
Two CTC profiles were discovered, which both provide prognostic value on top of a CTC count 
in metastatic breast cancer patients. This study further underscores the potential of molecular 
characterization of CTC.
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INTRODUCTION
In an effort to improve the individualization of metastatic breast cancer treatment, many 
prognostic and predictive factors have been identified in primary tumors, including mRNA 
and microRNA (miRNA) expression profiles
137,286,310-312
. However, at the time metastatic 
disease becomes apparent, the characteristics of metastatic lesions can greatly differ from 
those of the primary tumor. It has been hypothesized that only specific subclones within the 
primary tumor have the ability to metastasize, contributing to heterogeneity between primary 
and metastatic tissue
7
. In addition, genomic instability, a key feature of malignancy, further 
increases discrepancies between primary tumors and metastatic lesions over time and under 
pressure of systemic treatment
6
. Heterogeneity between primary tumor and metastasis has 
been described for a number of clinically highly relevant factors such as ER
47,49
, HER2
47-48
 and 
KRAS
5,313
. When trying to establish prognostic and predictive factors for metastatic disease, 
such discrepancies between primary tumor and metastases can be crucial. Consequently, 
characterization of metastatic tissue rather than that of the primary tumor may lead to better 
prognostic and predictive models. Unfortunately, metastatic tissue is hard to obtain, which 
has limited the discovery of predictive and prognostic factors in metastases. Circulating tumor 
cells (CTCs), which are thought to represent metastatic tissue, can be repeatedly isolated from 
blood, and present an attractive alternative
314
.
A CTC count is an established prognostic factor in metastatic breast cancer
25-27
, and a rise or 
decline in CTC count above or below the clinical cut-off value of 5 CTCs per 7.5 mL blood after 
the first cycle of systemic therapy is an early predictor of therapy response
25
. Additionally, CTC 
characterization by immunocytochemistry
43-44
, FISH
315
, mutation analysis
316
 and quantitative 
reverse transcriptase PCR (qRT-PCR)
38-39
 holds great promise as a tool to improve treatment 
tailoring, but remains challenging. CTCs are extremely rare cells that, even after the sensitive 
CellSearch® (Veridex™ LLC, Raritan, NJ) EpCAM-based enrichment, need to be identified 
and characterized among up to a thousand of remaining leukocytes
9
. With respect to CTC 
characterization by qRT-PCR, one method to overcome this problem of contaminating leukocytes 
is to focus only on genes that are not, or at a much lower level, expressed in leukocytes. Using 
these stringent selection methods combined with sensitive pre-amplification, we were able to 
reliably quantify a CTC-specific gene panel in blood of metastatic breast cancer patients
38
.
In this study, we explore the clinical relevance of CTC characterization by assessing the 
prognostic value of CTC gene expression profiles in metastatic breast cancer patients.
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METHODS
Patients
We conducted a prospective trial at six participating hospitals in the Netherlands and 
Belgium. Inclusion criteria were metastatic breast cancer and start of first-line endocrine or 
chemotherapeutic treatment; prior adjuvant therapy was permitted. Prior to administration 
of the first cycle of treatment, two 7.5 mL blood samples were drawn for CTC enumeration and 
gene expression profiling (for details see next). After 2 – 5 weeks of therapy, two additional 7.5 
mL blood samples were taken for CTC enumeration and gene expression profiling. This study 
was approved by the Erasmus MC and local Institutional Review Boards (METC 2006-248), and 
all patients gave their written informed consent.
CTC enumeration
For CTC enumeration, 7.5 mL blood drawn in CellSave tubes (Veridex) was maintained at room 
temperature and processed within 96 hours after collection. Samples were processed on the 
CellTracks AutoPrep System (Veridex) using the CellSearch Epithelial Cell Kit and CTC counts were 
determined on the CellTracks Analyzer according to the manufacturer’s instructions
8,64,250
.
RNA isolation from CTCs, qRT-PCR and quantification of gene transcripts
For gene expression studies, in parallel with the enumeration studies, 7.5 mL of blood was 
drawn in EDTA tubes and enriched for CTCs on the CellTracks AutoPrep System using the 
CellSearch Profile Kit (Veridex) within 24 hours after collection. RNA isolation was performed 
with the AllPrep DNA/RNA Micro Kit (Qiagen, Venlo, Netherlands), and cDNA synthesis, pre-
amplification, PCR and normalization procedures to quantify gene expression levels were 
performed as described in detail before
38
.
Statistical analysis
Primary endpoint was time to treatment switch (TTS), defined as the time elapsed between 
start of first-line treatment and start of second-line treatment or death, whichever came first. 
Patients who were alive and had not started second-line treatment were censored at last 
follow-up date.
Overall survival (OS) was defined as the time elapsed between start of first-line treatment and 
date of death. All living patients were censored at last follow-up date. Hazard ratios (HR) for 
TTS and OS were estimated by univariate and multivariate analysis, for the latter of which all 
variables with P <0.05 in univariate analysis were used.
After quality control and normalization procedures
38
 of gene expression data, to establish a 
prognostic gene score, patients were divided into a poor prognosis and a good prognosis group. 
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Patients with a therapy switch or death <9 months were classified as the poor prognosis group, 
and patients alive and with or without a therapy switch ≥9 months after start of treatment were 
classified as the good prognosis group. The 9-month cut-off was chosen based on the median 
PFS in first-line metastatic breast cancer patients in the literature
317-318
. In these patients, a 
leave-one-out cross validation was conducted using the Compound Covariate Predictor (CCP) 
within Biometric Research Branch ArrayTools (http://linus.nci.nih.gov/BRB-ArrayTools.html) 
starting with the previously established 55 CTC-specific mRNAs
38
. A panel of 16 genes was 
identified, of which the combined score was used to select a cut-point at which 90% of poor 
prognosis patients were correctly predicted. The score was calculated by summing the product 
of the expression and weight, obtained with the CCP, of individual genes. A separate gene 
profile was constructed in patients with ≥5 CTCs based on all 96 mRNAs in our gene expression 
panel
9,38
 using the same methodology.
All described P-values are two-sided. Survival curves were compared by log-rank testing.
RESULTS
Patient characteristics
Between February 2008 and April 2011, 130 metastatic breast cancer patients were included. 
CTC counts at baseline and follow-up were available for all 130 and for 82 patients, respectively. 
The possible prognostic value of CTC-gene expression was established in those patients for 
whom RNA of sufficient quantity and quality [QQ] was isolated and who had a minimal follow-
up of 9 months or an event (treatment switch or death) within 9 months. Sixteen of the 130 
patients were excluded because of insufficient mRNA QQ and an additional 11 were excluded 
because less than 9 months had passed since inclusion and no events had occurred yet, leaving 
us with 103 suitable patients to establish prognostic CTC gene expression profiles (Figure 1). 
Characteristics of all 130 patients and of the 103 patients eligible for generation of the CTC 
profiles are depicted in Supplementary Table 1. Patient characteristics were comparable, with 
the exception of the number of patients that had received adjuvant endocrine treatment, 
which was relatively less frequent in the 103 QQ mRNA patients than in the total cohort of 130 
patients (Fisher’s exact, P 0.016).
CTC count predicts TTS
For this study, we chose TTS as the primary endpoint in order to reflect the heterogeneity in 
daily clinical decision-making in metastatic breast cancer patients. TTS is a reliable reflection of 
the benefit a patient derives from a certain therapeutic regimen, as it captures the time gained 
by administering that treatment. However, in contrast to progression-free survival (PFS)
25-26
, 
122 Chapter 6
TTS has not previously been correlated with CTC count. Therefore, we first verified whether 
CTC numbers at baseline were associated with TTS in our entire cohort of 130 metastatic breast 
cancer patients. Indeed, the 63 patients with ≥5 CTCs at baseline had a shorter TTS than the 67 
patients with <5 CTCs (median TTS 10.3 vs. 20 months, HR 2.92 [95%CI 1.71 – 4.95] P <0.0001) 
(Supplementary Figure 1a). After 2 - 5 weeks of therapy, CTCs were again enumerated in 82 
patients. Patients with ≥5 CTCs at follow-up had a shorter TTS (HR 2.83 [95%CI 1.39 – 5.76] 
P 0.004) than did the patients with <5 CTCs (Supplementary Figure 1b). Looking at change in 
CTC count during therapy, all patients with ≥5 CTCs at follow-up, regardless of CTC count at 
baseline, had a shorter TTS than patients with persistently low CTC counts (HR 3.83 [95%CI 
1.71 – 8.86] P 0.001, Supplementary Figure 1c). The difference in median TTS of patients with 
persistently low CTC counts versus those with a decline to <5 CTCs after a high CTC count at 
baseline did not reach statistical significance (P 0.066). CTC count at baseline (HR 2.44 [95%CI 
1.27 – 4.69] P 0.007), at follow-up (HR 2.77 [95% CI 1.18 – 6.52] P 0.019) and CTC count change 
during therapy (HR 3.26 [95%CI 1.23 – 8.61] P 0.017) were also associated with OS. In univariate 
analysis, besides the aforementioned CTC counts, the presence of visceral metastases and 
the number of metastases were associated with TTS (Supplementary Table 2). In multivariate 
analysis, only CTC count at baseline remained an independent prognostic factor in the analysis 
for TTS (HR 2.54 [95%CI 1.45 – 4.46] P  0.001, Supplementary Table 2).
CTC gene expression
After establishing the prognostic value of CTC count for TTS in our patient cohort, we sought 
to determine the prognostic value of CTC gene expression. We chose to base our initial 
analysis on the 55 mRNA genes which were previously determined to be CTC-specific, i.e., 
significantly more abundantly expressed in patients with ≥5 CTCs than in patients without 
detectable CTCs and healthy blood donors (HBDs)
38
. While this 55-gene panel is based on its 
expression in patients with ≥5 CTCs, cell line spiking experiments showed the ability of this 
panel to detect epithelial signal in as little as 1 tumor cell spiked into 7.5 mL blood
9,38
. For this 
reason, we included all 103 patients with QQ mRNA data and sufficient follow-up, regardless 
of accompanying CTC count, for the subsequent analyses.
16-gene CTC profile predicts for TTS
Of the 103 patients, 42 patients were classified as the poor prognosis group (therapy switch 
or death <9 months) and 61 patients as having a good prognosis (no therapy switch or death 
<9 months). The 9-month cut-off was chosen based on the median PFS in first-line metastatic 
breast cancer patients in literature
317-318
, and was deemed valid as the median TTS in our 
cohort was 8.9 months (95%CI 7.3 – 10.2).
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In these 103 patients, a predictor was built based on the expression of the 55 CTC-specific 
genes. In univariate analysis, 9 genes were at a P of 0.05 (t-test, Table 1) and 16 genes at a 
P of 0.1 differentially expressed between the good and poor prognosis group. A leave-one-
out cross validation was performed with these latter 16 genes, and a compound covariate 
predictor was calculated for each sample, for which the ROC-curve is depicted in Figure 2b. 
At an area-under-the curve (AUC) of 0.69 (95%CI 0.59 – 0.80, P 0.0001), the 16-gene CTC 
profile performed at least comparable to the CTC count, which had an AUC of 0.62 (95%CI 
0.51 – 0.73, P 0.0145) (Figure 2a). Because we are primarily interested in correctly predicting 
patients in need of an early therapy switch, an actionable test result, we aimed for our 16-gene 
CTC profile to identify poor prognosis patients with 90% sensitivity. At this cut-off, 76 patients 
had an unfavorable profile and were predicted to belong to the poor prognosis group, half of 
whom switched treatments before 9 months and half after, resulting in a positive predictive 
value (PPV) of 50%. Twenty-seven patients had a favorable profile and were thus predicted to 
belong to the good prognosis group, of whom 23 indeed experienced no treatment switch, 
conferring to a negative predictive value (NPV) of 85%. The resulting test characteristics of 
both the 16-gene CTC profile and count in this population are depicted in Figure 2c&d.
The Kaplan-Meier curves for the 16-gene CTC profile, CTC count and for the combination of 
CTC profile and count are shown in Figure 3. Figure 3a shows that based on a CTC count of ≥5 
cells per 7.5 mL blood, the 103 patients in whom the 16-gene CTC profile was generated are 
separated into a good and a poor prognosis group (Logrank P <0.001). In Figure 3b, an early 
and clear distinction into a poor and good prognosis group is seen before the 9 month time 
point when separating patients according to the 16-gene CTC profile (Logrank P <0.001). The 
added value of the profile appears to lie mainly in its ability to further classify patients with <5 
CTCs (Figure 3c&d, Logrank for trend P <0.001), while in contrast, this profile does not identify 
groups with different prognosis among patients with ≥5 CTCs.
In univariate analysis, the 16-gene CTC profile was significantly associated with TTS (HR 4.57 
[95%CI 2.20 – 9.50] P <0.0001, Table 2), as were number of metastases (HR 1.39 [95%CI 1.13 – 
1.72] P 0.002), presence of visceral metastases (HR 1.84 [95%CI 1.05 – 3.23] P 0.035) and CTC 
count at baseline (HR 3.0 [95%CI 1.73 – 5.19] P <0.001). In multivariate analysis that included 
all these prognostic factors, only the 16-gene CTC-profile was an independent predictor of TTS 
(HR 3.15 [95%CI 1.35 – 7.33] P 0.008, Table 2).
CTC biology in patients with ≥5 CTCs
As mentioned previously, the 55 mRNAs used for the generation of our 16-gene CTC profile 
were selected based on their differential expression between patients with ≥5 CTCs versus 
patients without detectable CTCs and HBDs
38
. These 55 mRNAs are thus by definition highly 
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expressed in patients with ≥5 CTCs, and are likely to predominantly reflect the presence of 
an epithelial signal in blood. A further discrimination among patients with ≥5 CTCs might 
therefore not be expected from the 16-gene CTC profile. Indeed, based on the 16-gene CTC 
profile generated in all patients irrespective of CTC count, no further distinction in terms of 
prognosis could be made among patients with ≥5 CTCs (Figure 3d). To provide additional 
information in these patients, we proceeded to perform an exploratory analysis generating 
a CTC profile aimed at further characterizing CTCs and possibly predicting prognosis in only 
the 50 patients with ≥5 CTCs, starting with all 96 genes, including 3 reference genes, that can 
be reliably measured in CellSearch enriched CTC samples
9,38
. This 96-gene panel does not as 
such discriminate between patients who have ≥5 CTCs and those who have none, and thus 
had to be disregarded in the analysis of all patients to obtain sufficient specificity to allow 
identification of circulating tumor load in samples containing <5 CTCs. However, these genes 
can be reliably measured in samples containing ≥5 CTCs
9
 and include potentially prognostic 
and drug target genes. By focussing only on patients with ≥5 CTCs, we expected a prognostic 
profile to be less driven by the presence or absence of circulating tumor load, and more by the 
biology of CTCs. Thus, this time starting with the 96 mRNA genes, the genes that were at a P of 
0.1 in univariate analysis differentially expressed between the good and poor prognosis group 
were used to establish a predictor by leave-one-out cross validation. Using a predefined cut-
off of 90% sensitivity to identify poor prognosis patients, a 9-gene CTC profile was identified, 
including among others ESR1 and MET, the genes encoding for estrogen receptor and met 
oncogene, respectively (Table 1). This 9-gene profile identified patients with ≥5 CTCs who were 
very likely to experience early treatment switch (AUC 0.89 [95%CI 0.80 – 0.98] P <0.0001) 
(Figure 4a) with test characteristics and performance at least comparable to the 16-gene 
CTC profile (Figure 4b&c). The Kaplan-Meier curves for the 9-gene CTC profile (Figure 4d), 
also plotted against the CTC count (Figure 4e), show that the 9-gene CTC profile identifies 
two groups with different prognosis among patients with ≥5 CTCs. The good prognosis group 
experiences rapid relapses after the 9 month time-point, which translates into an inability to 
predict TTS in univariate Cox regression analysis (HR 1.36 [95%CI 0.66 – 2.78] P 0.40 Table 2) 
in the 50 patients with ≥5 CTCs. 
DISCUSSION
CTCs provide a unique opportunity to characterize metastatic tumor cells and assess prognostic 
and predictive markers repeatedly during the course of disease, and increase insight into 
mechanisms involved in drug resistance. We have previously shown that measurement of 
a CTC-specific panel of 55 mRNAs in CTCs is feasible despite their low numbers and their 
 Chapter 6  125
presence in a leukocyte background
38
.
In the current study, a 16-gene CTC profile could distinguish patients with poor prognosis 
(defined as treatment switch or death <9 months after start of treatment) from patients with 
good prognosis. The profile was designed based on a cut-off with 90% sensitivity to ensure a 
high NPV, as we are most concerned with identifying poor prognosis patients. With a NPV of 
85%, the percentage of patients wrongfully predicted to have a good prognosis is limited to 
15%. Of the patients with an unfavorable CTC profile, half indeed experience early treatment 
switch and would benefit from earlier and more frequent response evaluation in an attempt 
to minimize prolonged administration of ineffective and toxic therapy.  In patients with <5 
CTCs, who would be classified as good prognosis according to their CTC count, the 16-gene CTC 
profile distinguished a truly good from an intermediate prognosis group, providing additional 
information on top of a CTC count. Because this 16-gene profile is heavily influenced by the 
presence of epithelial markers such as various cytokeratins and TACSTD1 (the gene encoding 
for EpCAM), it probably identifies patients with CTCs or CTC fragments that do not meet the 
CellSearch criteria in terms of morphology or marker expression
64,319
, and could thus identify 
patients with false-negative CTC counts. It is therefore our hypothesis that in these patients 
with <5 CTCs as determined by CellSearch CTC count, our 16-gene CTC profile better reflects 
the actual circulating tumor load than the CTC count does.
However, in patients with ≥5 CTCs, the 16-gene CTC profile did not provide prognostic 
information, which could be expected as the 55 mRNAs were selected based on their high 
expression in patients with ≥5 CTCs versus patients without detectable CTCs and HBDs
9
. As a 
consequence, this 55 mRNA panel comprises predominantly genes associated with epithelial 
cell load, rather than genes associated with aggressive tumor cell behaviour. To be able to 
provide prognostic information in patients with ≥5 CTCs, we generated a second CTC profile 
solely for these ≥5 CTC patients based on all 96 genes that can be reliably quantified in CTCs
9,38
. 
We expected the profile to be less driven by epithelial gene expression and more by biologic 
factors associated with tumor aggressiveness. The resulting 9-gene CTC profile could indeed 
separate patients with ≥5 CTCs according to prognosis, and identified a patient group swiftly 
progressing under 1
st
 line systemic treatment. Among the 9 genes are epithelial genes such 
as KRT17, but also drug targets such as MET
320
 and ESR1. MCAM (CD146)
224
, CCNE2
321
 and 
COL1A1
139
 have previously been associated with poor prognosis, while CD146 also allows for 
CTC detection in EpCAM-negative breast cancer
250
. These latter genes might thus reflect the 
malignant potential of CTCs, and allow for the further classification of CTCs. While the 96-gene 
panel is informative in patients with ≥5 CTCs, we decided to limit ourselves to the 55 CTC-
specific mRNAs in the total patient group. We anticipated that the other genes in the 96-gene 
panel that are not CTC-specific would not be informative in patients without circulating tumor 
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load, and would strongly dilute the power to detect CTC-derived gene expression correlated 
with prognosis in patients with <5 CTCs.
This study again shows that while a CTC count is a strong prognostic factor, there are probably 
more tumor cells of cell fragments that can be detected in the circulation, with each distinct 
phenotypes and possibly varying clinical value. Breast cancer heterogeneity, which is for 
instance reflected by its five intrinsic subtypes
220
, is likely to lead to differing clinical value 
of CTCs among breast cancer subtypes. Recently, it was shown that CellSearch CTCs are not 
prognostic in patients with HER2-positive primary tumors treated with anti-HER2 therapy, in 
strong contrast to its prognostic value in the overall study population
322
. In our own work, we 
have shown that breast cancer of the normal-like subtype, which has features of epithelial-to-
mesenchymal transition (EMT), lacks EpCAM
64
 and cytokeratin expression
319
, the markers by 
which CTCs are commonly defined. Together, these studies show that caution is needed when 
applying CTC count as a prognosticator to all breast cancer subtypes. Molecular characterization 
of CTCs allows for the assessment of multiple markers and could lead to detection of a more 
all-encompassing circulating tumor load.
In conclusion, we show that gene expression signatures of CTCs correlate with prognosis, 
additional to –but also irrespective of– CTC count. Validation in an independent patient cohort 
is warranted to confirm whether these profiles can be used as a patient stratification tool at the 
time of metastatic disease. The ability to measure clinically relevant genes in CTCs underlines 
the potential of CTC characterization as a tool to improve individualized cancer treatment.
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Top	  panel;	  the	  nine	  genes	  that	  were	  at	  a	  
P	   of	   0.05	   differentially	   expressed	  
between	   103	   good	   and	   poor	   prognosis	  
patients	   in	   univariate	   analysis.	   Poor	  
prognosis	  was	  defined	  as	  a	  switch	  to	  2nd	  
line	   systemic	   treatment	   or	   death	  within	  
9	  months	  after	  start	  of	  1st	  line	  treatment.	  
Middle	  panel;	  the	  16	  genes	  that	  were	  at	  
a	   P	   of	   0.1	   differentially	   expressed	  
between	   103	   good	   and	   poor	   prognosis	  
patients	   in	   univariate	   analysis,	   and	   thus	  
make	  up	  the	  prognostic	  CTC	  gene	  profile	  
that	   was	   generated	   by	   leave-­‐one-­‐out	  
cross	  validation	  starting	  with	  the	  55	  CTC-­‐
specific	  genes.	  
Bottom	  panel;	   the	  9	  genes	   that	  were	  at	  
a	   P	   of	   0.1	   differentially	   expressed	  
between	   good	   and	   poor	   prognosis	  
patients	   among	   the	   50	   patients	   with	   a	  
CTC	   count	  of	  5	  or	  more,	   and	   thus	  make	  
up	   the	   prognostic	   CTC	   gene	   profile	   for	  
patients	   with	   ≥5	   CTCs	   that	   was	  
generated	   by	   leave-­‐one-­‐out	   cross	  
validation	  starting	  with	  all	  96	  genes	  that	  
can	  be	  reliably	  measured	  in	  CTCs.	  
Table	  1	   	  	   	  	   	  	  
Genes	  associated	  with	  prognosis,	  and	  those	  making	  
up	  the	  16-­‐gene	  and	  9-­‐gene	  CTC	  panel	  
Significantly	  differentially	  expressed	  genes	  
between	  103	  good	  and	  poor	  prognosis	  patients	  
	  	   Genes	   P-­‐value	   	  	  
	  	   CXCL14	   0.003	   	  	  
	  	   KRT7	   0.007	   	  	  
	  	   PKP3	   0.021	   	  	  
	  	   PTRF	   0.021	   	  	  
	  	   KRT19	   0.031	   	  	  
	  	   TIMP3	   0.039	   	  	  
	  	   LAD1	   0.040	   	  	  
	  	   S100A16	   0.043	   	  	  
	  	   FKBP10	   0.048	   	  	  
	  	   	  	   	  	   	  	  
Genes	  selected	  from	  55	  CTC-­‐specific	  mRNAs	  
through	  leave-­‐one-­‐out	  cross	  validation	  in	  103	  
patients	  
	  	   Genes	   	  	  
	  	   TACSTD1	   FKBP10	   	  	  
	  	   KRT7	   LAD1	   	  	  
	  	   KRT17	   PIP	   	  	  
	  	   KRT18	   PKP3	   	  	  
	  	   KRT19	   PTRF	   	  	  
	  	   CLDN3	   S100A16	   	  	  
	  	   CXCL14	   S100A7	   	  	  
	  	   ERBB3	   TIMP3	   	  	  
	   	  	   	  	   	  	  
Genes	  selected	  from	  96	  mRNAs	  through	  leave-­‐one-­‐
out	  cross	  validation	  in	  50	  patients	  with	  ≥5	  CTCs	  
	  	   Genes	   	  	  
	  	   KRT17	   MET	   	  	  
	  	   CXCL14	   LOXL2	   	  	  
	  	   ESR1	   SNAPC2	   	  	  
	  	   COL1A1	   MCAM	   	  	  
	  	   CCNE2	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Figure 2
ROC-curves (panel a & b), test performance (panel c) and test characteristics (panel d) of CTC count and 
16-gene CTC profile in 103 patients. AUC; area under the curve, PPV; positive predictive value, NPV; nega-
tive predictive value
Figure 3: see section ‘Color figures’
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Figure 4: see section ‘Color figures’
Supplementary data:
https://docs.google.com/open?id=0B9Etqm_r7T2mNnN5STlLajcyZFU 
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ABSTRACT
Background & aims
Circulating tumor cell (CTC) counts have prognostic value in metastatic colorectal cancer (CRC), 
but CTCs can also be isolated for subsequent characterization. CTCs are thus a very promising 
tool for the repeated and non-invasive evaluation of drug targets and predictive and prognostic 
factors. We describe the identification of CTC-specific mRNAs and miRNAs in colorectal CTCs.
Methods
For this study, we included 30 healthy donors (HDs) and 161 CRC patients prior to liver 
metastasis resection. CTCs were enumerated in and isolated from 2 x 30 mL patient blood 
using the CellSearch Epithelial Cell Kit (Veridex LLC) and Profile Kit, respectively; 30 mL HD 
blood was subjected to the same isolation procedure. RNA was isolated from the enriched CTC 
and HD fractions, in which 41 miRNAs and 95 mRNAs were measured by quantitative reverse 
transcriptase PCR.
Results
miRNA and RNA of sufficient quality and quantity was available for 146 and 98 patients 
with pathology-confirmed liver metastasis of colorectal origin, respectively. Thirteen CTC-
specific miRNAs and 34 CTC-specific mRNAs were identified, of which the transcripts were 
more abundantly expressed in patients with ≥3 CTCs as compared to HDs (Mann-Whitney 
U-test P<0.05). Cluster analysis distinguished patient clusters associated with epithelial gene 
expression, among others. Among patients without detectable CTCs, a subgroup was identified 
of which CTC gene expression suggested the presence of circulating tumor load.
Conclusions
In this study, we show that extensive characterization of colorectal CTCs is feasible and is 
informative in patients with and without detectable CTCs, greatly increasing the amount of 
information that can be obtained from colorectal CTCs.
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INTRODUCTION
Colorectal cancer (CRC) is a highly heterogeneous disease, in its presentation as well as its 
prognosis. The liver is a predominant site of metastases; approximately 25% of CRC patients 
present with synchronous hepatic metastases, and ultimately more than 50% of patients 
initially presenting with non-metastatic CRC will develop liver metastasis in the course of their 
disease
323
. When the metastases are confined to the liver and are deemed resectable, patients 
are increasingly undergoing partial liver resection aiming for curation
324-325
. Nevertheless, up 
to half of patients undergoing such major abdominal surgery will develop disease relapse in 
the liver or at other distant sites within one year
326-331
. Despite these disappointing figures, 
recent data suggest that a selected patient group undergoing this surgical approach achieves 
long-term survival
332
.
While surgical resection might improve outcome for a selected group of patients, the factors 
on which to base selection for this procedure have not been elucidated, prompting the need 
for new prognostic factors to identify this specific subgroup. Candidate factors are mRNA 
and microRNA (miRNA) expression profiles, which have been shown to be prognostic in 
primary colorectal cancer
333-335
. However, at the time of metastatic disease, clonal selection 
and genomic instability can lead to discrepancies between primary tumor and metastases, 
which can be augmented by the passing of time and administration of systemic therapy
6
. 
Heterogeneity between primary tumor and metastasis has been described for clinically highly 
relevant predictive factors such as KRAS
5,313
, and when new prognostic and predictive factors 
are sought after, such discrepancies between primary tumor and metastases can be crucial. 
In this regard, better predictive and prognostic models could be established when metastatic 
tissue, rather than the primary tumor, is used to generate such models on. Unfortunately, 
metastatic tissue is often hard to obtain for diagnostic purposes, and only through invasive 
procedures. An alternative approach is the characterization of circulating tumor cells (CTCs) 
which can be repeatedly isolated from blood
314
. 
A CTC count has recently been identified as a powerful prognostic marker in metastatic 
colorectal
29
, breast
25
 and prostate cancer
31,336
, and their rise or decline after the first cycle 
of chemotherapy predicts therapy response
25,29,31
. Additionally, CTC characterization for drug 
target expression
43-44,315
, mutations
316
 and gene expression by quantitative reverse transcriptase 
PCR (qRT-PCR)
38-39
 could greatly improve treatment decision making, but some challenges 
remain. CTCs are extremely low-frequent in the circulation and, even after CellSearch EpCAM-
based enrichment, need to be characterized among up to a thousand remaining leukocytes
9
. 
To enable CTC characterization by real-time quantitative reverse-transcriptase polymerase 
chain reaction (qRT-PCR), we have circumvented this problem of contaminating leukocytes 
by focussing solely on genes that are not, or at a much lower level, expressed by leukocytes. 
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Using stringent selection methods combined with a sensitive but robust pre-amplification, we 
were able to reliably quantify a CTC-specific gene panel in blood of metastatic breast cancer 
patients
38
 and have recently established its prognostic value in 103 patients (manuscript in 
preparation).
In the current study, a large panel of mRNAs and miRNAs is quantified in the CTCs of metastatic 
CRC patients prior to partial liver resection. From this panel, we identified CTC-specific mRNAs 
and miRNAs, and explored their clinical relevance both in patients with and without detectable 
CTCs.
METHODS
Blood samples
From 161 patients with metastatic colorectal cancer, 2 x 30 mL blood samples were taken for 
CTC enumeration and characterization (for details see next) by way of venipuncture before 
liver metastasis resection and prior to tumor manipulation. This study was approved by the 
Leiden University Medical Center and Erasmus University Medical Center Institutional Review 
Boards (METC P05.182) and all patients were included in the Erasmus University Medical 
Center, Rotterdam, Netherlands after written informed consent was obtained. Additionally, 
30 mL blood samples were drawn from 30 healthy volunteers (age 21 – 58) to evaluate gene 
expression in healthy donors (HDs). 
Enumeration and isolation of CTCs
Two samples of 30 mL blood from the 161 metastatic CRC patients prior to liver metastasis 
resection were drawn in CellSave™ tubes (Veridex LLC, Raritan, NJ) for enumeration or 
EDTA tubes for isolation. Prior to CTC enumeration and isolation, a density gradient-based 
enrichment step was applied as described before
337-338
. Briefly, 30 mL blood was pooled and 
centrifuged for 10 minutes at 800xg. After removal of plasma, 15 mL CTC buffer was added and 
mixed, and the total volume carefully placed onto 6 mL of Lymphoprep (Axis-Shield, Dundee, 
Scotland), a density-gradient medium. After centrifuging at 400xg for 10 minutes, the top buffer 
layer was discarded. Then, 7.5 mL of suspension including the buffy coat was aspirated with a 
reversed 10 mL pipette, allowing optimal isolation of the mononuclear cell layer, and pipetted 
into a regular CellTracks™ tube (Veridex). For CTC enumeration, samples were processed on 
the CellTracks™ AutoPrep System (Veridex) using the CellSearch™ Epithelial Cell Kit (Veridex) 
within 96 hours after collection and CTC counts were determined on the CellTracks™ Analyzer 
(Veridex) according to the manufacturer’s instructions and as described before
9,250
.
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mRNA and miRNA isolation from CTCs, qRT-PCR and quality control
For gene expression studies, in parallel with the enumeration studies, 30 mL of blood from 
patients and HDs was drawn in EDTA tubes, subjected to Ficoll enrichment as described above 
and enriched for CTCs on the CellTracks™ AutoPrep System using the CellSearch™ Profile 
Kit (Veridex) within 24 hours after collection. RNA isolation was performed with the AllPrep 
DNA/RNA Micro Kit (Qiagen, Valencia, CA), and cDNA synthesis, pre-amplification, PCR and 
normalization procedures to quantify gene expression levels were performed as described in 
detail before
38
. The measures that were taken to ensure the linear and homogeneous nature 
of pre-amplification, adequate PCR efficiency and reproducibility of each assay have also been 
described in detail before
38
. 
Statistical analysis
Stata and Analyse-it were used for statistical analysis and generation of box-plots. The strength 
of the associations between continuous variables was tested with the non-parametric 
Spearman rank correlation test. Differences in the median expression levels in various groups 
were tested with the non-parametric Mann-Whitney U test, and differences in baseline 
patient and tumor characteristics by the Fisher’s exact test. CTC-specific profiles were 
identified by Class Comparison in Biometric Research Branch ArrayTools (http://linus.nci.nih.
gov/BRB-ArrayTools.html), using a permutation P-value cut-off of <0.05 (two-sample t-test). 
Hierarchical cluster analysis was performed using Cluster and Treeview
294
 and a custom Perl 
script to visualize the gene expression values. DAVID (Database for Annotation, Visualization, 
and Integrated Discovery
295-296
) was used to functionally annotate genes and identify the 
over-represented functions, with P-values corrected for multiple testing via the Benjamini-
Hochberg’s procedure. Unless stated otherwise, all statistical tests are 2-sided with P<0.05 
considered statistically significant.
RESULTS
Patient characteristics
Among 161 included patients, four did not have a pathology-confirmed metastasis of colorectal 
origin (lesions were either benign or from a different primary origin) and 11 had miRNA 
of insufficient quality and quantity (QQ), leaving 146 patients evaluable for miRNA gene 
expression. mRNA from 43 of the 146 patients had already been used for mutation analysis 
(manuscript in preparation), and five did not pass QQ control, leaving us with 98 patients with 
QQ mRNA. Detailed clinicopathological information for all 146 patients is available in Table 1 
and Supplementary Table 1a, and the subset of 98 patients with QQ mRNA data is described in 
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Supplementary Table 1a. Most patients (60%) presented with synchronous metastatic disease. 
For the remaining 58 metachronous patients, median time between primary tumor resection 
and metastasis was 23 months (range 0 – 161). In 25% of patients, the primary tumor was still 
in situ at the time of blood draw before liver resection, either as part of a liver-first approach, 
i.e., liver metastasis resection followed by primary tumor resection in a second surgery
324-325
, 
or the primary tumor was resected simultaneously with the liver surgery. Twenty percent of 
patients had been given neoadjuvant and/or adjuvant chemotherapy prior to or after primary 
tumor resection, while 57% had received induction chemotherapy before liver resection. 
Sixteen patients had extrahepatic metastatic disease at the time of liver resection, which were 
mostly peritoneal lesions discovered during liver surgery. Among all patients, median CTC 
count was 1 (range 0 – 35) per 30 mL blood and 40 (27%) patients had ≥3 CTCs, the clinically 
relevant prognostic cut-off level in metastatic CRC patients
29
. The number of patients below 
and above the cut-off of 3 CTCs was not equally distributed among males and females; both 
in all 146 patients and in the 98 patients with QQ mRNA, relatively more female than male 
patients had CTC counts above 3 cells per 30 mL blood (Fisher’s exact, P=0.001 and P=0.004 
respectively, Supplementary Table 1a). In the total patient cohort, but not in the smaller QQ 
mRNA cohort, proportionally more patients for whom ≥ 6 months had passed since resection 
of the primary tumor had 3 or more CTCs than those who underwent metastasis resection at 
the same time or within 6 months after primary tumor resection (P=0.05).
Circulating tumor load in patients without detectable CTCs
Ninety-five mRNAs (Supplementary Table 2a) and 41 miRNAs (Supplementary Table 2b) 
were selected to be putatively CTC-specific, i.e., were described in silico to be relatively low 
expressed in leukocytes compared to colorectal cancer (SAGE Genie Database of the Cancer 
Genome Anatomy Project (http://cgap.nci.nih.gov/SAGE/AnatomicViewer), and could be 
reliably and linearly measured based on the above mentioned quality control measures. For 
each assay, a differential expression of at least 5 Ct compared to the median of HDs was set as a 
first cut-off to eliminate false-positive gene expression signals due to leukocyte contamination, 
leading to the exclusion of genes H19 and MMP3. From the remaining genes, we set out to 
select colorectal cancer-specific genes, i.e., genes of which the measured expression levels are 
cancer-related and derived from CTCs, by comparing enriched blood from patients without 
CTCs with CTC-containing blood fractions. First, we assessed whether patients without 
detectable CTCs could be grouped with HDs to form the non-CTC group. For this analysis, we 
performed cluster analysis of mRNA expression data of all 33 patients without detectable CTCs 
and 30 HDs. As can be seen in Figure 1, a subgroup of patients without detectable CTCs was 
clearly distinct from HDs and other patients without CTCs. These patients had high expression 
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of epithelial genes such as KRT19 and KRT20, but also of the genes IGFBP5, AGR2, S100A16 
and LAD1, which were previously established to identify epithelial tumor load in breast cancer 
patients
38
. According to DAVID Functional Annotation Clustering analysis
295-296
, “signaling” (15 
of 29 genes, 3.1-fold enriched, Benjamini P=0.0006) and growth factor binding (7 of 29 genes, 
39.3-fold enriched, Benjamini P=0.0006) were among the most significant common categories 
in this gene cluster. By the high expression of these genes, a HD-unlike group was identified, 
while the remaining HD-alike patients lacked expression of these genes and clustered together 
with HDs. To further characterize these subgroups, we used a supervised analysis to identify 
genes that were differentially expressed between 11 HD-alike and 22 HD-unlike patients, 
which are depicted in Table 2. Among the 51 differentially expressed mRNAs were the above 
mentioned epithelial genes, but also REG1A, a prognostic marker
339
, ERBB3, a drug target
340
, 
and multiple collagens (COL4A1, COL5A1, COL1A2 and COL1A1), which have previously been 
associated with prognosis in stage III colorectal cancer
341
.
CTC-markers in HDs and patients with low CTC counts
Thus, we had identified a group of patients in whose blood no CTCs were detected with 
CellSearch CTC enumeration, but whose CTC-enriched blood strongly suggested the presence 
of circulating tumor content. A possible explanation for the inability to enumerate CTCs in 
these patients could be an insufficient expression of one of the epithelial markers needed for 
CTCs to be enumerated according to the CellSearch criteria (the cytokeratins KRT8, KRT18 and 
KRT19) in the presence of sufficient EpCAM expression to enable their capture for subsequent 
gene expression profiling. To explore this, we focused on the expression of the epithelial 
markers EPCAM (previously named TACSTD1) and KRT8, KRT18 and KRT19 in the RNA fractions 
isolated from blood of HDs and patients without detectable CTCs after CellSearch enrichment. 
As expected, both EPCAM and KRT expression was low in HDs (Figure 2). For EPCAM, which 
should be expressed to enable both CTC isolation and enumeration by the anti-EpCAM based 
CellSearch CTC detection method, no clear difference was noted between HD-alike and HD-
unlike patients (Figure 2a). 
KRT expression is not necessary for the isolation of CTCs through anti-EpCAM capture, but only 
for their enumeration. KRT8, KRT18 and KRT19 were higher expressed in HD-unlike than in HD-
alike patients without detectable CTCs (Mann Whitney U test, P=0.0003, P=0.03 and P<0.0001, 
respectively, Figure 2c-d).
CTC-specific mRNAs and miRNAs
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Based on the presence of a subgroup of patients with a HD-unlike gene expression profile and 
expression of epithelial-specific genes, we deemed the patient group with 0 CTCs as a whole 
not suited to combine with the HD group to identify CTC-specific genes. To identify CTC-specific 
genes we therefore compared the 30 HDs with patients with ≥3 CTCs, i.e., 24 patients in the 
mRNA analysis and 40 patients in the miRNA analysis. We identified a panel of 34 mRNAs and 
13 miRNAs of which the transcripts were at a P<0.05 higher expressed in the patients with ≥3 
CTCs compared with HDs (Class comparison BRB-array tools, Supplementary Table 3).
Unsupervised hierarchical clustering of CTC-specific mRNAs
Next, we used the identified 34 CTC-specific mRNA genes to perform unsupervised 
2-dimensional average linking hierarchical cluster analysis of the 98 patients with QQ mRNA 
data (Figure 3). This cluster analysis revealed two main clusters, 1 and 2. Cluster 2 could be 
further divided into two patient clusters, which, contrarily to patient cluster 1, were both 
characterized by a relatively high expression of epithelial genes such as KRT19 and KRT20, but 
were distinguished by two gene clusters. Patient cluster 2a was characterized by the expression 
of genes such as FABP1, CDX1 and CDH17. FABP1 is higher expressed in good-prognosis primary 
tumors and metastases
342
 and a marker of differentiation
343
 but has also previously been 
described as a useful CTC detection marker
39
. CDX1 has been described as a tumor suppressor 
gene
344 
reducing proliferation through Cyclin D1
345
, and is frequently rearranged in relation to 
rearrangements at the APC locus
346
. CDH17 mediates cell-cell adhesion in intestinal epithelial 
cells
347
, is specific to cancers of the digestive system
348
 and has previously been associated 
with poor prognosis
349
 (genes are marked by the blue rectangle). No specific common 
category was identified to be significantly enriched in this gene cluster by DAVID functional 
gene annotation analysis. Patient cluster 2b largely lacked expression of these genes, but did 
express IGFBP5 and AGR2, which were both previously determined to be epithelial-specific in 
our breast cancer studies
38
, while AGR2 is also upregulated in microsatellite instability-high 
(MSI-H) tumors
350-351
; and REG1A, a gene correlated with poor prognosis
339
 and microsatellite 
instability
352
 (red rectangle). DAVID analysis identified “secreted” as the most significant 
category for seven genes (PRSS8, RARRES2, COL4A1, LAD1, AGR2, IGFBP3, IGFBP5) in this 
15-gene cluster (5.3-fold enrichment, Benjamini P=0.04).
Unsupervised hierarchical clustering of CTC-specific miRNAs
Unsupervised cluster analysis of the 146 patients with QQ miRNA data based on the 13 CTC-
specific miRNAs resulted in discrimination into two main groups (Figure 4). No relation with 
CTC count could be established among the clusters, nor were there clear miRNA clusters by 
which the patients were characterized. Cluster 2 did have high expression of hsa-miR-452 and 
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hsa-miR-187, but no common function of these miRNAs could be identified.
Association with clinicopathologic characteristics
When the patients in the two respective mRNA clusters (1 and 2 a&b) were compared for 
their baseline clinicopathologic characteristics, no differences between the clusters reached 
statistical significance (Supplementary Table 1a). Contrarily, more patients in miRNA cluster 
2 had received induction chemotherapy prior to liver metastasis resection and thus prior to 
blood draw for CTC gene expression profiling (Fisher’s exact, P=0.017, Supplementary Table 
1b). 
DISCUSSION 
CTCs offer an exciting new opportunity to assess prognostic and predictive markers repeatedly 
during the course of cancer. CTCs are presumed to represent actual metastatic tumor load, and 
may thus provide more accurate information to guide treatment decisions than the primary 
tumor. After having previously shown the feasibility of measuring a CTC-specific gene panel 
in the CTCs of metastatic breast cancer patients
38
, we show here that, this time using genes 
clinically relevant in CRC, the same method can be successfully applied to CTCs in CRC.
While several studies have described the expression levels of up to 10 different genes in the 
blood of CRC patients
22,202,353-355
, no work has been published on the broad-scale molecular 
characterization of CTCs of CRC patients after CellSearch enrichment. This EpCAM-based 
CellSearch enrichment has the significant advantage of being semi-automated and approved 
by the FDA for use as a prognostic marker, but does not result in a pure CTC population. To still 
enable reliable measurement of clinically relevant genes, we selected, in silico, genes that are 
not or at a very low level expressed by leukocytes. Among these, we identified CTC-specific 
genes by comparing HDs and patients with ≥3 CTCs. We first established whether we could group 
patients without detectable CTCs with the HDs. However, when comparing patients without 
detectable CTCs with HDs, a cluster of patients had a gene expression profile strongly differing 
from that of HDs. These HD-unlike patients were characterized by the expression of known 
epithelial markers such as cytokeratins and EPCAM, but also of four other genes previously 
determined to be epithelial-specific (S100A16, AGR2, IGFBP5 and LAD1
38
). Two of these, 
S100A16 and AGR2, have also been described by others to be expressed in CTCs
39
. Together, 
the gene expression pattern of these patients strongly suggests the presence of circulating 
tumor load, CTCs or cell fragments, which are not being detected or recognized as such in 
the blood drawn in parallel for CTC enumeration. A few factors could cause this discrepancy 
between CTC count and CTC molecular profile. Literature suggests that colorectal cancer cells 
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can lack CK8, 18 or 19 expression
356
, the markers by which a CTC is defined in CellSearch. In 
breast cancer as well, we have described a lack of cytokeratin expression for certain breast 
cancer subtypes
319
, reflecting the epithelial-to-mesenchymal (EMT)-like phenotype of these 
cells. A lack of CK8/18/19 expression would result in the enrichment of CTCs based on their 
EpCAM-expression for both subsequent CTC isolation and characterization, without these cells 
being counted as CTCs. Indeed, HD-unlike patients had lower expression of all cytokeratins 
needed for CTC enumeration compared to HD-alike patients, while this difference was much 
smaller for EPCAM. Adding to the discrepancies between CTC counts and gene expression could 
also be an imperfect correlation of mRNA and protein expression and the well-known issue of 
stochastic variation
357
. Moreover, the strict morphological criteria that have to be met for cells 
to be counted as CTCs excludes counting of small CTCs or CTC fragments
61
, which nonetheless 
do confer a mRNA signal. Whatever the cause, measurement of CTC-specific gene expression 
seems to be able to detect circulating tumor load among patients without detectable CTCs, 
and may possibly identify a poor prognosis group among patients with a “false-negative” CTC 
count that would otherwise confer to a good prognosis.
By comparing HDs and patients with ≥3 CTCs, we identified 47 CTC-specific genes, of which 
34 were mRNAs and 13 miRNAs. Based on the unsupervised cluster analysis with the 34 CTC-
specific mRNAs, we could distinguish three patient clusters, one of them characterized by the 
absence of epithelial gene expression. We did not see a clear relation with CTC-count, possibly 
caused by the aforementioned issues resulting in discrepancies between CTC enumeration and 
gene expression. With regard to the clustering based on miRNA expression data, distinguishing 
patient clusters was more challenging and like for the mRNA data, no relation with CTC count 
was seen. These results underline the complexity of miRNA data interpretation due to their 
regulatory role, which, combined with lack of epithelial association
250
, could lead to a decidedly 
different expression pattern than that of mRNAs. 
Our colorectal CTC-specific 47-gene panel enables the large-scale characterization of CTCs 
despite their presence among remaining leukocytes. The generation of this colorectal CTC-
specific gene panel enables the exploration of CTC characterization as a novel means to 
further individualize cancer treatment based on better prognostic and predictive factors, and 
specifically in this study population, identify those patients who will derive benefit from liver 
metastasis resection.
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Table	  1	   	   	   	   	  
Clinicopathological	  data	   	  	   	  	   	  	   	  	  
CTC	  count	  
Patient	  characteristics	  
No.	  of	  
patients	   <3	   ≥3	   P-­‐value	  
	  	   	  	   	  	   	  	   	  	  
All	  patients	   146	  
(100%)	  
106	  (73%)	   40	  (27%)	   	  	  
Sex	   	  	   	  	   	  	   	  	  
Female	   55	  (38%)	   31	  (56%)	   24	  (44%)	   0.001	  
Male	   91	  (62%)	   75	  (82%)	   16	  (18%)	   	  	  
Age	  at	  time	  of	  surgery	   	  	   	  	   	  	   	  	  
<60	   44	  (30%)	   31	  (70%)	   13	  (30%)	   	  	  
≥60	   102	  (70%)	   75	  (74%)	   27	  (26%)	   	  	  
Presentation	  of	  metastasis	   	  	   	  	   	  	   	  	  
synchronous	   87	  (60%)	   65	  (75%)	   22	  (25%)	   	  	  
metachronous	   59	  (40%)	   41	  (69%)	   18	  (31%)	   	  	  
Primary	  tumor	  in	  situ	  at	  time	  of	  surgery	   	  	   	  	   	  	   	  	  
yes	   37	  (35%)	   30	  (81%)	   7	  (19%)	   	  	  
no	   109	  (75%)	   76	  (70%)	   33	  (30%)	   	  	  
Elapsed	  time	  between	  primary	  tumor	  and	  
metastasis	  resection*	   	  	   	  	   	  	   	  	  
<6	  months	   26	  (18%)	   23	  (88%)	   3	  (12%)	   0.05	  
≥6	  months	   100	  (68%)	   69	  (69%)	   31	  (31%)	   	  	  
	  	   	  	   	  	   	  	   	  	  
Primary	  tumor	  characteristics	   	  	   	  	   	  	   	  	  
Location#	   	  	   	  	   	  	   	  	  
right	  hemicolon	   29	  (20%)	   22	  (76%)	   7	  (24%)	   	  	  
left	  hemicolon	   65	  (45%)	   48	  (74%)	   17	  (26%)	   	  	  
rectum	   51	  (35%)	   36	  (71%)	   15	  (29%)	   	  	  
Dukes	  classification#	   	  	   	  	   	  	   	  	  
A	   2	  (1%)	   1	  (50%)	   1	  (50%)	   	  	  
B	   23	  (16%)	   16	  (70%)	   7	  (30%)	   	  	  
C	   26	  (18%)	   21	  (81%)	   5	  (19%)	   	  	  
D	   89	  (61%)	   66	  (74%)	   23	  (26%)	   	  	  
Neoadjuvant	  chemotherapy#	   	  	   	  	   	  	   	  	  
yes	   21	  (14%)	   18	  (86%)	   3	  (14%)	   	  	  
no	   106	  (73%)	   75	  (71%)	   31	  (29%)	   	  	  
Adjuvant	  chemotherapy#	   	  	   	  	   	  	   	  	  
yes	   15	  (10%)	   12	  (80%)	   3	  (20%)	   	  	  
no	   112	  (77%)	   81	  (72%)	   31	  (28%)	   	  	  
Induction	  chemotherapy	  before	  liver	  
resection#	   	  	   	  	   	  	   	  	  
yes	   83	  (57%)	   59	  (72%)	   24	  (28%)	   	  	  
no	   61	  (42%)	   45	  (74%)	   16	  (26%)	   	  	  
Site	  of	  metastasis	   	  	   	  	   	  	   	  	  
liver-­‐only	   130	  (89%)	   96	  (74%)	   34	  (26%)	   	  	  
liver	  and	  other	  sites	   16	  (11%)	   10	  (63%)	   6	  (37%)	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Clinicopathologic	  characteristics	  of	  all	  146	  patients	  with	  pathology-­‐confirmed	  colorectal	  liver	  metastases	  
and	  miRNA	  data	  available.	  Only	  significant	  P-­‐values	  as	  obtained	  by	  the	  Fisher’s	  exact	  test	  are	  depicted.	  
The	  subset	  of	  98	  patients	  for	  whom	  mRNA	  data	  were	  available	  is	  described	  in	  Supplementary	  Table	  1.	  
*numbers	   do	   not	   add	   up	   to	   100%	   because	   patients	   undergoing	   primary	   tumor	   resection	   after	   liver	  
resection,	   and	   patients	   who	   have	   not	   undergone	   primary	   tumor	   resection	   at	   all,	   were	   left	   out;	   #	  
numbers	  do	  not	  add	  up	  to	  100%	  because	  of	  missing	  data.	  
	  
	  
Table	  2	   	   	   	  
Genes	  differentially	  expressed	  between	  HD-­‐unlike	  and	  HD-­‐alike	  patients	  
Gene	  symbol	  
Parametric	  P-­‐
value	  
P-­‐value	  (FDR	  
10%)	  
Permutation	  P-­‐
value	  
	  	   	  	   	  	   	  	  
REG1A	   <	  1.00E-­‐07	   <	  1.00E-­‐07	   <	  1.00E-­‐07	  
TSPAN8	   <	  1.00E-­‐07	   <	  1.00E-­‐07	   <	  1.00E-­‐07	  
COL4A1	   1.00E-­‐07	   2.74E-­‐06	   <	  1.00E-­‐07	  
KRT19	   1.00E-­‐07	   2.74E-­‐06	   <	  1.00E-­‐07	  
S100A16	   1.00E-­‐07	   2.74E-­‐06	   <	  1.00E-­‐07	  
PRSS8	   7.00E-­‐07	   1.60E-­‐05	   <	  1.00E-­‐07	  
CKB	   2.00E-­‐06	   3.91E-­‐05	   1.00E-­‐04	  
ERBB3	   4.30E-­‐06	   7.36E-­‐05	   <	  1.00E-­‐07	  
AGR2	   7.90E-­‐06	   1.20E-­‐04	   1.00E-­‐04	  
GPX2	   1.43E-­‐05	   1.96E-­‐04	   <	  1.00E-­‐07	  
COL5A1	   3.04E-­‐05	   3.79E-­‐04	   1.00E-­‐04	  
IGFBP5	   4.03E-­‐05	   4.60E-­‐04	   <	  1.00E-­‐07	  
TM4SF1	   4.69E-­‐05	   4.94E-­‐04	   <	  1.00E-­‐07	  
ASS1	   8.61E-­‐05	   8.39E-­‐04	   1.00E-­‐04	  
SOX9	   9.19E-­‐05	   8.39E-­‐04	   <	  1.00E-­‐07	  
COL1A2	   1.14E-­‐04	   9.78E-­‐04	   1.00E-­‐04	  
COL1A1	   2.14E-­‐04	   1.72E-­‐03	   1.00E-­‐04	  
KRT8	   2.35E-­‐04	   1.79E-­‐03	   3.00E-­‐04	  
MCAM	   2.78E-­‐04	   1.90E-­‐03	   2.00E-­‐04	  
DUOX2	   2.78E-­‐04	   1.90E-­‐03	   1.00E-­‐04	  
RARRES2	   3.44E-­‐04	   2.25E-­‐03	   3.00E-­‐04	  
TRIM2	   4.51E-­‐04	   2.67E-­‐03	   4.00E-­‐04	  
COL3A1	   4.67E-­‐04	   2.67E-­‐03	   4.00E-­‐04	  
LCN2	   1.05E-­‐03	   5.54E-­‐03	   1.30E-­‐03	  
IGFBP2	   1.56E-­‐03	   7.92E-­‐03	   1.50E-­‐03	  
MUC1	   2.66E-­‐03	   1.30E-­‐02	   1.80E-­‐03	  
LAD1	   2.98E-­‐03	   1.41E-­‐02	   2.60E-­‐03	  
ACTB	   3.50E-­‐03	   1.54E-­‐02	   2.10E-­‐03	  
CTTN	   3.73E-­‐03	   1.55E-­‐02	   3.70E-­‐03	  
SPRY4	   5.47E-­‐03	   2.14E-­‐02	   3.80E-­‐03	  
CDH5	   7.52E-­‐03	   2.75E-­‐02	   6.80E-­‐03	  
CCND1	   7.63E-­‐03	   2.75E-­‐02	   7.00E-­‐03	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KRT20	   8.37E-­‐03	   2.85E-­‐02	   7.80E-­‐03	  
MT1E	   9.17E-­‐03	   2.91E-­‐02	   9.30E-­‐03	  
VWF	   9.18E-­‐03	   2.91E-­‐02	   7.50E-­‐03	  
SLC7A5	   9.33E-­‐03	   2.91E-­‐02	   7.50E-­‐03	  
LMNA	   1.15E-­‐02	   3.50E-­‐02	   9.40E-­‐03	  
TGM2	   1.37E-­‐02	   3.99E-­‐02	   1.01E-­‐02	  
MACC1	   1.52E-­‐02	   4.33E-­‐02	   9.10E-­‐03	  
IGFBP3	   1.69E-­‐02	   4.74E-­‐02	   1.28E-­‐02	  
MACROD1	   2.02E-­‐02	   5.52E-­‐02	   1.71E-­‐02	  
CCNB1	   2.11E-­‐02	   5.66E-­‐02	   1.47E-­‐02	  
GMDS#	   2.23E-­‐02	   5.86E-­‐02	   1.94E-­‐02	  
MKI67	   2.84E-­‐02	   7.07E-­‐02	   2.40E-­‐02	  
LSP1	   2.93E-­‐02	   7.17E-­‐02	   2.90E-­‐02	  
EPCAM	   3.42E-­‐02	   8.22E-­‐02	   2.60E-­‐02	  
CDH1	   3.57E-­‐02	   8.37E-­‐02	   2.51E-­‐02	  
IGFBP4	   3.61E-­‐02	   8.37E-­‐02	   2.60E-­‐02	  
KRT18	   3.88E-­‐02	   8.62E-­‐02	   2.89E-­‐02	  
CEACAM5	   3.90E-­‐02	   8.62E-­‐02	   3.58E-­‐02	  
BST1	   4.21E-­‐02	   9.15E-­‐02	   4.00E-­‐02	  
	  	   	  	   	  	   	  	  
Statistical	  significance,	  tested	  with	  a	  two-­‐sample	  t-­‐test	  and	  depicted	  as	  parametric	  P-­‐value	  and	  P-­‐value	  
after	   correction	   for	  multiple	   testing	   (10%	   false	   discovery	   rate	   [FDR])	   and	  permutation	  P-­‐value,	   of	   the	  
differential	   expression	   between	   HD-­‐unlike	   and	   HD-­‐alike	   patients	   among	   patients	   without	   detectable	  
CTCs.	   All	   genes	   were	   higher	   expressed	   in	   HD-­‐unlike	   patients,	   with	   the	   exception	   of	   GMDS.	   #higher	  
expressed	  in	  HD-­‐alike	  patients.	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 1: see section ‘Color figures’
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Figure 2: Expression of CTC-markers in HDs, HD-unlike and HD-alike patients with low CTC counts
Expression levels of EPCAM, KRT8, KRT18 and KRT19 are depicted for HDs, HD-alike and HD-unlike patients. 
Expression levels are depicted as deltaCt to the median of the reference genes (GUSB, HMBS and HPRT1). 
Box plots represent median, 1
st
 – 3
rd 
quartile (box), 5% – 95% (whiskers) and outlier (dots) expression 
levels. Level of significance tested with Mann Whitney U test. HD; healthy donor.
Figure 3: see section ‘Color figures’
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Figure 4: see section ‘Color figures’
Supplementary data:
https://docs.google.com/open?id=0B9Etqm_r7T2mNnN5STlLajcyZFU 
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ABSTRACT
Background
Although anti-EGFR therapy has established efficacy in metastatic colorectal cancer, only 10-
20% of unselected patients respond. This is partly due to KRAS and BRAF mutations, which 
are currently assessed in the primary tumor. To improve patient selection, assessing mutation 
status in circulating tumor cells (CTCs), which possibly better represent metastases than the 
primary tumor, could be advantageous. We investigated the feasibility of KRAS and BRAF 
mutation detection in colorectal CTCs by comparing three sensitive methods and compared 
mutation status in matching primary tumor, liver metastasis and CTCs.
Methods
CTCs were isolated from blood drawn from 49 patients before liver resection using CellSearch™. 
DNA and RNA was isolated from primary tumors, metastases and CTCs. Mutations were 
assessed by co-amplification at lower denaturation temperature (COLD)-PCR (Transgenomic™), 
real-time PCR (EntroGen™), and nested Allele-Specific Blocker (ASB-)PCR and confirmed by 
Sanger sequencing.
Results
In 43 of the 49 patients, tissue RNA and DNA was of sufficient quantity and quality. In these 
43 patients, discordance between primary and metastatic tumor was 23% for KRAS and 7% for 
BRAF mutations. RNA and DNA from CTCs was available from 42 of the 43 patients, in which 
ASB-PCR was able to detect the most mutations. Inconclusive results in patients with low CTC 
counts limited the interpretation of discrepancies between tissue and CTCs.
Conclusion
Determination of KRAS and BRAF mutations in CTCs is challenging but feasible. Of the tested 
methods, nested ASB-PCR, enabling detection of KRAS and BRAF mutations in patients with as 
little as two CTCs, seems to be superior.
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INTRODUCTION
The introduction of new drugs such as monoclonal antibodies directed against EGFR has 
improved the life expectancy of colorectal cancer patients
358
. Unfortunately, only 10 - 20% 
of unselected metastatic colorectal cancer patients respond
358-360
, which is partly due to 
activating mutations in genes downstream of the EGF-receptor, such as KRAS and BRAF.
KRAS mutations are present in 30 - 40% of colorectal cancer patients
361
. Extensive descriptions 
of the inactivity of anti-EGFR therapy in KRAS-mutated patients
4,334,362-365
 show that these 
agents generate a response in 17 - 40% of patients with KRAS wild-type (wt) tumors versus 0% 
of patients with KRAS mutated (mt) tumors
4
. Based on these results, the European Medicines 
Agency has approved the use of monoclonal antibodies against EGFR solely for patients with 
KRASwt tumors
366
. 
Another potentially predictive mutation for response to EGFR-inhibiting therapy is BRAF, which 
is present in ~10% of colorectal cancer patients
361
. Evidence for the predictive value of BRAF 
mutations is not as abundant as for KRAS
367-368
, and a mutated BRAF is not yet an exclusion 
criterion for this therapy. However, if the same mechanism applies, which is very likely given 
the similar important role of BRAF and KRAS in the EGFR pathway, BRAF mutations could be as 
an important predictive factor as KRAS.
Although KRAS and BRAF mutation status are currently determined in the primary tumor, 
primary tumor tissue is not always available, is of insufficient quality, or has been obtained 
years before the diagnosis of metastatic disease. Importantly, mutation status of the primary 
as well the metastatic lesions can change over time and during the course of therapy
369-370
. 
In this regard, ideally, mutation status of the patient’s actual metastatic tumor load would be 
assessed right before treatment is started. However, metastatic tissue is often hard to obtain, 
and usually only through invasive and painful procedures. These drawbacks could potentially 
be overcome by assessing mutation status of circulating tumor cells (CTCs), which can be 
present in the peripheral blood of metastatic colorectal cancer patients
371-372
. 
Here we describe the use of three techniques to assess KRAS and BRAF mutation status in 
enriched CTC fractions, consisting of CTCs and >100-fold excess DNA from leukocytes
9
. A 
fast nested Co-amplification at Lower Denaturation temperature (COLD-)PCR combined with 
Surveyor®/WAVE® denaturing High-Performance Liquid Chromatography (HPLC) followed 
by sequencing (Transgenomic®, Omaha, NE), a commercially available real-time PCR kit 
(EntroGen™, Tarzana, CA), and a nested Allele-Specific PCR with a Blocking reagent (ASB-PCR)
373
 
were tested and compared for their ability to detect mutations in CTCs of colorectal cancer 
patients with liver metastases undergoing partial liver resection. In addition, the mutation 
status in matched primary and metastatic tumor tissue was determined and correlated to each 
other and to CTC mutation status.
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METHODS
Patients and ethics statement
From 63 patients with metastatic colorectal cancer, 2 x 30 mL blood samples were taken for CTC 
enumeration and characterization by way of venipuncture before liver metastasis resection 
and prior to tumor manipulation. This study was approved by Leiden University Medical 
Center and Erasmus University Medical Center Institutional Review Boards (METC P05.182), 
and all patients were enrolled in Erasmus MC, Rotterdam, Netherlands after written informed 
consent was obtained.
Cancer cell lines and synthetic DNA
Colorectal cancer cell lines HCT116 and breast cancer cell line SK-BR-3 were obtained from 
ATCC (Manassas, VA) and cultured under recommended conditions. HCT116 was previously 
established to harbor a heterozygous G13D, G>A KRAS mutation
374
, and SK-BR-3 is BRAF and 
KRAS wild-type
226
. For cell line experiments, cells were harvested at log phase and counted by 
Improved Neubauer Hemacytometer (Hausser Scientific, Horsham, PA). A range of synthetic 
DNA concentrations as supplied in the EntroGen kit (see next) were tested in the EntroGen kit 
and in the ASB-PCR to assess assay detection limits.
Enumeration and isolation of CTCs
Two samples of 30 mL blood from 49 metastatic colorectal cancer patients about to undergo 
liver metastasis resection were drawn in CellSave™ tubes (Veridex LLC, Raritan, NJ) for CTC 
enumeration or EDTA tubes for CTC isolation. Prior to enumeration and isolation, a density 
gradient-based enrichment step was applied as described before
337-338
. For CTC isolation, 
samples were then processed on the CellTracks™ AutoPrep System (Veridex LLC) using the 
CellSearch™ Profile kit (Veridex LLC). For CTC enumeration, samples were processed using 
the CellSearch™ Epithelial Cell Kit (Veridex LLC) and CTC counts were determined on the 
CellTracks™ Analyzer (Veridex LLC) according to the manufacturer’s instructions. 
mRNA and DNA isolation from CellSearch-enriched  CTC fractions and tissue
After removal of the supernatant using a MagCellect Magnet (R&D Systems, Minneapolis, USA), 
the cells in the enriched CTC fractions were lysed by adding 250 μL of Qiagen AllPrep DNA/RNA 
Micro Kit Lysis Buffer (RLT+ lysis buffer) (Qiagen, Valencia, CA) and stored immediately at -80°C 
until DNA and RNA isolation was performed with the AllPrep DNA/RNA Micro Kit (Qiagen) 
according to the manufacturer’s instructions and as described before
38
. For analysis of primary 
and metastatic tumors, total RNA and DNA was isolated from fresh frozen tissue with RNA-
Bee (AMSBIO, Abingdon, UK) as described before
290
 and from FFPE tissue with the column-
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based High Pure RNA Paraffin Kit (Roche Applied Science, Penzberg, Germany) according to 
the manufacturer’s instructions. After DNA and RNA extraction from CellSearch-enriched CTCs 
and tissues, quality and quantity checks were performed by evaluating the levels of a set of 
reference genes by real time PCR as described before
38,375
. For tissue RNA, this was preceded 
by measurements with a Nanodrop Spectrophotometer and agarose gel electrophoresis, and 
for genomic DNA (gDNA) by measurements with the Quant-iT PicoGreen dsDNA reagent (Life 
technologies, Carlsbad, CA).
Fast COLD-PCR & Surveyor/WAVE technology
Fast COLD-PCR (Transgenomic, Omaha, NE) exploits the observation that a single-nucleotide 
mismatch along a double-stranded DNA sequence results in a change of the melting temperature 
(T
m
) for that sequence, so that when PCR denaturation temperature is set to a temperature 
slightly lower than T
m
, DNA amplicons differing by a single nucleotide are selectively denatured 
and amplified, enriching the sample for mutated alleles
329
. Assay sensitivity was established by 
the manufacturer to be 0.1% (http://www.transgenomic.com/lib/ps/602136-00.pdf).
For COLD-PCR, 10ng gDNA from CellSearch-enriched CTC fractions, consisting of CTCs and 
>100-fold excess DNA from leukocytes, was selectively pre-amplified with KRAS and BRAF 
primers by two rounds of COLD-PCR as described before
376
. Amplified exons were analyzed 
by Surveyor digestion using the Transgenomic SURVEYOR kit, in which the surveyor nuclease 
digests mismatch-containing DNA. After purification of digested DNA using the QIAquick 
PCR purification kit (Qiagen), samples were analyzed by WAVE technology according to 
the manufacturer’s instructions
376
. For sequencing, amplified exons were fractionated by 
denaturating HLPC, and fractions of interest were again amplified by PCR. PCR products were 
purified as above and sequenced using the Applied Biosystems PRISM® 3730 sequencer. 
EntroGen KRAS/BRAF kit
EntroGen provides a commercially available real-time PCR kit for KRAS and BRAF mutation 
detection, which uses allele-specific primers without employing a pre-amplification step. 
For the EntroGen assay, 50 ng gDNA from tissues was amplified with gene specific primers 
and the KRAS codons 12, 13 and 61 and BRAF V600E mutations were detected using allele-
specific probes (EntroGen), as described previously
377
. For CTC samples, a nested PCR was first 
performed on 10ng gDNA extracted from CellSearch-enriched CTCs, followed by a second PCR 
with the allele-specific probes as described before
377
.
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ASB-PCR assay
ASB-PCR is an assay developed to suppress the amplification of primer:template mismatches. 
Two key features of the assay are a mutant-specific primer that is shortened at its 5’-end 
to reduce the T
m
 to approximately 10°C below the annealing temperature of the assay, and 
the use of a blocking oligonucleotide, which has a sequence complementary to the wild-type 
sequence but is phosphorylated at the 3’-end to prevent its extension. The combination of 
these two modifications results in suppression of the amplification of wild-type allele, and the 
assay has been reported to be capable of detecting mutant alleles with DNA inputs between 2 
and 250 pg among a thousand-fold excess of wild-type DNA
373
. 
ASB-PCR was performed essentially as described before
373
. Briefly, cDNA was synthesized using 
5 µL CTC RNA with Invitrogen’s cDNA Reverse Transcriptase kit (Life Technologies, Carlsbad, 
CA). All 10 µL of the resulting cDNA was then used in a nested PCR using 2x Expression Master 
Mix (TaqMan Gene Expression MasterMix kit, Life Technologies) and 2 µL 0.5 µM Primer Mix 
in a 20 µL reaction volume. For CTC samples, 2 µL PCR product from the first amplification 
(above) was used for the second round of amplification; while with DNA isolated from tissues, 
5 10 ng gDNA was used, both in a 20 µL assay with 2 x TaqMan Gene Expression Mastermix and 
10x Primer/Probe/Blocker mix (sequences and cycling conditions in Supplementary Table 1).
TOPO TA cloning and Sanger sequencing
PCR products from samples that were estimated to have sufficient mutation were cloned with 
the TOPO® TA Cloning® Kits for Sequencing (Life Technologies) according to the manufacturer’s 
instructions. Positive colonies were amplified individually under the same PCR conditions as 
the first round of amplification of the nested-PCR. Amplified products were purified using 
QIAquick PCR Purification kit (Qiagen) and sent to GENEWIZ (South Plainfield, NJ) for Sanger 
dideoxy terminator sequencing
378
.
RESULTS
Patients
DNA and RNA isolated from primary tumor and metastatic tumor tissue was available for 
analysis from 43 patients. The 20 excluded patients had no primary tumor or metastatic tissue 
available, either because the primary tumor had not been resected at the time of this analysis 
or because the liver lesion was benign or not from colorectal cancer origin. CTC count and 
isolated CTCs were available for 42 of the 43 patients. Median CTC count in all 42 patients 
was 1 (range 0-37); 16 patients had no detectable CTCs (38%). Most patients had metastatic 
disease confined to their liver; six patients also had metastases elsewhere, mostly pulmonary. 
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Twenty-one patients had received induction chemotherapy prior to liver resection, and fifteen 
patients had undergone neoadjuvant or adjuvant treatment for their primary tumor, leaving 
10 patients chemo-naïve at the time of liver resection. Detailed patient characteristics are 
depicted in Table 1. 
KRAS and BRAF mutation status in primary tumors
Because of the established nature of the test and high sensitivity of 0.1% according to the 
manufacturer (http://www.transgenomic.com/lib/ps/602136-00.pdf), KRAS and BRAF 
mutation analysis was first performed by COLD-PCR in all primary and metastatic tumor 
tissues. When available, fresh frozen (FF) tissue was used for analysis; in other instances, 
formalin-fixed, paraffin-embedded (FFPE) tissue was used, resulting in analysis of five FF and 
37 FFPE primary tumors. Nine primary tumors (21%) harbored a KRAS mutation, which were 
reproducibly detected in duplicate and confirmed by sequencing (Table 2). Mutation frequency 
ranged from 5 to 100%, and all but one mutations involved codon 12 or 13. One T35I mutation 
was detected, caused by a C>T substitution, a missense mutation that has previously been 
described
379
. BRAF mutations were detected in three primary tumors (7%), two V600E and one 
D594G caused by an A>G substitution. No samples harbored both BRAF and KRAS mutations, 
in line with other reports
3,5
 on their mutual exclusivity. 
KRAS and BRAF mutation status in metastatic tissue
Determination of mutation status by COLD-PCR was technically feasible in all 31 FF and 12 FFPE 
metastatic tissue specimens. A KRAS mutation was detected in 10 of the 43 patients (23%), all 
of which involved codon 12 or 13 (Table 2). A BRAF mutation was present in the metastasis of 
four of the 43 patients (9%), two of them V600E and two others; D594N and D594G. As with 
primary tumors, KRAS and BRAF mutations were never present in the same specimen.
Correlation of primary tumor and metastases mutation status
The same KRAS mutation was present in the metastatic tissue of four of the nine patients in 
whom a KRAS mutation was detected in the primary tumor. Of the remaining five patients 
with a mutated primary tumor, four patients had a KRASwt metastasis, and one patient 
had a different KRAS mutation in the metastatic lesion than in the primary tumor (CTC192, 
Table 2). Of 34 patients with a KRASwt primary tumor, five (15%) did have a KRAS mutation 
in their metastasis. One of these patients had presented with synchronous metastases but 
had received induction therapy between primary surgery and metastases resection. The four 
other patients with discrepancy in KRAS mutation status had presented with metachronous 
metastases, and one had also received induction therapy prior to partial liver resection. 
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Two of the three patients with a BRAFmt primary tumor had the same mutation in their 
metastases; the third patient’s metastasis was BRAFwt. Of 40 patients with a BRAFwt primary 
tumor, two (5%) had BRAFmt metastases. While one of these patients had presented with 
synchronous metastases, both of them received induction chemotherapy prior to liver 
resection.
The only patient in this cohort who had been treated with anti-EGFR monoclonal antibodies 
before liver surgery had a wild-type primary and metastatic tumor (CTC203, Table 2).
COLD-PCR in CTCs
Because of its well-described high sensitivity, KRAS mutation detection in CTCs was first 
attempted by COLD-PCR. The DNA from the enriched CTC fractions of 13 patients, selected to 
contain both high and low CTC counts, as well as patients with both mutated and wild-type 
metastases, was analyzed.
A G12D KRAS mutation, caused by a substitution of G>A, was detected in one of these samples 
(CTC208, Figure 1 and Table 3). While no mutation was detected in the primary tumor, 
this patient’s metastasis contained the same mutation as detected in the CTC fraction at 
an estimated frequency of 80% (Table 2). In five other samples, a failed PCR product in the 
sequencing step meant that no mutation could be detected, and in five other CTC samples, no 
variant was detected despite a mutated primary or metastatic tumor (Table 3). 
EntroGen PCR assay in CTCs
Because of the disappointingly few mutations detected in CTCs by COLD-PCR, we tested two 
other assays with a probable high sensitivity
373,380
. First, the detection limit of EntroGen PCR 
assay was determined by testing a range of concentrations of synthetic DNA containing a KRAS 
mutation. The assay was able to detect as little as 0.6% KRASmt among KRASwt DNA (Table 4). 
KRAS mutation status was determined by the EntroGen PCR assay in all nine primary tumors 
with a KRASmt according to COLD-PCR, yielding reproducible results (Supplementary Table 
2). However, when testing gDNA from nine CTC samples for KRAS mutation status using the 
EntroGen kit, no mutations were detected (Table 3), even though eight of these patients had 
a KRASmt primary or metastatic tumor tissue according to COLD-PCR.
ASB-PCR in CTCs
Next, CTC mutation detection was attempted by the ASB-PCR approach. Assay sensitivity of 
the one-run KRAS and BRAF ASB-PCR assay was determined by testing a range of synthetic 
KRASmt DNA concentrations spiked in wild-type DNA (Table 5). As little as 0.2% of mutated 
among wild-type alleles could be detected, and in the nested ASB-PCR seven different KRAS 
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mutations were tested, which could all be detected in concentrations down to 0.6% mutated 
among wild-type copies (Table 6). Again, confirmatory results were obtained in all KRASmt 
primary tumors and V600E BRAFmt primary and metastatic tissues by (Supplementary Table 
2 & 3). Because our ASB-PCR was designed only for the detection of the most common V600E 
mutation, two other BRAF mutations detected by COLD-PCR could not be validated.
Considering the assay’s in vitro sensitivity, RNA isolated from the CellSearch-enriched CTCs of 
all available patients was tested for KRAS codon 12 and 13 and BRAF V600E mutation status 
by nested ASB-PCR (Table 2 & 3). Using this method, five KRAS mutations were detected at a 
frequency of <0.01 - 8.9%. Accompanying CTC counts ranged from 2 to 37, conferring to CTC 
input from 0.8 to 15.2 cells, as only 40% of the total sample was used for ASB-PCR. Four of 
these patients had the same KRAS mutation in their metastasis, while one patient (CTC284) 
had a KRASwt primary tumor and metastasis. In patient CTC196, whose primary tumor and 
metastasis were BRAFwt, a BRAF V600E mutation was detected. The ASB-PCR assay was 
designed to detect only the most common V600E BRAF mutation, precluding the detection 
of the D594N and D594G mutations from patients’ CTC204 and CTC207 metastases in their 
CTCs. 
Confirmation of CTC mutation status by sequencing
We next sought to confirm the CTC mutations as detected by ASB-PCR through traditional 
Sanger sequencing. In our hands, Sanger sequencing had a sensitivity of 12.5% in cell line 
experiments (data not shown). Based on estimates of KRASmt frequency in the enriched CTC 
fractions (Table 6), sequencing was potentially only feasible for patients CTC208, CTC245 and 
CTC284 (estimated mutation frequencies 8.9%, 6.1% and 2.0%, respectively). CTC222 had a 
too low mutation frequency (<0.01%) for sequencing, and for patient CTC202, no more DNA 
was available. Sample CTC208 had previously been sequenced following mutation detection 
with COLD-PCR. The purified PCR products of samples CTC245 and CTC284 were subjected to 
TOPO TA cloning, and we were able to sequence a G12V, G>A KRASmt (2 of 90 colonies) in the 
CTCs from patient CTC245. In patient CTC284, no KRASmt was detected in the 100 selected 
colonies (Table 3).
DISCUSSION
Determining KRAS and BRAF mutations in CTCs is extremely challenging due to the low 
number of CTCs, the lack of amplification of the genes of interest, and the presence of up 
to 1,000 leukocytes despite CTC enrichment
9
. We compared the performance of three 
mutation assays selected for their high sensitivity. COLD-PCR and ASB-PCR have specifically 
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been developed to enable detection of low-abundant mutated alleles among wild-type copies 
through enrichment of mutated alleles and specific blocking steps. Despite these adaptations, 
KRAS and BRAF mutation detection in CTCs is pushing the limits of the assays’ performance. 
ASB-PCR proved to be able to detect the most mutations in the CTC-fractions in our hands, 
as five of six mutations that could be detected by ASB-PCR were not detected with COLD-
PCR. Only two of the CTC fractions with a KRAS mutation as detected by ASB-PCR were also 
tested by the EntroGen PCR assay. As no mutations were detected in these two nor in six other 
CTC fractions of patients with a KRASmt primary tumor and/or metastasis, the sensitivity of 
the EntroGen assay is probably too low. Previous studies on the detection of mutations in 
the androgen receptor (AR)
36
 and EGFR
381
 mutations in CTCs have been more fruitful, quite 
possibly explained by the amplification of these genes accompanying their mutated status, 
which results in a larger number of mutated alleles per CTC. Additionally, CTC counts in these 
studies were generally much higher than in our patient cohort
382
.
We were able to detect KRAS or BRAF mutations in CTCs from six of 43 patients, five of whom 
had a CTC count above 3 cells in 30 mL blood. In two patients with KRASmt metastases and ≥3 
CTCs (CTC201 & CTC209), no KRAS mutation was detected in the CTCs. Despite optimization of 
the assays for detection of mutated amplicons amongst abundant wild-type copies, mutant DNA 
was probably too scarce. The lack of mutant DNA may also be explained by stochastic variation; 
CTCs can be present in the blood drawn for CTC enumeration, but not in the blood drawn for 
CTC isolation and mutation assessment
357
. In CTC201, with 28 CTCs, stochastic variation does 
not explain the inability to detect a KRAS mutation. In this and other patients with mutated 
metastases, CTCs might also be truly wild-type, reflecting tumor heterogeneity
6
.
In our 43 colorectal cancer patients, substantial discordance was seen between primary 
tumors and matched metastases. Five out of 33 initially KRASwt patients had a KRASmt 
metastasis; these patients have an indication for anti-EGFR treatment based on primary tumor 
characteristics, while  based on the mutation characteristics of the metastasis, no benefit can 
be expected. Conversely, four patients whose primary tumor KRASmt would exclude them 
from anti-EGFR treatment had KRASwt metastases. While the testing of the BRAF oncogene 
is not yet obligatory before anti-EGFR therapy is started, accumulating data do show its 
predictive value
367-369
. Two patients with BRAFmt metastases would probably not benefit 
from anti-EGFR treatment, although their BRAFwt primary tumor suggests otherwise. In our 
cohort, a higher discordance in mutation status between primary and metastatic tumors was 
observed than in earlier studies
5,369-370,383
, which could be caused by a number of reasons. 
First, several other studies used DNA sequencing methods, which are less sensitive than COLD-
PCR. Especially given the heterogeneity of tumors and the low percentage of vital tumor cells 
in fast-growing metastases, which can both result in small mutated cell fractions, sequencing 
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might underestimate mutation frequency. Also, in accordance with the liver-first approach 
employed in our clinic
325
, almost all patients in our cohort showing discordance between their 
primary tumor and metastasis had been pre-treated with systemic therapy, which might have 
led to more discrepancies.
The identification of patients benefitting from targeted treatments is increasingly important
366
. 
Because of the inherent genomic instability of cancer, possibly augmented by time and 
treatment, heterogeneity exists between primary tumor and metastases. Predictive factors are 
therefore probably more informative when assessed on metastases, but these are often not 
available. Taking CTC mutation status as a surrogate for metastases, KRAS and BRAF testing in 
CTCs could spare patients an expensive therapy that would otherwise be both futile and toxic, 
without the need for invasive biopsies. Our study was initiated to determine if CTC mutation 
analysis is feasible. At this point we cannot conclude that a CTC KRAS and BRAF mutation 
status can be reliably assessed in all patients with a CTC count below 3 cells/30 mL. Especially 
in patients with a low mutation frequency, the chances of false-negative results are substantial 
with the currently applied technology. To obtain reliable test results in all patients with CTCs, 
improvements are necessary. The presence of ~1,000 leukocytes even after CellSearch CTC 
enrichment complicates subsequent characterization
9,38
. Increasing the purity of the input 
CTC sample will reduce the number of wild-type alleles, possibly enabling next generation 
sequencing. Such adaptations should lead to reliable analysis of all patients with one mutated 
CTC in 30 mL blood, a requirement for this test to be taken into studies investigating the 
predictive value of CTC mutation status.
To the best of our knowledge, this is the first study to compare KRAS and BRAF mutation status 
in matched primary tumors, metastases and CTCs. Mutation assessment on CTCs offers the 
opportunity to test patients at the time of metastatic disease and to do so repeatedly during 
the course of treatment.
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Table	  1	   	  	   	  	  
Patient	  characteristics	   	  	   	  	  
Clinicopathological	  characteristic	   No.	  of	  patients	   %	  
	  	   	  	   	  	  All	  patients	   43	   100%	  
	  	   	  	   	  	  
Age	  (median,	  range))	  	  	  	   65	  (37–84)	   	  	  
Sex	   	  	   	  	  
	  	  	  	  Female	   15	   35%	  
	  	  	  	  Male	   28	   65%	  
Site	  of	  primary	  tumor	   	  	   	  	  
	  	  	  	  Right	  hemicolon	   11	   26%	  
	  	  	  	  Left	  hemicolon	   15	   35%	  
	  	  	  	  Rectum	   17	   40%	  
Tumor	  stage	   	  	   	  	  
	  	  	  	  T1	   0	   0%	  
	  	  	  	  T2	   6	   14%	  
	  	  	  	  T3	   24	   56%	  
	  	  	  	  T4	   7	   16%	  
	  	  	  	  pT0	   1	   2%	  
	  	  	  	  Tx	   5	   12%	  
Nodal	  stage*	   	  	   	  	  
	  	  	  	  N0	   21	   49%	  
	  	  	  	  N1	   10	   23%	  
	  	  	  	  N2	   4	   9%	  
	  	  	  	  Nx	   4	   9%	  
Site	  of	  metastasis	   	  	   	  	  
	  	  	  	  Liver	  only	   37	   84%	  
	  	  	  	  Other	  sites	   6	   16%	  
Dukes’	  stage*	   	  	   	  	  
	  	  	  	  A	   2	   5%	  
	  	  	  	  B	   10	   23%	  
	  	  	  	  C	   10	   23%	  
	  	  	  	  D	   19	   44%	  
Metastatic	  lesions*	   	  	   	  	  
	  	  	  	  Synchronous	   18	   42%	  
	  	  	  	  Metachronous	   25	   58%	  
Neo-­‐adjuvant	  therapy	  at	  time	  of	  primary	  tumor*	   	  	   	  	  
	  	  	  	  Yes	   10	   23%	  
	  	  	  	  No	   31	   73%	  
Adjuvant	  therapy	  at	  time	  of	  primary	  tumor*	   	  	   	  	  
	  	  	  	  Yes	   5	   12%	  
	  	  	  	  No	   35	   81%	  
Induction	  therapy	  at	  time	  of	  metastasis*	   	  	   	  	  
	  	  	  	  Yes	   21	   49%	  
	  	  	  	  No	   20	   47%	  
Any	  chemotherapy	  before	  partial	  liver	  resection*	   	  	   	  	  
	  	  	  	  Yes	   30	   70%	  
	  	  	  	  	  No	   10	   23%	  
Monoclonal	  antibodies	  against	  EGFR	  before	  liver	  resection	   	  	   	  	  
	  	  	  	  Yes	   1	   2%	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  No	   40	   93%	  
Primary	  tumor	  in	  situ	  at	  time	  of	  CTC	  blood	  draw	   	  	   	  	  
	  	  	  	  Yes	   5	   12%	  
	  	  	  	  	  No	   38	   88%	  
Median	  time	  (months)	  between	  primary	  and	  metastasis	  resection	  (range)	   18.4	  	  
(0	  –	  51.2)	  
	  	  
CTC	  count§	   	  	   	  	  
	  	  	  	  	  <	  3	   27	   64%	  
	  	  	  	  	  ≥	  3	   15	   36%	  
Median	  CTC	  count	  (range)§	   1	  (0	  –	  37)	   	  	  
	  	   	  	   	  	  
*numbers	  do	  not	  add	  up	  to	  100%	  due	  to	  missing	  data;	  §CTC	  count	  per	  30	  mL	  blood	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Table	  4	   	   	  
Detection	  limit	  of	  Entrogen	  qRT-­‐PCR	   	  
	   KRAS	  Ct	   	  
%	  mutated	  alleles	   G13D	   Δ	  Ct	  to	  wt	  	  
	   	   	  
20%	   26.1	   13.9	  
10%	   27.1	   12.9	  
5%	   27.3	   12.7	  
2.5%	   28.8	   11.2	  
1.25%	   30.1	   9.9	  
0.625%	   31.4	   8.6	  
0%	   NVD*	   NA	  
	   	   	  
EntroGen	  assay	  sensitivity	  in	  mixed	  synthetic	  DNA	  samples.	  Delta	  Ct	  cut-­‐off	  mutation	  call	  criteria	  were	  	  	  	  
-­‐3.0.	   Sensitivity	   of	   the	   assay	   is	   determined	   by	   the	  minimum	   percentage	   of	  mutated	   (mt)	   alleles	   that	  
could	  be	  detected	  among	  wild-­‐type	  (wt)	  alleles	  at	  a	  delta	  Ct	  of	  -­‐	  3.0.	  Table	  shows	  the	  sensitivity	  of	  the	  
KRAS	  EntroGen	  kit	  using	  synthetic	  DNA.	  NVD*;	  no	  variant	  detected	  after	  40	  Ct,	  NA;	  not	  available.	  
	  
Table	  5	   	   	   	   	   	   	   	   	  
Detection	  limit	  of	  one-­‐run	  ASB-­‐PCR	  
	   	   	   	   	   	   	   	   	  KRAS	  Ct	   KRAS	  Ct	   KRAS	  Ct	   KRAS	  Ct	  
%	  mt	  
alleles	   12CGT	  
Δ	  Ct	  to	  
wt	   12TGT	  
Δ	  Ct	  to	  
wt	   12AGT	  
Δ	  Ct	  to	  
wt	   12GGT	  
Δ	  Ct	  
to	  wt	  
20%	   29	   11	   24.8	   15.2	   26.4	   12.1	   30.0	   10.0	  
2%	   32.5	   7.5	   28.0	   12.0	   29.9	   8.6	   33.4	   6.6	  
0.2%	   35.8	   4.2	   31.7	   8.3	   33.2	   5.3	   36.9	   3.1	  
0%	   NVD*	   NA	   NVD*	   NA	   38.5	   NA	   NVD*	   NA	  
	   	   	   	   	   	   	   	   	  
KRAS	  Ct	   KRAS	  Ct	   KRAS	  Ct	   	   	  
%	  mt	  
alleles	   12GCT	  
Δ	  Ct	  to	  
wt	   12GAT	  
Δ	  Ct	  to	  
wt	   12GAC	  
Δ	  Ct	  to	  
wt	   	  
	  
20%	   25.0	   15.0	   22.7	   17.3	   22.5	   17.5	   	   	  
2%	   28.5	   11.5	   26.1	   13.9	   25.9	   14.1	   	   	  
0.2%	   31.7	   8.3	   29.6	   10.4	   29.2	   10.8	   	   	  
0%	   NVD*	   NA	   NVD*	   NA	   NVD*	   NA	   	   	  
	   	   	   	   	   	   	   	   	  
One-­‐run	  ASB-­‐PCR	  (allele-­‐specific	  PCR	  with	  a	  blocking	  reagent)	  assay	  sensitivity	   in	  mixed	  synthetic	  DNA	  
samples.	  Delta	  Ct	  cut-­‐off	  mutation	  call	  criteria	  were	  -­‐3.0.	  Sensitivity	  of	  the	  assays	  is	  determined	  by	  the	  
minimum	  percentage	  of	  mutated	  (mt)	  alleles	  that	  could	  be	  detected	  among	  wild-­‐type	  (wt)	  alleles	  at	  a	  
delta	  CT	  of	  -­‐3.0.	  Table	  shows	  the	  sensitivity	  of	  the	  KRAS	  one-­‐run	  ASB-­‐PCR	  using	  synthetic	  DNA.	  NVD*;	  no	  
variant	  detected	  after	  40	  Ct,	  NA;	  not	  available	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Table	  6	   	   	   	   	  
Detection	  limit	  of	  nested	  ASB-­‐PCR	  
	   KRAS	  Ct	   	   KRAS	  Ct	   	  
%mt	  alleles	   12GGT	   Δ	  Ct	  to	  wt	   13GAC	   Δ	  Ct	  to	  wt	  
	   	   	   	   	  
5%	   26.7	   8.3	   26.4	   7.0	  
2.5%	   27.6	   7.4	   27.6	   5.8	  
1.25%	   28.2	   6.8	   28.4	   5.0	  
0.6125%	   29.4	   5.6	   28.6	   4.8	  
0%	   35.0	   NA	   33.4	   NA	  
	   	   	   	   	  
Nested	  ASB-­‐PCR	   (allele-­‐specific	   PCR	  with	   a	   blocking	   reagent)	   assay	   sensitivity	   in	  mixed	   synthetic	  DNA	  
samples.	  Delta	  Ct	  cut-­‐off	  mutation	  call	  criteria	  were	  -­‐3.0.	  Sensitivity	  of	  the	  assays	  is	  determined	  by	  the	  
minimum	  percentage	  of	  mutated	  (mt)	  alleles	  that	  could	  be	  detected	  among	  wild-­‐type	  (wt)	  alleles	  at	  a	  
delta	   Ct	   of	   -­‐3.0.	   Table	   shows	   the	   sensitivity	   of	   the	   nested	   ASB-­‐PCR	   for	  KRASmt	   detection	   sensitivity,	  
including	  the	  reproducibility	  of	  the	  detection	  of	  a	  G12V	  and	  a	  G13D	  mutation	  using	  synthetic	  DNA.	  NA;	  
not	  available	  
	  
	  
	  
	  
Figure 1: see section ‘ Color figures’
Supplementary data:
https://docs.google.com/open?id=0B9Etqm_r7T2mNnN5STlLajcyZFU 
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SUMMARY
Recently, miRNA-expression profiling in primary tumors has yielded promising results. However, 
establishing miRNA expression in the circulation probably has advantages over determination 
in primary tumor tissue, further augmenting the potential applications of miRNA determination 
in oncology. Circulating tumor cells (CTCs) have rapidly developed as important prognostic 
and therapy-monitoring biomarkers in metastatic breast, colorectal and prostate cancer 
when enumerated, and their isolation enables subsequent analysis using various molecular 
applications, including miRNA-expression analysis. In addition to CTC-associated miRNAs, free 
circulating miRNAs have been identified in whole blood, plasma and serum. Determination 
of miRNAs in peripheral blood, either cell-free or CTC-associated, is expected to become 
important in oncology, especially when linked to and interpreted together with epithelial 
CTCs. In this article, we will discuss miRNA-expression profiling in primary tumors, depict the 
potential applications of measuring miRNA in the circulation and review the literature on cell-
free circulating miRNAs, as well as offering some methodological and technical considerations 
on the measurement of circulating miRNAs. 
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INTRODUCTION
The implementation of assays enabling the detection of circulating tumor cells (CTCs) has 
sparked an additional boost of interest in blood-derived biomarkers for cancer patients. 
Numerous assays for CTC enumeration have been described lately and for one, the CellSearch® 
Epithelial Cell test (Veridex™ LCC, Raritan, NJ), FDA-approval has been acquired for use as 
a prognostic factor when measured in patients with metastatic breast
25-26
, colorectal
29
 and 
prostate cancer
31
. Additionally to its application as a prognosticator prior to treatment start, 
enumeration of CTCs may also guide treatment decisions, as a rise or decline in the number 
of CTCs after the first cycle of chemotherapy predicts for therapy response earlier than 
conventional radiographic evaluation does
237
. 
Probably even more interesting than mere counting, CTCs can be isolated from the blood of 
cancer patients for further analysis. In the case of metastatic disease, analysis of metastatic 
tissue can be very informative. Often, a considerable amount of time has passed since the 
occurrence and resection of the primary tumor and in many cases systemic adjuvant treatment 
has been administered. This means that clinically relevant changes can have occurred in the 
geno- and phenotype of residual cancer cells, and these changes could and probably should 
affect treatment decisions. Therefore, characterization of metastatic tissue, rather than that of 
the primary lesion, may show a better association with outcome in cancer patients. 
Clinicians are however understandably reluctant to perform invasive and complicated 
procedures to obtain tissue from patients for whom quality of life is a major concern. The 
isolation and subsequent characterization of CTCs provide the opportunity to bypass the 
problems associated with obtaining metastatic tissue, and serve as a ‘liquid biopsy’. CTCs 
have already been characterized for presence of gene amplification
40,306,315
 and genetic 
aberrations
36,381
, for expression of proteins
41
 and several mRNAs
9,43,244
, and recently, also for 
expression of certain miRNAs
38
. 
In recent years, miRNAs have been revealed as key regulators of gene expression. Given this 
crucial role, it is not surprising that miRNA expression in primary tumor tissue associates with 
outcome in several studies. However, determination of miRNA expression in the peripheral 
circulation, either CTC-associated or as cell-free circulating molecules, likely has several 
advantages over determination in primary tumor tissue, thereby further augmenting the 
potential applications of miRNA determination in oncology.
In this review, we will discuss the measurement of cell-free and CTC-associated miRNAs present 
in the peripheral circulation, and give examples of the clinical applications of this upcoming 
research field.
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MiRNAs
MiRNAs (miRs) are small single-stranded RNA molecules, measuring 21 - 23 nucleotides in 
length, which have, since their discovery in 1993
384
, been shown to play important roles in 
regulating gene expression
385
. Until recently, miRNAs were disregarded as degraded RNA 
fragments or non-translated small RNAs, but the discovery of their aberrant expression in a 
wide array of pathological events and their involvement in carcinogenesis has made them a hot 
topic in cancer research
270,386
. One of the big advantages of miRNAs is their stability, and it has 
been shown that cell-free miRNAs in body fluids are stable under harsh conditions such as high 
temperatures, extreme pH values, repeated freeze-thaw cycles and long-term storage
63,387-391
. 
They are well preserved, not only in blood, but also in tissues that have been formalin-fixed 
and paraffin-embedded years before
392
. This enables the retrospective analysis of large tissue 
collections, providing researchers with massive amounts of information. The identification of 
miRNAs has yielded an exciting new array of easy accessible molecular features, which may be 
employed in diagnostic and therapeutic decision making in cancer patients.
MiRNA biology
In the nucleus, miRNAs are transcribed by RNA polymerase II into large polyadenylated, 
capped primary miRNA transcripts (pri-miRNAs)
386,393
 (Figure 1, left panel). These pri-miRNAs 
are subsequently cleaved by a complex formed by the RNAse II enzyme Drosha and its binding 
partner DGCR8 (DiGeorge syndrome critical region 8, or Pasha) into precursor miRNAs (pre-
miRNAs). These pre-miRNAs are 70 - 90 nucleotides in length and have an imperfect stem loop 
hairpin structure. They are transported into the cytoplasm by Exportin 5 where the hairpin 
precursors are cleaved by a complex formed by the RNAse III enzyme Dicer and its binding 
partner TRBP (HIV-1 transactivating response RNA binding protein); resulting in a small dsRNA 
duplex that contains both the mature miRNA strand and its complementary strand. The mature 
miRNA strand is then incorporated into a RNA-induced silencing complex (RISC), which inhibits 
the function of its target mRNA by mRNA degradation or, most commonly, by translational 
repression after binding of the RISC to the target mRNA. Additionally, miRNAs can directly 
or indirectly increase the expression of their target mRNA
386,394
. An example of the multiple 
functions of miR-210 in the for cancer important process of hypoxia, which allows cancer cells 
to adapt to a low oxygen environment, is shown in Figure 1, right panel.
MiRNA function
MiRNAs are estimated to regulate up to 30% of all protein-coding genes
395
. They regulate 
post-transcriptional gene expression in a sequence-specific manner, recognizing their mRNA 
target with the 5’-end of the mature miRNA strand, which is often referred to as the ‘seed-
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sequence’
396
. After recognition of the target mRNA, regulation of gene expression can occur 
through two different mechanisms, depending upon the complementarities of the miRNA 
sequence with its target mRNA. When perfect base-paring homology exists between the 
miRNA and the mRNA, the RNA-mediated interference pathway is induced, which leads to 
cleavage of the mRNA by Argonaute, present in the RISC complex. When imperfect binding 
to partially complementary sequences in the 3’-untranslated region of target mRNAs occurs, 
which is more frequent than perfect binding, the target mRNA is regulated by repression of 
protein translation. Consequently, proteins are regulated by miRNAs without significantly 
affecting the corresponding mRNA expression levels. Such knowledge underscores the need 
to combine mRNA and miRNA data to generate improved predictive and prognostic models.
MIRNAS IN PRIMARY CANCER AND THEIR POTENTIAL APPLICATIONS
MiRNAs are thought to play two distinctly different roles in carcinogenesis, functioning both 
as ‘oncomirs’ and as tumor suppressors. This hypothesis is supported by the observation that 
miRNA expression in tumors can be up- or downregulated compared to normal tissue
397
. 
The miRNA expression profiling of tumors has provided many new insights into states of 
differentiation and lineages within different tumor types.
As a consequence of the crucial role of miRNAs in tumor biology, there is a broad range of 
potential applications of miRNA measurement in oncology. Besides being informative of tumor 
biology, miRNA signatures can also be a diagnostic tool, serve as prognostic factors, predictive 
factors, potential drug targets and as pharmacodynamic markers. All of these applications are 
possible in primary tumors and metastases, but the stability of miRNAs also enables their 
detection in the circulation. In this field, circulating miRNAs can serve as biomarkers that can 
be measured repeatedly and non-invasively in a wide array of cancer types.
Research to date has however mainly focused on primary tumor tissue. We will, without 
attempting to give a complete overview, provide examples of miRNAs being used as any of the 
aforementioned biomarkers, before proceeding with how this knowledge can and has been 
applied to circulating miRNAs. 
MiRNAs to identify cancer tissue origin
MiRNAs can serve to determine the tissue of origin for cancers of unknown primary origin, as 
has been shown with a classifier based on 48 miRNAs
398-399
. This microarray-based classifier 
was generated on 205 primary tumors and 131 metastases of 22 different tumor origins. The 
classifier was validated in an independent test set, in which it reached an overall sensitivity 
of 72% and a specificity of 99%. This application could be very informative in the still existing 
problem of metastatic cancer patients in whom no primary tumor can be identified, and for 
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whom no standard chemotherapy exists.
MiRNA expression profiles to classify cancers
Lu and co-workers were also able to successfully classify poorly differentiated tumors using 
miRNA expression profiles. Contrarily, messenger RNA profiles were highly inaccurate in 
classifying tumors when applied to the same samples
397
. Breast cancer is a notoriously 
heterogeneous disease, but miRNAs can help to identify the subtype origin of tumor cells, as 
was demonstrated by Sempere and co-workers using an in situ hybridization method to reveal 
the spatial distribution of miRNA expression in archived formalin-fixed, paraffin-embedded 
breast tumors
400
.
MiRNAs as prognostic factors
Many investigators have focused on identifying miRNAs that can separate patient groups 
according to prognosis. It would be beyond the scope of this review to discuss all studies that 
have identified such prognostic miRNAs, and we refer to Ferracin et al
401
 for a complete and 
comprehensive overview.
Predictive miRNAs
Not many data have been generated identifying specific miRNAs that can predict response 
to systemic therapy. This is not surprising, as determining true predictive value of a miRNA 
requires studies designed very carefully specifically for that research question. 
Ovarian cancer
In ovarian cancer, miR-214 has been identified as a miRNA involved in resistance to cisplatin, 
through targeting of PTEN
402
. In this study, 4 of the most differentially expressed miRNAs 
among a total of 515 miRNAs tested in 10 ovarian tumors and 10 normal cell line pools were 
further validated. MiR-214 was one of the most frequently upregulated miRNAs in 30 primary 
ovarian tumors; and the expression of miR-214 in miR-214-negative cell lines led to resistance 
to cisplatin-induced cell death, and subsequent knockdown of miR-214 resulted in increased 
sensitivity to cisplatin-induced cell death
402
. These promising results should be validated in 
patients treated with cisplatin before miR-214 can be used as a valid biomarker to predict 
cisplatin response. 
Non-small cell lung cancer
This validation in patient samples was performed in a study looking at the predictive value of 
miR-128b expression on response to gefitinib, an EGFR inhibitor, in non-small cell lung cancer 
(NSCLC)
403
. MiR-128b was chosen based on its regulatory role for EGFR and the fact that loss 
of chromosome 3p, where miR-128b is located, is one of the most frequent and earliest events 
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in lung carcinogenesis. An inverse relationship between miR-128b and EGFR expression was 
observed in NSCLC cell lines, and while EGFR expression as assessed by immunohistochemistry 
did not correlate with gefitinib response in 58 NSCLC patients, EGFR mutations and loss of 
miR-128b were associated with improved response to gefitinib. In multivariate analysis, only 
histology, line of treatment and loss of miR-128b, and not EGFR expression or mutation, were 
found to be predictive of response
403
.
Hepatocellular carcinoma (HCC)
Ji et al. undertook a carefully designed study in three independent cohorts of a total of 
455 HCC patients, and identified miR-26 to be lower expressed in tumors than in paired 
noncancerous tissue
404
. Additionally, of the patients who were not treated with interferon, 
the control arm of the cohorts, those with lower expression of miR-26 in their tumor had a 
shorter overall survival. Contrarily, of the patients in the treatment arm of the cohorts who did 
receive interferon, those with lower miR-26 expression had an improved survival compared to 
patients with higher miR-26 expression. In multivariate analysis too, a significant interaction 
was observed between miR-26 expression and response to interferon therapy
404
.
Breast cancer
While data have been generated on breast cancer cell lines
405-406
 we recently selected 5 
candidate predictive miRNAs from 249 miRNAs measured in a small discovery set of breast 
cancer specimens and analyzed their expression in an independent series of 246 ER-positive 
primary breast tumors. In multivariate analysis, higher expression of miR-30c was associated 
with benefit from first line tamoxifen monotherapy and longer progression-free survival
407
. 
MiRNAs as drug targets
Because of their pivotal role in cancer development, progression and treatment, several 
preclinical findings point at the great potential to use miRNA as drug targets, either by 
inhibiting overexpressed ‘oncomirs’ or replacing underexpressed tumor suppressor miRNAs. 
Inhibition of miR-21 has been shown to reduce tumor development and metastatic potential in 
breast cancer cells
408
. Inhibition of miR-21, combined with miR-200b, also enhanced response 
to gemcitabine in cholangiocarcinoma cells
409
. In breast cancer cells, reintroducing miR-205 
resulted in improved response to tyrosine kinase inhibitors through HER3 silencing
410
.
Finally, researchers have demonstrated that hepatocellular carcinoma cells have reduced 
expression of miR-26, while this miRNA is highly expressed in normal tissues. Re-expression 
of miR-26 caused cells to arrest in G1, probably through repression of cyclin D2 and cyclin E2. 
When administering miR-26 to a mouse model using an adeno-associated viral vector, cancer 
cell proliferation was reduced and apoptosis increased
411
. 
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MEASURING MIRNAS IN THE CIRCULATION
As depicted above, promising results have been obtained in primary tumor material with 
respect to miRNAs as cancer biomarkers. There are however a number of situations in which 
it is likely that the value of miRNAs can be further augmented by measuring miRNAs in blood, 
either as cell-free circulating miRNAs or as CTC-associated miRNAs. Below we will now discuss 
the potential applications of circulating miRNAs.
Circulating miRNAs can help to more accurately predict patient outcome
Many studies have focused on identifying prognostic miRNAs in primary tumors, and these 
prognostic factors are now known for a large variety of tumor types. While these prognostic 
miRNAs do distinct those patients with a favorable outcome from those with an unfavorable 
outcome, measuring miRNAs in the primary tumor does not take into account two important 
things; not all cells in the primary tumor have the ability to metastasize, and the subset of 
spreading tumor cells might differ in genetic make-up. Secondly, at the time of metastatic 
disease, genetic characteristics of the remaining or relapsing tumor cells can differ from those 
of the primary tumor, because by the time a patient presents with metastatic disease, years 
might have gone by since first presentation, and various different anti-tumor treatments can 
have been administered. Both these factors can cause profound differences in genetic and 
epigenetic make-up between primary tumor and metastatic tissue. At the time of disseminated 
disease, optimally, metastatic tissue would be used to determine prognosis; however, acquiring 
such tissue can often only be done through painful and invasive procedures. Circulating tumor 
cells can serve as a ‘liquid biopsy’ representing the patient’s tumor load, and thereby provide 
a unique opportunity to assess prognosis in real time.
Furthermore, the presence of miRNAs that are associated with the process of metastasis 
or epithelial-to-mesenchymal transition, a process that is thought to be necessary for 
haematogenous spread of disease to occur, might identify those patients that already have 
distant micrometastases too small to diagnose otherwise.
Circulating miRNAs to predict response to anti-tumor therapy
When systemic therapy is warranted, either in the adjuvant or metastatic setting, the choice 
of first line treatment can be crucial for ultimate patient outcome. Depending on tumor type, 
various patient and tumor characteristics are taken into consideration when deciding on 
the optimal treatment, but still, for a proportion of patients, ineffective therapy is started. 
Especially in patients receiving targeted therapy, such as EGFR inhibitors, factors determining 
their benefit are still being discovered. While most attention has been given to predictive factors 
such as KRAS mutations and EGFR expression, it may be expected that miRNAs will turn out 
 Chapter 9  183
to play an equally important role, given their pivotal role in cancer progression. As discussed 
before, circulating miRNAs can be measured repeatedly, which is especially important for their 
use as a predictive factor. One can imagine wanting to administer a certain systemic therapy as 
second-line treatment, for which a predictive miRNA has been established. While this miRNA 
can be measured in the primary tumor, earlier administered systemic therapy can have affected 
the expression of this miRNA in residual cancer cells. It is, therefore, very conceivable that a 
treatment adapted to circulating tumor characteristics is more beneficial than a treatment 
based on primary tumor characteristics. 
Whenever a certain treatment has been started based on miRNA expression data, re-
assessment can occur each time the patient becomes refractory to the installed treatment. 
Acquired resistance to systemic anti-tumor treatment is a major problem in cancer treatment, 
and overcoming that resistance by administering targeted therapy based on changed tumor 
characteristics might greatly improve patients’ prognosis.
Circulating miRNAs as a monitorable drug target
One of the big theoretical advances of targeting miRNAs is the ability to monitor their 
expression in the circulation. When anti-miRNA treatment is started, miRNA expression 
levels could be monitored in blood at various time points, and their increase could predict 
treatment resistance and warrant a switch in therapeutic regimen. Already, it was shown that 
the administration of intravenous anti-miR-16, anti-miR-122, anti-miR-192 and anti-miR-194 
caused a decrease in the levels of the corresponding miRNAs across all organs in mice
412
. In 
this sense, circulating miRNAs could serve as combined drug targets and pharmacodynamic 
markers.
CELL-FREE CIRCULATING MIRNAS
In view of the potential advantages of determining miRNA expression in the peripheral 
circulation over that in primary tumor tissue, several studies have already identified free 
circulating miRNAs that are expressed in the circulation of cancer patients. Importantly, most of 
these miRNAs were found to be differentially expressed between cancer patients and healthy 
donors. These miRNAs were found to be either diagnostic or prognostic, but little study has 
been done on their potential roles as predictive factors or drug targets. The main findings of 
the studies on circulating miRNAs in relation to diagnosis and prognosis are reviewed below 
and summarized according to 12 different primary tumor types in Table 1. We have focused 
on solid tumors for this review, and refer to Fabbri et al
413
 for a comprehensive review of the 
many research advances in the field of miRNAs in hematological malignancies.
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Carcinomas of unknown primary
MiRNAs can serve to determine the tissue of origin for cancers of unknown primary origin, 
as has been shown with a classifier based on 48 miRNAs determined in primary or metastatic 
tumor tissue
398-399
. Lodes et al. focused on the evaluation of miRNA expression patterns in 
human serum for five types of human cancer, prostate, colon, ovarian, breast and lung, using 
a pan-human microRNA, high density microarray, and identified a serum classifier based on 
28 circulating miRNAs able to separate cancer cases from normal individuals
414
. In serum of 
cancer patients, specific miRNA expression patterns for lung cancer and colorectal cancer 
have been identified
387
, providing evidence that miRNAs present in the circulation contain 
fingerprints for various diseases. 
Breast cancer
In 148 breast cancer patients and 44 healthy controls, seven candidate miRNAs were measured 
in whole blood by RT-PCR without a preceding enrichment step. All miRNAs could be measured 
in patients and controls alike, but miR-195 and let-7a were expressed higher in breast cancer 
patients than in controls, with a mean fold change of 19 and 11, respectively. Additionally, the 
levels of these two miRNAs decreased significantly after curative tumor resection
415
.
The first study that reported circulating miRNAs as potential biomarkers of early stage breast 
cancer with different results for Caucasian American (CA) versus African American (AA) women, 
concerns the study of Zhao and co-workers. After comparing levels of circulating miRNAs in 
plasma samples of 20 patients with early stage breast cancer and 20 matched controls, they 
reported 17 upregulated and 14 downregulated miRNAs in the 10 CA women and 9 upregulated 
and 9 downregulated miRNAs in the 10 AA women. Furthermore, they were able to link these 
differentially expressed miRNAs to specific pathways using target prediction algorithms
416
.
In a larger study evaluating miR-21 expression in the serum of 102 breast cancer patients and 
20 healthy controls, this miRNA was found to be higher expressed in patients, especially in 
stage IV breast cancer
417
. Recently, 4 breast cancer associated miRNAs were measured in the 
serum of 59 localized breast cancer patients after primary tumor surgery, 30 metastasized 
breast cancer patients and 29 healthy controls. MiR-10b, miR-34a and miR-155 discriminated 
metastasized breast cancer patients from controls, and the latter was higher expressed 
in localized breast cancer patients than healthy controls but also than metastasized breast 
cancer patients
418
. Another study measured three miRNAs (miR-16, miR-145 and miR-155) in 
the serum of 13 breast cancer patients and 8 healthy controls, but did not find a difference in 
expression between these two groups
419
.
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Non-small cell lung cancer
Hu et al. used serum of NSCLC patients to look for miRNAs that were differentially expressed 
between 30 patients with longer survival and 30 patients with shorter survival, matched by 
age, sex and stage. Eleven miRNAs were found to differ more than five-fold between the two 
groups, and four of those were confirmed by RT-PCR to be associated with survival, also in 
a larger validation set of 243 NSCLC patients. While these data are very encouraging, the 
investigators unfortunately measured these miRNAs in only one healthy donor, and their 
specificity for NSCLC is thus not sufficiently clear
420
. A comparison with more healthy controls 
was done with a pooled sample of 11 Chinese lung cancer patients, in whom 28 miRNAs were 
downregulated and 63 miRNAs were upregulated compared to 11 male and 10 female normal 
controls. Two of the highest expressed miRNAs, miR-25 and miR-223, were validated in an 
independent set of 152 lung cancer sera and 75 normal sera and also found to be higher 
expressed in these patients
387
.
A different approach was used by Silva et al, who preceded their tests by an EpCAM-based 
immunomagnetic enrichment step. Out of 365 candidates, no miRNAs were found to be 
upregulated in 28 patients as compared with 20 controls, but 10 miRNAs were downregulated. 
Three of these were differentially expressed in the validation step as well, and lower levels of 
let-7f were associated with shorter overall survival, while patients with lower levels of miR-
30e-3p had shorter disease-free survival, without difference in overall survival
421
.
Prostate cancer
In prostate cancer patients, a panel of six candidate miRNAs, selected on their expression in 
prostate tumors and lack of expression in healthy donor blood, was analyzed in two pools of 25 
metastatic prostate cancer patients and 25 healthy controls, respectively. Out of the candidate 
miRNAs, miR-141 showed the greatest differential expression between the two pools, and 
this miRNA was confirmed to be higher expressed in cancer patients on an individual level as 
well
389
. 
Brase and co-workers unfortunately did not validate their interesting findings of the upregulation 
of 5 miRNAs out of a panel of 667 candidate miRNAs in the serum of prostate cancer patients 
in healthy controls. They did observe that the expression of two of the 5 miRNAs, miR-375 and 
miR-141, was upregulated in malignant prostate tissue compared to benign prostate tissue, 
but concerns about the specificity of these miRNAs in serum remain
422
.
Using an array method, Moltzahn and co-workers screened the expression level of 384 miRNAs 
in 12 healthy controls and 36 prostate cancer patients divided into three groups according to 
a validated risk score. The twelve miRNA candidates that were most differentially expressed 
between cancer patients and controls were validated by individual qRT-PCR, which confirmed 
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the differential expression of nine miRNAs. No significant correlation was seen with risk scores 
or other clinicopathological parameters
52
.
Lodes et al. used microarray profiling and found 15 miRNAs to be over-expressed in serum 
from 6 prostate cancer patients (all stage 3 and 4) relative to expression in 8 normal male 
controls
414
.
Ovarian cancer
In ovarian cancer too, interest has been generated to detect miRNAs in the peripheral blood of 
cancer patients. Comparing 9 serum samples from ovarian cancer patients to 4 serum samples 
from healthy donors, 21 differentially expressed miRNAs were identified. Eight could be 
confirmed in 19 cancer versus 11 normal specimens to be differentially expressed by RT-PCR, 
of which 5 (miR-21, -29a, -92, -126 and -29a) were upregulated expression in cancer patients, 
probably making these more suitable for clinical implementation
423
.
MiRNA expression was also measured in EpCAM-positive exosomes. Exosomes are microvesicles 
that are actively released by tumors into the peripheral circulation
424
 and it was hypothesized 
that miRNAs detected in exosomes reflect those present in CTCs. Exosomes were isolated from 
50 ovarian cancer patients and 20 controls using an immunomagnetic enrichment method 
based on anti-EpCAM. Eight miRNAs were found to be differentially expressed between the 
two groups
63
.
Gastric cancer
Analyzing plasma samples of 69 gastric cancer patients taken before surgery and 30 healthy 
donors, five miRNAs were found to be differentially expressed
425
. Two of these five, miR-
106a and miR-17, were also identified in samples of 90 patients (of which, remarkably, 49 
were taken after resection of the primary tumor), to be differentially expressed compared to 
27 healthy donors. Both miRNAs were expressed at a lower level after surgery compared to 
before surgery, but still differed about 10-fold from healthy controls
426
.
As part of a larger study looking at liver pathology-specific miRNAs, gastric cancer patients 
were also evaluated for differential miRNA expression compared to controls. MiR-885-5p, 
which was also found to be upregulated in hepatocellular carcinoma patients (see below), was 
higher expressed in gastric cancer patients
427
 compared to controls.
Hepatocellular carcinoma
MiR-500 was identified as highly expressed during fetal liver development and thus postulated 
to be involved in proliferation. Indeed, miR-500 was highly expressed in hepatocellular 
carcinoma cell lines, but its expression was higher in only 18 of 40 hepatocellular carcinomas 
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compared to adjacent non-tumorous tissue, and in the serum of 3 of ten HCC patients
428
.
Another study looking at HCC identified miR-885-5p as a miRNA of interest in this disease, 
being expressed higher in HCC patients than in healthy controls, liver cirrhosis and chronic 
hepatitis B patients
427
.
Colorectal cancer
At least three studies have looked into the occurrence of selected candidate miRNAs in the 
plasma of colorectal cancer patients. A large study looked at samples from 120 primary 
colorectal cancer patients and 37 advanced adenoma patients, both taken before surgery, 
and compared them to 59 age-matched healthy controls who were confirmed to be without 
colorectal cancer by extensive diagnostic procedures including colonoscopy and CT scan. Two 
miRNAs, miR-29a and miR-92a, were identified from a training set and confirmed in the larger 
validation set to be upregulated in CRC plasma compared to controls. In adenoma patients 
too, these miRNAs were expressed higher than in controls, but significantly lower than in 
true cancer patients. Additionally, these two miRNAs decreased after surgery in another 20 
colorectal cancer patients, suggesting that these miRNAs are in fact cancer-specific
429
. 
Another study also found miR-92a to be higher expressed in CRC patients. Five miRNAs were 
selected based on higher expression in CRC plasma compared to healthy control plasma and 
higher expression in primary cancerous biopsies compared to adjacent non-cancerous colon 
tissue. Of these miRNAs, the two that were significantly elevated in 25 CRC patients compared 
to controls and decreased after tumor resection (miR-92a and miR-17), were validated in an 
independent cohort of 90 CRC patients and 50 controls. Additionally, both miR-92a and miR-
17 were not expressed higher in patients with gastric cancer or inflammatory bowel disease, 
confirming their specificity
430
.
Pu et al. chose to investigate miR-221 out of three miRNAs abundantly expressed in CRC, 
because of the good linearity in spiking samples obtained with this miRNA. In 103 CRC patients, 
miR-221 expression was higher than in 37 controls, however with a low specificity of 41% 
at the optimal cut-off level. MiR-221 expression did correlate with overall survival and p53 
expression
431
.
Pancreatic cancer
In pancreatic cancer, two miRNAs, miR-200a and miR-200b, involved in epithelial mesenchymal 
transition, were identified to be hypomethylated and overexpressed in primary tumors 
compared to surrounding normal pancreas tissue. In 45 serum samples obtained from 
pancreatic cancer patients before surgery, both miRNAs were expressed at a higher level than 
in samples from 32 healthy controls and 11 chronic pancreatitis patients
432
.
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Ho et al. looked for pancreatic cancer-specific expression of miR-210 in the circulation, as 
this miRNA increases under hypoxic conditions, which are known to correlate with poorer 
prognosis. MiR-210 expression was measured in the plasma of a total of 22 locally advanced 
pancreatic cancer patients and 25 age-matched healthy controls, and confirmed to be 1.7 – 
4-fold higher expressed in the patients
433
. 
Head and neck cancer
Wong et al. examined the expression of a large panel of miRNAs in tongue carcinomas and 
paired normal tissues, which identified 24 up regulated and 13 down regulated miRNAs. 
Because of its 59-fold higher expression in tumor tissue, miR-184 was further validated in an 
independent dataset and observed to be more abundant in plasma of patients with tongue 
squamous cell carcinoma than in controls. Additionally, miR-184 levels dropped after resection 
of the primary tumor
434
.
Esophageal squamous cell carcinoma (SCC)
In esophageal SCC, one large study was recently published in which 25 miRNAs measured in 
serum were found to be upregulated in a pool of 141 cancer patients compared to controls. Of 
these 25, 7 miRNAs were confirmed to be differentially expressed by individual qRT-PCR in a 
separate patient cohort, yielding higher AUCs than carcinoembryonic antigen (CEA)
435
.
Rhabdomyosarcoma
Besides carcinomas, research has also been focused on specific miRNAs in rhabdomyosarcoma 
(RMS). Looking at RMS cell lines and primary tumor tissues, miR-206 was found to be most 
abundantly expressed among several muscle-specific miRNAs. MiR-206 was also the marker 
with the highest sensitivity and specificity in discriminating 10 RMS-patients from 28 patients 
with other pediatric tumor and 17 healthy donors, but miRs-1, -133a and -133b, involved in 
muscle proliferation and differentiation
436
, were also higher expressed in RMS patients than in 
controls or non-RMS patients
437
.
CTC-ASSOCIATED MIRNAs
CTC-associated vs. cell-free miRNAs
As depicted above, studies on cell-free circulating miRNAs yield very interesting results and 
show the measurement of miRNAs in the circulation to be both feasible and clinically relevant. 
However, it is to be expected that not all miRNAs can actually be measured in the peripheral 
circulation. Especially in view of the fact that at least 100 different miRNAs already circulate 
 Chapter 9  189
in the blood of healthy donors
387,416
, it is very likely that measuring these miRNAs in whole 
blood, serum or plasma from cancer patients can yield false-positive results. Several studies 
have identified circulating miRNAs that are differentially expressed between patients and 
healthy donors (Table 1). Most of these studies have measured miRNAs in the serum, plasma 
or exosome fractions of blood, instead of using whole blood. Using serum or plasma does for 
the most part eliminate the leukocyte background present in whole blood, but evidence has 
been presented that most miRNAs measured in these fractions are not actually derived from 
circulating epithelial cells
389
. Also, cellular miRNA expression patterns can differ from miRNA 
patterns released into the blood
438
. These studies raise the concern that cell-free miRNAs 
present in the circulation may not be a reliable representation of metastatic or primary tumor 
tissue, and that measuring CTC-associated miRNAs would be preferable. Besides possibly 
better representing the tumor load, measuring miRNAs in CTCs has the additional benefit of 
being able to correlate a miRNA signal to a CTC count, which aids in the interpretation of 
epithelial specificity.
Despite the potential benefits of measuring CTC-associated miRNAs, most work so far 
has been done on cell-free miRNAs. Data have been generated suggesting that the large 
majority of miRNAs are present in cell-free form and are not cell-associated
389
. These cell-
free miRNAs can enter the circulation roughly through three different potential pathways: (1) 
passive leakage from apoptotic or necrotic cells, which can occur in tissue damage or chronic 
inflammation, and has been shown to occur after heart tissue injury
439
; (2) active and selective 
secretion of microvesicle-free miRNAs, which could be derived from tumor cells or circulating 
microvesicles; and (3) active and selective secretion of miRNA-containing microvesicles, 
including microparticles and exosomes. These mechanisms can occur in malignant cells, 
enabling miRNA from circulating tumor cells or primary or metastatic tumor cells to enter 
the circulation, but also in non-malignant cells with a short half-life, such as platelets, or upon 
tissue damage in non-malignant cells.
Another question surrounding cell-free miRNAs is what enables them to remain in the 
circulation despite the presence of endogenous RNAses. In this regard, the secretion of 
microvesicles is made more plausible, as the inclusion of miRNA in microvesicles could protect 
them from degradation
440
. However, more hypotheses have been postulated to explain the 
stability of miRNAs in the circulation, including modification of circulating miRNAs through 
processes such as methylation and adenylation
441
 or binding of circulating miRNAs to as of yet 
unknown proteins
442
. 
Function of cell-free miRNAs
The function of the release of cell-free miRNAs as an active process remains largely unclear. 
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Recent evidence suggests that the transportation of miRNAs in microvesicles results in 
regulation of gene expression in the recipient cells
443
. Exosomes in general are thought to 
play a role in the communication between cells
424
, as has been shown in vitro by Skog et 
al., who showed that glioblastoma-derived microvesicles were incorporated by human brain 
microvascular endothelial cells
62
. 
It is an attractive hypothesis that exosomal miRNAs can be selectively transferred to other cells, 
thus enabling tumor cells to manipulate both their direct and distant environment, possibly 
leading to increased metastatic potential. These microvesicles containing miRNAs could then 
theoretically also form an attractive drug target.
Enrichment of CTC-specific miRNAs
When testing whether identified cell-free miRNAs can be measured in CTCs, or identifying new 
CTC-associated miRNAs, an enrichment step is crucial. Most methods aimed at specifically 
molecularly characterizing CTCs in whole blood are preceded by such an enrichment step. 
Many methods are available, including enrichment based on size, density or specific marker 
expression
219
. These enrichment steps aim to isolate all CTCs from full blood, while getting rid 
of as many contaminating peripheral blood mononuclear cells (PBMCs) as possible. However, 
even when applying tumor-specific marker enrichment, hundreds to thousands of leukocytes 
are still present in the CTC-enriched fraction
9
. Also, the actual number of leukocytes may 
differ depending on tumor stage
418
. These leukocytes generate a background signal and thus 
complicate the measurement of CTC-specific miRNA expression, as only epithelial-specific 
miRNAs that are hardly expressed in leukocytes can be reliably measured. Many efforts are being 
made to develop a CTC isolation method that provides a purer CTC fraction for downstream 
analysis, based on for instance micromanipulation techniques
444
. Obtaining a higher purity 
of the enriched CTC fraction through more specific CTC isolation techniques would eliminate 
the need to only measure epithelial-specific genes, i.e., genes that are much higher expressed 
in CTCs than in leukocytes. So far, however, these techniques have not become widespread 
available and need further validation.
Despite these challenges, measuring CTC-associated has proven to be feasible. In our own 
work (manuscript submitted), we were able to identify 10 miRNAs more abundantly expressed 
in patients with >5 CTCs compared to patients without detectable CTCs and healthy donors.
Remaining technical issues concerning the measurement of CTC specific miRNAs
It is to be expected that the development of enrichment methods that provide a purer CTC 
fraction will simplify the measurement of CTC-associated miRNAs. In the meantime, a number 
of aspects need to be taken into consideration when measuring these CTC-specific miRNAs. 
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Because of the low numbers of CTCs in the circulation, frequently less than 5 CTCs in 7.5 mL 
blood
8
, sensitive RNA isolation techniques and unbiased pre-amplification steps are needed. 
Fortunately, kits are now on the market which enable the isolation of DNA, large RNA fragments 
(mRNA, >200 bp), small RNA fragments (micro- and non-coding RNA, <200 bp) and proteins 
in 4 separate aliquots from as little as one cell (Figure 2). After this sensitive fractionated RNA 
isolation, it is crucial that only epithelial-specific miRNAs are measured that are not or very 
weakly expressed in leukocytes. To estimate the ratio of the tumor cell-specific signal over 
leukocyte-derived signal, which is unfortunately present even after enrichment procedures, 
transcript levels of CTCs-specific miRNAs such as those in the miR-200/141 family
389,445
 and 
leukocyte-specific miRNAs such as miR-429 can be compared
445
. The suitability of any miRNA 
combination to estimate epithelial-specific signal does however depends on the epithelial 
tumor cell type or subtype studied. Furthermore, due to the presence of cell-free EpCAM-
positive exosomes in serum
63
, it remains to be established which part of the miRNA signal 
from EpCAM-enriched CTC-fractions is actually derived from CTCs and which part from other 
EpCAM-enriched cells or cell fragments including exosomes. Another factor complicating 
miRNA measurement is the lack of an established constitutively expressed set of reference 
miRNAs that can be used to normalize candidate miRNA expression levels. MiR-16 has 
been used as a reference in several studies
390,418
, but concerns have been raised due to its 
inconsistent expression in sera
 414
. RNU/SNORs are also frequently used (Table 1), but it needs 
to be realized that these small RNA’s are longer than the actual mature miRNAs being studied, 
making them less suitable for normalization. Furthermore, RNU6B (U6) has been reported to 
be degraded in serum samples
435
. Until consensus has been established on a robust reference 
miRNA set, normalizing on the mean expression of all expressed and CTC-specific miRNAs is 
probably the optimal method when multiple miRNA transcripts are measured at the same 
time
292
. In Figure 2 we summarize the steps that need to be taken to ensure epithelial tumor 
cell specific gene expression profiling of CTCs. 
CONCLUDING REMARKS
When critically looking at the data generated thus far measuring miRNA expression in the 
circulation, a few remarks must be made. 
Firstly, the methods that are used to identify differentially expressed miRNAs vary greatly; many 
researchers start off with candidate miRNAs of interest that have previously been associated 
with a cancer type, while others look at all differentially expressed miRNAs between healthy 
controls and patients or between tumor tissue and normal adjacent tissue. This latter approach 
also enables the identification of potential up- or downmodulated pathways associated with 
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differentially expressed miRNA transcripts. Furthermore, a combination of several higher and 
lower expressed miRNAs is likely more informative than analysis of the expression of a single 
marker alone. 
Secondly, some studies have unfortunately failed to validate their results in healthy controls, 
raising concerns about the specificity of potentially interesting miRNAs. Similarly, as with CTC 
enumeration, and also with regard to gene expression profiling in CTCs, specificity is pivotal 
when trying to identify tumor-specific signal particularly when contaminating leukocytes are 
present.
Lastly, any miRNA that is identified in a patient cohort to be differentially expressed or 
associated with prognosis should be validated in an independent cohort and reach acceptable 
sensitivity and specificity before it can be implemented into the clinic for routine analysis. 
While some studies have used validation sets, most have not, hampering the translation from 
bench to bedside.
Despite these possible flaws in some studies, measuring circulating miRNAs, cell-free or CTC 
associated, has proven to be feasible, can generate tumor-specific results, and may thus be of 
clinical relevance if their expression can be robustly measured and is sufficiently correlated 
with clinical outcome parameters such as overall survival or therapy response. The value of 
circulating miRNAs is expected to increase rapidly with the development of techniques that are 
able to isolate a more pure CTC fraction. Such an improvement will enable the measurement 
of any of the discussed prognostic and predictive miRNAs that have been identified in primary 
tumor tissue. Even more so than prognostic factors, the oncology field is devoid of reliable and 
robust predictive factors that adequately guide oncologists in the choice of optimal treatment 
for their patients. MiRNAs in the circulation may provide a new opportunity in this direction 
because of their stability and far-stretched effects in cancer biology and disease progression, 
and research should be aimed towards identifying and validating the predictive potential of 
these markers.
MiRNAs are a valuable addition to the information that CTCs already provide. In Figure 3 we 
have depicted our view of the future role of CTC analysis before and during treatment of 
cancer patients, providing both prognostic, predictive and drug target information at different 
time points.
EXPERT COMMENTARY
MiRNAs have become an important research field, and have proven their value as regulators in 
carcinogenesis and cancer progression in many different cancer types. If these relatively stable 
small RNAs can be robustly detected by highly sensitive PCR methods routinely available in 
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most laboratories, they can become a new class of biomarkers. More important for the clinical 
setting, the prognostic value of certain miRNAs has been established in various cancer types 
and data are slowly emerging on their predictive value. These clinically relevant miRNAs are 
subsequently sought for in the circulation of cancer patients to enable their repeated and non-
invasive measurement. A few issues have to be accounted for before miRNA expression in the 
circulation as a tool to predict prognosis or therapy response is ready for the clinic. 
Firstly, consensus should be established on which fraction of peripheral blood should be used 
to measure miRNAs. Current studies have been performed in non-enriched or enriched whole 
blood, serum and plasma, without clear data being available on the distribution of miRNAs 
is these different blood compartments. It is conceivable that only a selection of miRNAs is, 
actively or passively, shed from circulating tumor cells. Also, the use of an enrichment marker 
for whole blood can greatly influence the amount and type of CTCs that are subsequently 
characterized. 
Secondly, more data should be generated on the occurrence and expression levels of circulating 
miRNAs in healthy individuals. This can be done either by testing selected panels of miRNAs 
in a large cohort of gender- and otherwise matched healthy controls in parallel with cancer 
patients. 
Thirdly, the discussion on which constitutively expressed miRNAs to use as a reference gene 
set is ongoing and it remains to be seen if a cell type-independent panel can be identified. 
Until that time, it is imperative that each study clearly states their normalization method and 
their reasons to choose said method.
FIVE-YEAR VIEW
While enumeration of CTCs has already proven its strength, the future of molecular analysis 
lies in the development of CTC isolation assays that generate higher CTC numbers and thus 
increased tumor DNA, mRNA and miRNA content, and reduce the number of contaminating 
leukocytes. We have already shown that the enrichment marker used in one of the most 
common CTC detection assays, the EpCAM-based CellSearch technique, is not expressed 
in all breast cancer subtypes
64
. This epithelial cell adhesion molecule (EpCAM) does not 
detect normal-like breast cancer cells, which can however be detected by adding CD146 in 
the enrichment step
250
. This is just one example of a probably more widespread problem of 
marker heterogeneity among cancer subtypes, which causes us to miss a subset of CTCs. The 
development of a method that either uses a panel of antibodies to detect CTCs, or a method 
that is independent of marker expression, but instead on for example physical properties of 
tumor cells, is probably the answer to this problem. Especially the latter option, selecting CTCs 
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based on unique properties such as membrane stiffness, is a still developing field
446
. Following 
this selection step by micromanipulation will enable the isolation of single CTCs, which makes 
them available for downstream applications such as whole genome DNA or transcriptome 
sequencing, but also allowing culturing of these cells.
In a few years time, anti-miRNA treatments will probably become available, and it is very likely 
that at least some of these miRNAs will be detectable in the circulation. This could simplify and 
fasten the testing of these drugs in phase I and II clinical trials, as the level of the target miRNAs 
can be directly measured in the patients’ blood.
KEY ISSUES
o There is an urgent need for additional diagnostic, prognostic and predictive markers in  
 oncology
o These markers should preferably be measurable at any time during the course of the  
 disease
o Circulating tumor cells provide an unique opportunity to diagnose the origin and type  
 of primary tumor, and to assess prognosis, response to therapy and drug targets non- 
 invasively and repeatedly
o Among these markers, miRNAs are especially promising because of their stability and  
 pivotal regulatory role in carcinogenesis
o Many miRNAs have already been identified to be of prognostic value in primary tumors
o Some miRNAs have shown predictive value in cell lines and patients
o Measuring miRNAs in the circulation is feasible and, depending on the choice of   
 miRNA, can be cancer-specific
o A properly sized control cohort of healthy blood donors is a pre-requisite for these kind  
 of studies
o So far, very few circulating tumor cell associated miRNAs have been associated with  
 prognosis or therapy response
o The technical challenge is to discriminate between epithelial tumor cell-specific miRNAs  
 and miRNAs from background leukocytes
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Figure 1: see section ‘Color figures’
Figure 3: see section ‘Color figures’
Figure 2: see section ‘Color figures’


Chapter 10
Summary and discussion

Over the past years, the field of oncology has seen rapid and profound changes. High-throughput 
genomic, proteomic and epigenomic analyses have enabled the deeper understanding of 
crucial signal transduction pathways involved in tumor cell proliferation, metastasis and drug 
resistance. This surge of new data has, if anything, convinced researchers and physicians that 
big improvements in the treatment of cancer are probably further away than was envisioned 
before the omics-era. The complexity of the mechanisms involved in metastasis and drug 
response has convinced us that patient or tumor response prediction is not a black-or-white 
matter, which is probably why good predictive and prognostic factors remain an unmet need 
in cancer treatment.
 
THE NEED FOR PREDICTIVE AND PROGNOSTIC FACTORS
The implementation of new cancer therapies has improved patient’s chances of survival and 
prolonged quality of life, but at the same time, worldwide cancer burden is increasing. Higher 
cancer incidence due to environmental and lifestyle factors as well as a higher prevalence due 
to early detection and improved treatment options result in a dramatic increase in the cost of 
cancer care worldwide, jeopardizing its affordability in both high- and low-income countries. 
While this increase in cost is multifactorial
447
, and many of the most important drivers are 
beyond the scope of this thesis, cost-effectiveness can be markedly improved by the proper 
selection of patients for both clinical research trials and off-study treatment. As a consequence 
of specific patient and tumor characteristics, only a subset of patients will benefit from cancer 
treatment at all, and, perhaps more importantly, benefit from specific anti-tumor agents. 
Better response prediction will improve cancer care affordability but could also aid in ensuring 
optimal quality of life for cancer patients, as the trade-off between efficacy and toxicity can 
become more favorable. In this regard, better prognostic factors and predictive factors are 
urgently needed to more reliably estimate patients’ life expectancy and predict their response 
to specific anti-tumor agents. Especially in the field of targeted treatment, the specific inhibition 
of a component of a signaling pathway is often followed by the counter-reactive activation 
of downstream targets of alternative pathways, which enables the tumor to circumvent the 
inhibitory effect of the targeted agent. Moreover, not all tumors are equally addicted to certain 
targeted pathways, and inhibition of such a bystander pathway will not result in a significant 
tumor response. Predictive factors should therefore ideally identify which patients’ tumors 
are dependant upon the targeted pathway and are not inherently or acquired resistant to the 
drug of choice, and are thus most likely to show a clinically relevant response. Patient selection 
can determine the success of clinical trials; some of the hallmark cancer therapies of today, 
such as trastuzumab, had not passed phase II/III trials had it not been for the right selection 
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of patients
448
. Certain therapies might only work in a few percent of all patients, but deliver 
significant clinical benefit in that small subgroup; their efficacy will only come to light in a 
properly designed clinical trial pre-selecting for sensitive patients based on reliable predictive 
factors. With the conduction of such clinical trials, treatment can be adapted for small patient 
subgroups or even individual patients, resulting in truly personalized medicine.
TUMOR HETEROGENEITY
Even when selection is based on tumor characteristics, response prediction in patients is 
often far from perfect. Markers that are expected to correspond to a black-or-white tumor 
response often fail to show such predictive value in clinical trials. Partly, this could be due to 
the tissue in which the marker is determined, which is currently almost always the primary 
tumor. However, in the metastatic disease setting, years have often passed since removal of 
the primary tumor, leading to heterogeneity between these tissues
7
 due to processes such as 
clonal selection and genomic instability. This heterogeneity between primary and metastatic 
tissue could explain why patient selection based on primary tumor characteristics does not 
always result in a response in metastatic lesions, which ultimately determine the faith of most 
cancer patients.
Heterogeneity between primary tumor and metastases is a compelling argument for the 
assessment of predictive and prognostic markers on metastatic tumor tissue, and important 
efforts are ongoing to initiate trials based on in-depth genomic analysis of metastatic lesions
449
. 
The implementation and physician and patient acceptance of metastatic biopsies can however 
be limited by their invasive and painful nature, hampering especially the repeated analyses 
needed to determine drug resistance. To overcome these hurdles, circulating tumor cells 
(CTCs) present an attractive alternative.
CTCs can be analyzed repeatedly during the course of treatment to re-assess predictive 
factors as time and drug pressure influence the predominant clones and sensitivity of tumor 
lesions. Moreover, CTC counts can predict patients’ prognosis
25,27,29,31,34,450
 and can be used 
as an early marker of therapy response
451-452
. Together, counting and characterizing CTCs hold 
great promise as a tool for patient stratification, selection and monitoring, but important 
steps forward are needed to fulfill this promise. In this thesis, we have described a number 
of advances in the field of CTCs, both in terms of optimization of their detection and of their 
large-scale characterization.
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ADVANCES IN CTC DETECTION
Many different CTC detection methods have and are continuing to be developed in an effort 
to obtain an as big and representative fraction of these rare cells as possible, while preserving 
them for downstream characterization and culturing. Because of the scarcity of CTCs and the 
overwhelming number of peripheral blood mononuclear cells amongst which they have to be 
identified, extremely high sensitivity and specificity is needed from these assays. Until now, 
only CellSearch® (Veridex™ LLC, Raritan, NJ) has obtained FDA approval for use as a prognostic 
marker in metastatic breast
25-27
, colorectal
29
, lung
30
 and prostate cancer
31,453
. While the papers 
in this thesis and other work
64
 have shown that CellSearch is not the perfect assay, its FDA-
clearance does enable its use in the clinic and as a stratification marker in clinical trials. To 
further improve the amount and quality of information that can be obtained from peripheral 
blood, numerous advances can and have been made, specifically in the choice of enrichment
454
 
and selection markers to enable detection of all circulating tumor cells.
Detection of EMT-like CTCs
We have described the value of adding CD146 to anti-EpCAM as an enrichment marker to the 
CellSearch assay, in order to enable the detection of EpCAM-negative CTCs. These EpCAM-
negative cells are predominantly of the normal-like subtype, which has been described to have 
EMT characteristics
455
 and stem-cell features
456
, and display an aggressive behavior
10
. CD146 
is expressed in the majority of normal-like breast cancer cell lines and thus enables their 
detection. For CTC characterization purposes, the additional cell populations that are isolated 
by combined anti-EpCAM/CD146 enrichment do result in a less favorable tumor cell-leukocyte 
ratio, as a result of which tumor cell transcripts will have to be measured among even more 
leukocyte transcripts. For this reason, the characterization of CD146-positive CTCs will probably 
benefit from a single-cell approach
457
, in which single cell EpCAM-positive and CD146-positive 
CTCs from the same patients can be compared and their individual characteristics correlated 
with disease outcome and patient characteristics.
The counting of CD146-positive CTCs can readily be implemented into clinical trials, and we are 
currently conducting a prospective multicentre clinical study in primary breast cancer patients 
treated with neoadjuvant chemotherapy, in whom both EpCAM-positive and CD146-positive 
CTCs are enumerated. This study will allow us to establish the frequency of CD146-positive 
CTCs, and especially in primary breast cancer patients, in whom EpCAM-positive CTCs are even 
less frequent
34
, the addition of CD146 might increase CTC detection frequency. Importantly, 
recent evidence shows that CD146 expression in breast cancer cell line cells is associated with 
down regulation of epithelial marker expression in favor of mesenchymal marker expression 
and increased tumor and metastasis formation in mice models
458
. EpCAM-negative, CD146-
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positive CTCs could thus represent cells that have undergone EMT and are possibly more 
malignant in nature, and the dual-enrichment of CD146 and EpCAM positive CTCs may increase 
the clinical relevance of CTC counting.
While the addition of CD146 as an enrichment marker resulted in an important increase in 
coverage of breast cancer subtypes, a subgroup of EMT-like breast cancer cells still remained 
undetected as a consequence of insufficient expression of the cytokeratins 8, 18 and 19, 
which are the positive selection markers employed in the standard CellSearch assay. Loss of 
cytokeratin expression also occurs in the context of EMT
11
, and these cytokeratin-negative 
cells could be highly relevant in the process of metastasis. Other studies have shown that 
CK-negative circulating cells display properties of CTCs, such as HER2 amplification
454
, adding 
to the notion that these CK-negative cells too are in fact derived from tumors and clinically 
relevant. CD49f, a stem-cell marker
254
 associated with increased tumor aggressiveness
262,264
, 
was broadly expressed across breast cancer subtypes, including cytokeratin-negative cells. We 
showed that the addition of CD49f to cytokeratin 8/18/19 as CTC selection markers resulted in 
the improved detection of cytokeratin-negative CTCs. 
Together, CD146 and CD49f have improved the ability of the CellSearch assay to detect all 
breast cancer subtypes, and will hopefully lead to increased clinical value in more breast 
cancer patients.
Room for improvement
With the difficulty in finding one or a set of markers covering all tumor types, one has to 
wonder whether CTCs should be detected based on marker expression at all. Assays have also 
been described isolating CTCs based on morphological or functional characteristics, such as 
size
19,76,459
, cell stiffness
460
 or cell membrane capacitance
446
. Besides possibly enabling higher 
CTC detection rates, these methods do not require cell fixation and permeabilization steps, 
resulting in viable cells suitable for subsequent cell culturing.
In addition to the choice of method, the preferred timing and place of blood draw for CTC 
detection also needs further elucidation. CTCs have been speculated to be released into the 
blood stream in a circadian rhythm
461
, but are also heavily influenced by the administration of 
anti-tumor therapies
462
. When it comes to the preferred place of blood draw, CTCs are most 
often obtained by venipuncture because of its convenience and minimally invasive nature. 
However, the size of CTCs in relation to that of capillaries will probably lead to trapping of 
CTCs in capillaries, and a lower CTC count in the periphery compared to the central venous 
compartment or arteries has been described
463
. 
Despite all the unknowns in the field of CTC detection, clinical studies should continue with 
currently available and validated methods while efforts to improve detection methods are 
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ongoing. For all of the uncertainty, the value of CellSearch-enumerated CTCs as a prognostic 
and therapy response marker is well-established, and should not be disregarded while we 
await identification of the ‘perfect’ circulating particle.
ADVANCES IN CTC CHARACTERIZATION
CTC-specific genes in colorectal and breast cancer
When going beyond CTC counting and employing their features as prognostic and predictive 
factors, a number of challenges arise. Probably most crucial is the low amount of tumor-
derived nucleic material that can be obtained from a tube of blood. This can in part be 
overcome by analysis of larger blood volumes
337
 or optimization of the sensitivity of the 
CTC enrichment assay
20,250
, but also by employing a pre-amplification step before molecular 
analysis
9,64
. Additionally, most current CTC isolation methods, such as the CellSearch EpCAM-
based immunomagnetic enrichment, result in a cell fraction containing a few CTCs amongst 
still up to a thousand leukocytes
9
, significantly complicating subsequent molecular analysis. 
We have shown that this problem can at least in part be tackled by strictly selecting genes 
with no or very low expression in leukocytes and a much higher expression in breast cancer, 
followed by careful validation of their CTC-specificity.
Through comparison of healthy donors (HDs) with patients with 5 or more CTCs, we were 
able to identify a large panel of CTC-specific genes.  These genes identified distinct patient 
subgroups based on epithelial, ER-associated and growth factor receptor-associated gene 
expression. The CTC-specific gene panel also allowed for the comparison of primary tumors 
and CTCs, which revealed clinically relevant discrepancies for ER and HER2 expression.
Similarly, we selected genes clinically relevant in colorectal cancer and searched for CTC-
specific genes by comparing healthy donors with patients with 3 or more CTCs. We did not 
feel confident to group patients without detectable CTCs together with the healthy donors to 
make up the no-CTC group, because among patients without detectable CTCs we identified 
a subgroup with a gene expression profile clearly distinct from that of HDs, suggesting the 
presence of circulating tumor load. This discrepancy between CTC counts and molecular profile 
can be the consequence of low CK8/18/19 expression in CTCs
356,464
, which can lead to the 
inability to count CTCs while, based on EpCAM expression, they are enriched for subsequent 
molecular analysis. Consequently, CTC-specific mRNAs and miRNAs were identified in CRC 
patients by comparing HDs to patients with 3 or more CTCs, resulting in a panel of 47 genes 
that clustered patients primarily based on epithelial gene expression. 
CTC gene expression profiles to predict treatment benefit
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In our clinical breast cancer study, we were able to proceed with the CTC-specific gene 
expression panel and assess its prognostic value in a large set of 103 metastatic breast cancer 
patients. By leave-one-out cross validation, a 16-gene CTC profile was discovered that could 
predict time to treatment switch, and was able to further divide the good-prognosis group as 
defined by a CTC count <5 in a good and intermediate prognosis group. In patients with 5 or 
more CTCs, prognosis was almost universally poor, and the 16-gene CTC profile was not capable 
of identifying patients with an even more dismal prognosis. This lack of value in CTC-high 
patients is probably the result of the strong influence of the presence or absence of epithelial 
cell content on the 16-gene profile. Many genes in the 16-gene profile are epithelial markers, 
allowing for identification of patients who, despite a CTC count below 5, have circulating tumor 
load in their blood. However, they also assign an unfavorable profile to almost all patients with 
a high CTC count and thus high epithelial gene expression.
In patients with more than 5 CTCs, we also wished to better predict prognosis, but more 
importantly, provide information on CTC characteristics in terms of their biology and malignant 
potential. To his end, we developed a separate prognostic 9-gene profile in patients with 5 
or more CTCs, starting with all 96 mRNAs that could be reliably measured in CTCs
9,38
. The 
presence in the 9-gene profile of ER, a well-established predictive
465
 and prognostic
466
 factor 
in breast cancer, and MET, which encodes for the oncogene met
320
, suggests that this 9-gene 
profile is less driven by circulating tumor load and more by CTC characteristics.
The external validity of these two CTC gene profiles awaits validation in an independent 
patient cohort, but already CTC characterization has proven to be able to be of additive value 
to a CTC count.
DNA mutations in colorectal CTCs
Besides CTC gene expression, we have also shown the feasibility of detecting DNA mutations in 
colorectal CTCs, which is an important advancement in this era of targeted treatments. Many of 
these targeted treatments can be used solely in the presence of companion diagnostics, which 
identify patients sensitive to these therapies. Like gene and protein expression, important 
discrepancies can exist between primary and metastatic tumors in terms of their mutation 
status
369-370,467-468
, and patient selection could possibly improve by selecting therapies based 
on CTC mutation status. For monoclonal antibodies targeting the EGF-receptor, a potent 
treatment in a variety of solid tumors
358,469
, KRAS
4
 and, to a lesser extent, BRAF
367
 mutations 
are important predictors of response, resulting in approval of their use solely for KRAS wild-
type patients
366
. In our prospective clinical study in colorectal cancer patients about to 
undergo partial liver resection for their metastases, we assessed KRAS and BRAF mutation 
status in matching primary tumors, metastases and CTCs by three different highly sensitive 
210 Chapter 10
assays. Important discrepancies were seen between primary tumors and metastases, but 
mutation detection in CTCs proved to be challenging due to low CTC counts in this patient 
population, the known abundance of remaining leukocytes and lack of amplification of the 
genes of interest. KRAS and BRAF mutations were detected in CTCs, but false-negative results 
can currently not be excluded in patients with low CTC counts and low mutation frequencies. 
Increasing the clinical use of CTCs 
Our difficulties with assessing KRAS and BRAF mutation status in CTCs, but also the current 
inability to measure all genes of interest in CTCs as we are limited to truly cancer-specific 
genes, demand attention. If anything, they are compelling evidence of the fact that the road to 
more in-depth molecular characterization methods such as whole-genome sequencing would 
be greatly facilitated by the further development of CTC detection methods that result in a 
pure CTC population
470
.
Nonetheless, CTC counts are an established prognostic factor in metastatic breast
25
, 
colorectal
283
, prostate
471
 and lung cancer
30
, and we and others have started to elucidate the 
prognostic value of their characteristics. While prognostic factors are important stratification 
tools in clinical studies, can be informative of tumor biology and guide the administration of 
adjuvant treatment, they usually do not guide oncologists in the optimal choice of a specific 
therapeutic agent for an individual patient. For this, predictive factors are needed, and given 
the poor patient selection for most current cancer therapies
447
, this need is urgent. Fortunately, 
CTC characterization provides ample opportunity to establish better predictive factors, and in 
the near future we aim to evaluate the predictive value of numerous CTC characteristics, on 
the protein, mRNA as well as DNA level, in prospective clinical studies. At the same time, 
we are continuing our efforts to improve the methods by which CTCs are isolated from and 
counted in the blood. Together, this can lead to the identification and validation of better 
predictive factors, and maximize the potential of CTC counts and characterization as a means 
to individualize and improve cancer treatment.
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Samenvatting

De levensverwachting van patiënten met kanker is de laatste jaren sterk verbeterd, onder 
andere door de introductie van nieuwe behandelingen. Echter met de komst van meer effectieve 
therapieën is ook de noodzaak om de juiste therapie voor de individuele patiënt te selecteren 
groter geworden. Voor het bepalen van de juiste therapiekeuze zijn betrouwbare prognostische 
en predictieve factoren onontbeerlijk. De afgelopen jaren zijn veel van dergelijke factoren 
geïdentificeerd in primair tumormateriaal, maar de uiteindelijke prognose van patiënten met 
kanker wordt bepaald door het gedrag van metastases en niet zozeer door dat van de primaire 
tumor. Daarnaast wordt het de laatste jaren steeds duidelijker dat er grote discrepanties 
kunnen bestaan tussen de kenmerken van de primaire tumor en die van de metastasen. Vaak 
zijn, alvorens anti-tumor therapie gestart wordt voor gemetastaseerde ziekte, jaren verstreken 
sinds het chirurgisch verwijderen van de primaire tumor en is tussentijds anti-tumor therapie 
gegeven. Door genetische instabiliteit, die karakteristiek is voor kankercellen, kunnen zo grote 
verschillen ontstaan in allerlei kenmerken die van invloed zijn op het gedrag van tumorcellen. 
Predictieve en prognostische factoren zouden dus waarschijnlijk het beste in metastatisch 
weefsel bepaald kunnen worden, maar het verkrijgen van weefsel van metastasen is vaak 
technisch moeizaam en pijnlijk voor de patiënt.
Circulerende tumorcellen
Een veelbelovend alternatief voor de analyse van metastasen is de detectie en karakterisatie 
van circulerende tumorcellen (CTC’s). CTC’s zijn cellen afkomstig van primaire tumor of 
metastasen die zich bevinden in het perifere bloed. CTC’s zijn voor het eerst beschreven in de 
19
e
 eeuw, maar lange tijd waren er geen goede methodes om CTC’s te identificeren. Vooral 
tijdens het laatste decennium zijn er vele pogingen gedaan om betrouwbare, reproduceerbare 
technieken te ontwikkelen, wat uiteindelijk geresulteerd heeft in verschillende methoden 
waarmee CTC’s gedetecteerd kunnen worden.
CTC’s kunnen op verschillende manieren worden toegepast in de behandeling van 
kankerpatiënten. Een CTC-aantal kan gebruikt worden als prognostische factor voorafgaand 
aan therapie, als parameter om de effecten van anti-tumortherapie te meten en voor de 
vroegtijdige detectie van recidieven.
Naast het tellen, kunnen CTC’s ook worden geïsoleerd uit bloed en vervolgens op moleculair 
niveau verder worden gekarakteriseerd. Mogelijke toepassingen van het karakteriseren van 
CTC’s zijn het identificeren van eiwitten of genen die kunnen helpen bij de keuze van therapie, 
het detecteren van het ontstaan van resistentie tegen de ingestelde therapie en het vergroten 
van het inzicht in de tumorbiologie, door bijvoorbeeld eigenschappen van de primaire tumor 
te vergelijken met die van de CTC’s.
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HET TELLEN VAN CTC’S
Het tellen en isoleren van CTC’s is een grote uitdaging gebleken, vooral doordat er meestal 
sprake is van slechts één of enkele cellen te midden van miljarden leukocyten. Pas sinds een 
aantal jaren is een semigeautomatiseerde methode beschikbaar, de CellSearch methode 
genaamd, die goedgekeurd is voor het bepalen van CTC’s als prognostische factor in 
verschillende tumortypes. Deze methode maakt gebruik van de aanwezigheid van specifieke 
eiwitten op CTC’s. In de eerste stap van de test wordt bloed verrijkt voor cellen die expressie 
vertonen van EpCAM, een kankerspecifiek antigeen. Deze cellen worden uit het bloed 
geïsoleerd door gebruik te maken van zogenaamde ferrofluids, kleine ijzerdeeltjes, die beladen 
zijn met een antistof tegen EpCAM. Deze verrijkte celsuspensie kan worden gebruikt voor 
verdere moleculaire karakterisatie. Wanneer CTC’s geteld worden, volgt een aantal stappen 
waarin CTC’s in de verrijkte celsuspensie worden gedetecteerd op basis van de expressie van 
cytokeratines, een kernkleuring en de afwezigheid van CD45, een leukocytenmerker. Het met 
deze methode verkregen aantal CTC’s per 7.5 mL bloed is van prognostische waarde gebleken 
voor patiënten met gemetastaseerd prostaat-, colorectaal, long- en mammacarcinoom. 
Daarnaast voorspelt het stijgen of dalen van het CTC-aantal tijdens therapie, kort na het 
starten van de behandeling, de respons op die therapie.
Verbeterde CTC-detectie door additionele merkers
Hoewel het tellen van CTC’s van grote waarde is gebleken, is de huidige detectiemethode 
niet perfect. Bij een substantieel deel van de patiënten worden, zelfs wanneer sprake is van 
uitgebreid gemetastaseerde ziekte, geen CTC’s gedetecteerd. Borstkanker is een heterogene 
ziekte waarin verschillende subtypes kunnen worden onderscheiden. Eerder hebben we 
aangetoond dat in mammacarcinoompatiënten deze suboptimale detectie deels te verklaren 
is door het ontbreken van EpCAM, het membraaneiwit dat essentieel is voor de verrijking van 
CTC’s uit bloed, op de cellen van één van die subtypes mammacarcinoom. Cellijncellen van dit 
type, het zogenaamde ‘normal-like’ mammacarcinoom, werden dan ook niet gedetecteerd met 
de standaard CellSearch methode. In dit proefschrift hebben we laten zien dat het toevoegen 
van CD146, een eiwit dat wel voorkomt op het ‘normal-like’ type mammacarcinoom, als 
merker voor CTC-verrijking de detectie van ook dit mammacarcinoomsubtype mogelijk maakt. 
Daarnaast hebben we laten zien dat deze CD146-positieve CTC’s, al dan niet in combinatie 
met EpCAM-positieve CTC’s, voorkomen in het bloed van patiënten met gemetastaseerd 
mammacarcinoom.
Het toevoegen van CD146 aan EpCAM als merker voor CTC-verrijking verbeterde de CTC-
detectie in mammacarcinoom, maar er waren nog steeds mammacarcinoomcellijnen die niet 
gedetecteerd konden worden met deze nieuwe benadering. Dit bleek veroorzaakt te worden 
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door een te lage cytokeratine-expressie op diverse cellijnen, de merkers op basis waarvan CTC’s 
worden geselecteerd na verrijking uit het bloed. Een ander eiwit, CD49f, dat ook beschreven 
is als merker voor kankerstamcellen, kwam wel op deze cellen tot expressie en de toevoeging 
ervan aan cytokeratines als selectiemerker leidde tot een betere CTC-detectie. 
CTC KARAKTERISATIE
CTC-specifieke genen in mammacarcinoom
Wanneer CTC’s geïsoleerd worden uit bloed voor verdere moleculaire karakterisatie, kan de 
analyse van CTC’s dienen als een mogelijk alternatief voor analyse van metastatisch weefsel, 
dat lang niet altijd te verkrijgen is. In CTC’s kunnen vervolgens zowel prognostische als 
predictieve factoren bepaald worden, bijvoorbeeld door het meten van genexpressie of DNA 
mutaties. Het karakteriseren van CTC’s is daarmee veelbelovend, maar is technisch moeilijk 
gebleken. Net zoals bij het tellen van CTC’s is er sprake van zeer lage aantallen CTC’s te midden 
van een veelvoud aan leukocyten, zelfs na EpCAM-gebaseerde verrijking van bloed. Het is 
momenteel nog niet goed mogelijk om een suspensie te krijgen die alleen uit CTC’s bestaat. 
Dit maakt het lastig om in die gemengde suspensie van CTC’s en leukocyten de expressie van 
alleen de genen van de CTC’s te bepalen. Omdat de meeste genen niet volledig kankerspecifiek 
zijn, brengt het meten van die genen in een gemengde populatie het risico met zich mee dat 
de gevonden expressie van een gen grotendeels afkomstig is van de aanwezige leukocyten en 
niet van de CTC’s. In dit proefschrift beschrijven we een methode om toch tumorcelspecifieke 
genexpressie te meten in een verrijkte celsuspensie. Na een eerste selectie op klinisch relevante 
genen die niet of slechts zeer laag in leukocyten tot expressie komen, hebben we de expressie 
van deze genen in verrijkt bloed vergeleken tussen gezonde proefpersonen en patiënten met 
5 of meer CTC’s. Op deze manier hebben we een set CTC-specifieke genen geïdentificeerd 
die patiëntengroepen kon onderscheiden op basis van expressie van epitheliale, oestrogeen 
receptor (ER)-geassocieerde en groeifactorreceptor-geassocieerde genen. Ons CTC-specifieke 
genenpanel liet in een kleine groep patiënten ook mogelijk klinisch relevante verschillen zien 
tussen de primaire tumor en CTC’s wat betreft de expressie van genen zoals ER.
CTC-specifieke genen in colorectaal carcinoom
In analogie aan de studie in mammacarcinoompatiënten zijn we ook in de CTC’s van patiënten 
met gemetastaseerd colorectaal carcinoom op zoek gegaan naar een panel van CTC-specifieke 
genen met mogelijke prognostische waarde. Na een voorselectie op klinisch relevante genen 
die niet of nauwelijks tot expressie komen in leukocyten, hebben we deze genen gemeten in 
patiënten met gemetastaseerd colorectaal carcinoom bij wie bloed voor CTC-telling en -isolatie 
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was afgenomen vlak voor operatieve verwijdering van hun levermetastasen. Door het verrijkte 
bloed van gezonde proefpersonen te vergelijken met dat van patiënten met in dit geval 3 
of meer CTC’s hebben we een panel van 47 CTC-specifieke genen kunnen identificeren. In 
deze patiënten met colorectaal carcinoom konden we niet de patiënten zonder detecteerbare 
CTC’s groeperen met de gezonde donoren. In een subgroep van patiënten waarin geen 
CTC’s gedetecteerd werden met de CellSearch methode wees de expressie van diverse 
epitheelspecifieke genen namelijk op de aanwezigheid van tumormateriaal in het bloed. In 
deze subgroep van patiënten is waarschijnlijk sprake van tumormateriaal dat niet voldoet 
aan de criteria om in de CellSearch methode als een CTC geteld te worden, ofwel op basis 
van morfologische kenmerken, dan wel door een te lage expressie van de cytokeratines. 
Het genexpressieprofiel lijkt dus een gevoeliger methode om ook in deze patiënten zonder 
detecteerbare CTC’s de aanwezigheid van tumormateriaal aan te tonen.
Prognostische waarde van CTC genexpressieprofielen
Na de identificatie van het CTC-specifieke genenpanel in mammacarcinoompatiënten zijn we 
op zoek gegaan naar de mogelijke prognostische waarde van dit panel. Voor dit doel hebben we 
de genexpressieprofielen gemeten in 103 patiënten met gemetastaseerd mammacarcinoom 
bij wie CTC’s waren afgenomen voor start van eerstelijns medicamenteuze behandeling 
in de vorm van hormonale therapie of chemotherapie. We hebben de expressie van dit 
genenpanel vergeleken tussen een groep van patiënten met een overstap naar een volgende 
lijn medicamenteuze therapie of die overleden waren binnen 9 maanden na start en een groep 
van patiënten die geen nieuwe vorm van therapie nodig hadden en niet overleden waren 
binnen die periode. Hieruit hebben we een 16-genenprofiel geïdentificeerd dat dit verschil in 
prognose kon voorspellen. Dit 16-genenprofiel had een toegevoegde prognostische waarde 
aan een CTC-telling, en onderscheidde de patiënten die op basis van een CTC-getal <5 per 7.5 
mL bloed een goede prognose zou hebben, in twee groepen met een verschillende prognose. 
In de groep van patiënten met 5 of meer CTC’s kon het 16-genen profiel geen additionele 
prognostische informatie geven, waarschijnlijk door de grote invloed van de aanwezigheid van 
epitheliaal signaal op de score van het profiel. In deze groep hebben we om die reden een 
apart 9-genenprofiel gegenereerd dat wel prognostische waarde had. Dit 9-genenprofiel is 
minder afhankelijk van de expressie van epitheelspecifieke genen en is dus waarschijnlijk een 
betere afspiegeling van de biologie en mate van kwaadaardigheid van de aanwezige CTC’s.
218 Samenvatting 
DNA mutaties in CTC’s
Naast het meten van genexpressieprofielen in CTC’s hebben we ook de haalbaarheid 
onderzocht van het meten van DNA mutaties in de CTC’s van colorectaal carcinoompatiënten. 
Een relatief nieuwe optie binnen de behandeling van het colorectaal carcinoom is behandeling 
met monoklonale antistoffen gericht tegen de EGF-receptor (EGFR). Deze zijn echter alleen 
werkzaam in patiënten met een tumor zonder een mutatie in het KRAS gen. Deze KRAS mutaties, 
die een activerende werking hebben op de EGFR-RAS-RAF cascade, worden gevonden in de 
tumoren van ongeveer 40% van de patiënten met colorectaal carcinoom. Het is gebleken dat 
deze patiënten geen baat hebben bij behandeling met een antistof gericht tegen EGFR, reden 
waarom de behandeling met anti-EGFR therapie is voorbehouden aan patiënten zonder een 
gemuteerd KRAS gen. Ook een mutatie in het BRAF gen, die in ongeveer 10% van de patiënten 
voorkomt, zorgt voor resistentie tegen anti-EGFR therapie. Net als voor genexpressieprofilering 
geldt ook voor mutatieanalyse dat het bepalen in CTC’s waarschijnlijk van toegevoegde waarde 
is boven het bepalen in de primaire tumor. Het geven of onthouden van anti-EGFR therapie 
aan patiënten op basis van de mutatiestatus van deze genen in de primaire tumor, terwijl 
deze mogelijk verschillend is in de metastasen, zou onnodig toxiciteit induceren dan wel een 
kans op effectieve behandeling ontnemen aan deze patiënten. Gezien het grote klinische 
belang van mutatiedetectie hebben we mogelijke verschillen in de mutatiestatus van KRAS 
en BRAF bestudeerd in de primaire tumoren ten opzichte van de CTC’s en metastasen van 
patiënten die een gedeeltelijke leverresectie hadden ondergaan. Hoewel we klinisch relevante 
discrepanties vonden tussen de primaire tumoren en de metastasen, was de mutatiestatus 
van deze twee genen in de CTC’s moeilijk te interpreteren gezien de kans op vals-negatieve 
resultaten in patiënten met lage CTC-aantallen. Desondanks is het gelukt drie verschillende 
detectietechnieken te vergelijken, en met de meest sensitieve techniek KRAS en BRAF mutaties 
te vinden in patiënten met slechts 2 CTC’s.
CTC’s op weg naar de kliniek
In dit proefschrift worden methodes beschreven die de detectie van CTC’s verbeteren door het 
gebruik van alternatieve verrijkings- en selectiemerkers voor CTC-telling. Daarnaast beschrijven 
we een uiterst gevoelige methode waarmee een uitgebreid panel klinisch relevante genen 
gemeten kan worden in de CTC’s van mammacarcinoom en colorectaal carcinoompatiënten 
door ons te richten op kankerspecifieke genen. Het bleek bovendien dat een selectie van 
die genen van prognostische waarde is in mammacarcinoompatiënten. Deze ontwikkelingen 
samen maken het mogelijk in meer patiënten meer informatie uit CTC’s te winnen, wat de 
klinische relevantie van CTC’s vergroot. 
In de komende jaren kan de rol van CTC’s als prognostische en predictieve factor groter 
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worden wanneer het mogelijk wordt een volledig pure populatie CTC’s te verkrijgen, zodat 
we niet langer gehinderd worden door de aanwezigheid van leukocyten in de te analyseren 
celpopulatie. Daarnaast zullen de moleculaire karakterisatietechnieken gevoeliger worden en 
meer informatie opleveren, bijvoorbeeld door de mogelijkheid het volledige genoom van een 
enkele cel te analyseren. Al deze nieuwe toepassingen van CTC’s moeten uiteindelijk leiden 
tot een betere behandeling van kanker en een optimale therapiekeuze voor elke individuele 
patiënt.
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Chapter 2
Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer
Figure 1
This figure clarifies the various options for enriching CTCs. After blood is drawn from the patient, CTCs 
can be separated from hematopoietic cells based on size, density or immunological characteristics. ISET 
(Isolation by Size of Epithelial Tumor cells) filters CTCs based on their larger size compared to hematopoietic 
cells. Ficoll and Percoll are the most commonly used density-gradient based techniques. Immunomagnetic 
separation techniques separate CTCs from other hematopoietic cells based on marker expression; MACS 
(Magnetic Activated Cell Sorting) uses microbeads and RARE (RosetteSep-Applied imaging Rare Event) 
combines magnetic separation with CD45+-cell depletion. CellSearch and the CTC-Chip both enrich based 
on EpCAM; CellSearch separates cells bound to EpCAM-ferrofluid in a magnetic field, while the CTC-chip 
does so by binding EpCAM-positive cells to microposts.
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Chapter 3
Detection of circulating tumor cells in breast cancer may improve through enrichment with 
anti-CD146
Figure 3
CD146 staining. a Representative pictures of indicated cell lines stained for CD146 (brown). Both cell lines 
shown are of normal-like molecular subtype b Representative pictures of two primary normal-like breast 
tumors stained for CD146 (brown)
A.        SK-BR-7 (100% positive)     Inset: SK-BR-7                  BT549 (25 - 50% positive)
                Primary breast tumor 1 (5x)                Primary breast tumor 1 (20x)
B.    Primary breast tumor 2 (5x)                    Primary breast tumor 2 (20x)
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Chapter 5
mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of 
metastatic breast cancer patients
Figure 2 
For legend see page 237
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Figure 4 
Unsupervised hierarchical cluster analysis 
comparing gene expression profiles in CTC-
enriched blood samples of metastatic breast 
cancer patients and their corresponding 
primary tumor. Expression levels were analyzed 
with real-time RT-PCR with 65 TaqMan Gene 
Expression Assays in cDNA generated from 
RNA isolated from the CellSearch-enriched 
fractions of 8 breast cancer patients with 
metastatic disease and their corresponding 
primary tumors. Sample loading and RNA 
integrity were controlled with 3 additional 
universal reference genes (GUSB, HPRT1, and 
HMBS). Prior to real-time PCR, cDNA was pre-
amplified in 15 cycles with the PreAmp method 
from ABI, as described in the Materials and 
Methods section, by using the same TaqMan 
Gene Expression Assays that were used for 
the real-time PCR. Data shown have been 
subjected to median normalization of each 
individual gene across all samples followed 
by median normalization of each individual 
sample across all genes. Each horizontal row 
represents a gene, and each vertical column 
corresponds to a sample (T = tissue). The 3 
FFPE primary tumor tissues from patients 1, 
2, and 5 are colored gray on top in the graph 
for easy identification. Red color indicates a 
transcript level above the median level, black 
color indicates a median transcript level, and 
green color indicates a transcript level below 
the median level of the particular assay as 
measured in all samples.
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Chapter 6
Gene expression profiles in circulating tumor cells predict prognosis in metastatic breast 
cancer patients
Figure 3
Kaplan-Meier plots for patient subgroups as defined by CTC count (panel a), the 16-gene CTC-profile (panel 
b) and the combination of CTC count and 16-gene CTC profile (panel c). Only one patient had more than 
5 CTCs and a favorable 16-gene CTC profile, therefore no curve is depicted for this subgroup. Panel d 
combines panels a and c and shows that the 16-gene CTC panel is able to distinguish a truly good and an 
intermediate prognosis group among patients with <5 CTCs, while no added value is seen in patients with 
≥5 CTCs. unfav; unfavorable profile, fav; favorable profile
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Figure 4
ROC-curve (panel a), test performance (panel b) and test characteristics (panel c) of the 9-gene CTC profile 
as generated in 50 patients with ≥5 CTCs. Panel d and e depict Kaplan-Meier plots for patient subgroups 
as defined by the 9-gene CTC profile (panel d) and a combined graph of the curves according to CTC count 
(solid lines blue and red lines) and 9-gene profile (dashed red lines, panel e). AUC; area under the curve, 
PPV; positive predictive value, NPV; negative predictive value
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Chapter 7
mRNA and miRNA expression profiles in circulating tumor cells of metastatic colorectal 
cancer patients
Figure 1: Clustering of HDs and patients without detectable CTCs
Unsupervised hierarchical cluster analysis comparing mRNA gene expression profiles in colorectal CTC-enriched fractions from 
33 patients without detectable CTCs and QQ mRNA data available and 30 HDs. Data shown have been subjected to median 
normalization of each individual sample across all genes followed by median normalization of each individual gene across all 
samples. Columns represent patient samples, rows represent genes. Red color indicates a transcript level above the median 
level, white color indicates a median transcript level, and blue color indicates a transcript level below the median level of 
the particular mRNA in all samples. Depicted gene clusters were identified at an average linkage correlation greater than 0.2. 
At the top, the HD-unlike patient cluster is indicated in red; the HD-alike patient cluster in blue. Highly expressed genes that 
characterize the HD-unlike patient cluster are signified by the gray rectangle (at the right). Healthy donors (HD, green) and 
patients (pt, red) are depicted on the bottom of the graph.
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Chapter 8
KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation 
with primary and metastatic tumor tissue
Figure 1
Sequencing electropherograms of first round (panel a) and second round (panel b) enrichment PCR 
products. Panel a: Black arrow indicates the location of a G13D mutation (Mut) present in pure cells of the 
colorectal cancer cell line HCT116 (50% G>A mutant); black peak corresponds to the wild-type G and green 
peak to mutated A. Green arrow indicates the location of a G13D mutation present in 5% HCT116 cell 
line cells mixed with 95% KRASwt SK-BR-3 cell lines cells. Red arrow indicates location of G13D mutation 
present in patient sample CTC208. HT29 was the wild-type control. CTC200, CTC222, CTC245 and CTC252 
all had KRASmt tissue, but no mutation in their CTCs detected with COLD-PCR (see Table 2 and Results 
section)
Panel b: Sequencing electropherograms after a second round of enrichment; the same results are 
obtained for controls HCT116 (black arrow) and mixed cell line control (green arrow). Blue arrow indicates 
the location of a G13D mutation present in mixed KRASmt cancer cell lines diluted to 0.625% mutation 
frequency. Red arrow indicates a now more pronounced green A peak in mutated patients sample CTC208. 
Red peak; T, blue peak; C
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Chapter 9
Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer 
patients
Figure 1
miRNA processing resulting in altered protein expression. Left panel: miRNA processing; In the nucleus, 
miRNAs are transcribed into primary miRNA transcripts (pri-miRNAs). These pri-miRNAs are subsequently 
cleaved into precursor miRNAs (pre-miRNAs) by Drosha. These pre-miRNAs, 70 to 90 nucleotides in length, 
are transported into the cytoplasm by Exportin 5 where the hairpin precursors are cleaved by Dicer, resulting 
in a small dsRNA duplex that contains both the mature miRNA strand and its complementary strand. The 
20 to 25 nucleotides in length mature miRNA strand is then incorporated into a RNA-induced silencing 
complex (RISC), which inhibits the function of its target mRNA by mRNA degradation or, most commonly, 
by translational repression
393,472
 (Figure freely adapted from http://www.marligen.com and
473
).
Right panel: an example of the multiple functions of miR-210 in the for cancer important process of 
hypoxia, which allows cancer cells to adapt to a low oxygen environment. Increased miR-210 expression 
has been linked to increased metastatic capability and increased hypoxia signaling in lymph node-negative 
estrogen receptor-positive human breast cancer
286
. MiR-210 is regulated by hypoxia-inducible factor 
1-alpha (HIF-1alpha), and the expression of both is increased in response to hypoxia. The upregulated 
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expression of miR-210 expression during hypoxia results in the repressed translation of its multiple target 
genes. Through these miR-210 targeted genes a large number of proteins are up and down regulated 
in response to increased miR-210 expression
474
. The direct or indirect up and down regulation of these 
downstream proteins enables cells to adjust and adapt to a hypoxic environment, sustaining their rapid 
growth rate despite insufficient angiogenesis to match their proliferation rate.
Figure 2 (see page 228)
Unsupervised hierarchical cluster analysis comparing gene expression profiles in CTC-enriched blood 
samples of metastatic breast cancer patients. Expression levels were analyzed with real-time RT-PCR 
with 65 TaqMan Gene Expression Assays in cDNA generated from RNA isolated from the CTC-enriched 
fractions of 50 metastatic breast cancer patients. Sample loading and RNA integrity were controlled with 
3 additional universal reference genes (GUSB, HPRT1, and HMBS). Prior to real-time PCR, cDNA was pre-
amplified in 15 cycles with the PreAmp method from ABI, as described in the Materials and Methods 
section, by using the same TaqMan Gene Expression Assays that were used for the real-time PCR. Data 
shown have been subjected to median normalization of each individual gene across all samples followed 
by median normalization of each individual sample across all genes. Each horizontal row represents a 
gene, and each vertical column corresponds to a sample. Red color indicates a transcript level above the 
median level, black color indicates a median transcript level, and green color indicates a transcript level 
below the median level of the particular assay as measured in all samples. Depicted gene clusters were 
identified at an average linkage correlation greater than 0.2. The number of CTCs as established by the 
CellSearch Epithelial Kit is given below the graph, with the samples with at least 5 CTCs according these 
cell counts marked gray for easy identification.
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7AAD  7-Aminoactinomycin D
AA  African American
APC  allophycocyanin
AUC  area under the curve
CA  Caucasian american
CCP  compound covariate predictor
CD  cluster of differentiation
cDNA  complementary DNA
CECs  circulating endothelial cells
CK  cytokeratin
CRC  colorectal cancer
Ct  threshold cycle
CTCs  circulating tumor cells
CV  coefficient of variation
DAPI  4’,6-diamidino-2-phenylindole
DAVID  database for annotation, visualization, and integrated discovery
ddH2O  double-distilled water
dim  dim expression
dsRNA  double-stranded RNA
DTCs  disseminated tumor cells
EDTA  ethyleendiamine tetra-acetate
EGFR  epithelial growth factor receptor
EMT  Epithelial-to-Mesenchymal Transition
EpCAM  Epithelial Cell Adhesion Molecule
ER  estrogen receptor
FDA  Food and Drug Administration
FDR  false discovery rate
FF  fresh frozen
FFPE  formalin-fixed paraffin-embedded
FISH  fluorescence in situ hybridization
FITC  fluorescein isothiocyanate
FU  follow-up
gDNA  genomic DNA
HCC  hepatocellular carcinoma
HER2  human epidermal growth factor receptor 2
H(B)D  healthy (blood) donor
270 List of Abbreviations
HR  hazard ratio
ICC  immunocytochemistry
Ig  immunoglobulin
miRNA  micro ribonucleic acid
mRNA  messenger ribonucleic acid
NA  not available
NPV  negative predictive value
NSCLC  non small cell lung cancer
nt  nucleotide 
OS  overall survival
PBMCs  peripheral blood mononuclear cells
PBS  phosphate buffered saline
PD  progressive disease
PE  phycoerythrin
PFS  progression-free survival
PPV  positive predictive value
PR  progesterone receptor
pre-miRNA precursor miRNA
pri-miRNA primary miRNA
QQ  of sufficient quality and quantity
qRT-PCR  quantitative reverse transcribed polymerase chain reaction
RISC  RNA-induced silencing complex
RMS  rhabdomyosarcoma
RNU/SNOR small nucleolar RNAs
RT  reverse transribed
SCC  squamous cell carcinoma
s/n  signal-to-noise
TMA  tissue microarray
TTS  time to treatment switch
vs.  versus
WB  whole blood
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Een proefschrift wordt nooit alleen gemaakt, maar de studies in dit proefschrift zijn bij uitstek 
het resultaat van een nauwe samenwerking tussen verschillende afdelingen en disciplines. 
Ik ben dan ook heel veel mensen oprecht dankbaar voor hun inzet en de bereidheid om hun 
kennis en ervaring in te zetten voor dit project, alsmede voor hun geloof in het slagen van 
dit voor het Erasmus MC nieuwe samenwerkingsverband. Het starten van de CTC-werkgroep 
betekende de eerste samenwerking tussen de afdeling Medische Tumorimmunologie in de 
Daniel den Hoed Kliniek en de afdeling Breast Cancer Genomics and Proteomics van het 
Josephine Nefkens Instituut. Twee afdelingen die elkaar maar nauwelijks kenden en bovendien 
expertise hadden in toch behoorlijk verschillende onderzoeksgebieden. Onder de bezielende 
leiding van Stefan Sleijfer en John Foekens werd er een CTC-werkgroep gevormd, die mede door 
een heen- en weer fietsende promovenda een gesmeerd lopende machine moest worden. De 
bereidheid aan beide kanten van de Maas om de deuren van hun lab open te zetten, eindeloos 
vragen te beantwoorden en buiten de hokjes te denken, hebben ervoor gezorgd dat nu, lang 
voordat de fysieke nabijheid van de 2 afdelingen gerealiseerd is, niet alleen de onderlinge 
afstand overbrugd is maar er ook een wederzijdse waardering en interesse gegroeid is voor 
elkaars vakgebied. Ik hoop dat deze goede samenwerking in de komende jaren vastgehouden 
en uitgebreid kan worden.
Hierbij wil ik iedereen die dit proefschrift mogelijk heeft gemaakt heel hartelijk danken, en 
daarbij een aantal van hen bij naam noemen.
Mijn beide promotoren, Prof.dr. J.A. Foekens en Prof.dr. S. Sleijfer. Beste Stefan, ik heb je wel 
eens een aparte pagina in mijn dankwoord beloofd dus ik ga kijken hoe ver ik kom... Het is voor 
een heel groot deel jouw inzet geweest die ervoor gezorgd heeft dat de CTC-werkgroep en de 
samenwerking tussen de beide afdelingen die daarbij betrokken zijn, zijn uitgegroeid tot een 
succes. Je hebt, samen met John F, dit project geadopteerd en altijd, ook in extreem drukke 
tijden, je aandacht en tijd gegeven. De wetenschap dat je altijd voor mijn belangen en die van 
het CTC-werk op zou komen, gaf me vertrouwen in de goede afloop van mijn promotietraject 
ook wanneer ik het zelf even niet meer overzag. Je was het schoolvoorbeeld van een goede co-
promotor en later promotor: altijd laagdrempelig bereikbaar, onmetelijk intelligent, en je was 
het bijna altijd met me eens (of was het andersom?). Dan zijn er nog je talenten die misschien 
soms wat onderbelicht blijven (gelukkig vertel je er zelf graag over): je bent een briljant zanger, 
een weergaloze vrouwenvoetbalcoach, talentvolle dj en je hebt ook nog verstand van wijn. 
Behalve dat voetbal toch ook allemaal dingen waar ik voordeel bij heb gehad. Ik hoop dat we 
nog lang kunnen blijven samenwerken, en dat je ook als prof nog genoeg tijd voor me hebt en 
me verder wegwijs kan maken in de wondere wereld van de oncologie.
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Beste John, we waren dan wel in afstand van elkaar gescheiden, ook van jou wist ik dat het CTC-
project één van je ‘kindjes’ was en dat ik altijd een beroep kon doen op je jarenlange ervaring, 
moleculaire kennis en bemiddeling. Je bent altijd eerlijk en open over je standpunten, iets wat 
ik als Rotterdamse erg op prijs stel. Ik ben vereerd dat ik deel heb mogen uitmaken van de 
kans om de gedurende vele jaren ontrafelde moleculaire puzzel van het mammacarcinoom 
nu in de klinische praktijk te brengen, en heel blij dat ik gedurende die hele exercitie op je kon 
bouwen.
Mijn co-promotor, Dr. J.W. Gratama. Beste Jan-Willem, ook jou wil ik heel graag bedanken voor 
je betrokkenheid bij het CTC-werk. Je uitgebreide immunologische kennis en je vermogen om 
boven de materie uit te stijgen zijn van grote waarde geweest voor het onderzoek, en ik stel je 
inzet, ook in drukke en zware tijden, dan ook erg op prijs.
De leden van de kleine commissie, Prof.dr. J.N.M. IJzermans, Prof.dr. J.G.M. Klijn en Prof.dr. 
L.W.M.M. Terstappen wil ik zeer hartelijk danken voor het kritisch lezen van het manuscript en 
hun waardevolle commentaar.
De leden van de grote commissie, Prof.dr. R. de Wit, Prof.dr. C.J.A. Punt, Prof.dr. M.A. den Bakker 
en Dr. J.W.M. Martens, dank ik voor het plaatsnemen in deze commissie en het investeren van 
hun tijd in het lezen en beoordelen van dit proefschrift.
Jaco Kraan, sjakko, als wij als een getrouwd stel waren dan was dat toch zeker een dramatisch 
slecht huwelijk, maar dat heb je met die heksen... Je technische kennis van de flowcytometrie 
en je inventiviteit als het om de CTC’s ging waren onmisbaar. Ook voor koffie of even stoom 
afblazen kon ik bij je terecht, je bent een onmisbare en constante factor in het turbulente aio-
bestaan!
Petra van der Spoel, mijn hoop in bange dagen op het lab: nooit te beroerd om tot laat te 
werken, altijd een oplossing voor verstopte flowcytometers en meer van dat soort problemen 
en anders was er altijd nog chocolade om ons op te vrolijken! Het blijft jammer dat je het lab 
verlaten hebt, maar ik wens je alle goeds voor de toekomst.
Anieta Sieuwerts, ik kan toch wel met zekerheid willen stellen dat zonder jou dit boekje ongeveer 
¼ van zijn huidige dikte zou hebben. Je hebt een ongekende werklust, drive en enthousiasme 
en door jouw unieke kennis en vaardigheid in de karakterisatie van zeer zeldzame cellen heeft 
dit project kunnen slagen. Daarnaast waren er de gezellige Ooievaar-momenten en heb je me 
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ook buiten het lab om veel steun en aanwijzingen kunnen geven. Ik ga zéker niet de kliniek in 
verdwijnen, en hoop dat we nog veel papers samen kunnen uitdenken en schrijven onder het 
genot van een glas rode wijn!
John Martens, je bent de aangewezen persoon binnen de CTC-groep voor de kritische noot 
en het vermogen om altijd van een andere kant naar een probleem te kijken. Juist daardoor 
stelde je me op de proef en heb ik veel van je geleerd, veel dank daarvoor.
Joan Bolt-de Vries, ook jouw tomeloze inzet en vaardigheid om zelfs uit 1 cel geen RNA verloren 
te laten gaan, hebben dit proefschrift mogelijk gemaakt. Dank je wel voor je geduld met het 
kweken van eindeloos veel cellijnen en altijd een bemoedigend woord!
Els Berns en Jozien Helleman, jullie hebben je later bij het CTC-team gevoegd toen we ons 
ook gingen richten op het ovariumcarcinoom, en hebben gezorgd voor een frisse wind en 
talloze nieuwe ideeën. Het is super om te zien dat het CTC-werk ook in andere tumortypes en 
onderzoeksgroepen geïncorporeerd kan worden, en ik hoop dat de samenwerking vruchtbaar 
zal blijven.
Cor Lamers, hoewel we niet veel direct hebben samengewerkt, zijn je aanwezigheid bij de 
wekelijkse werkbesprekingen en de kritische vragen maar ook oplossingen die je daar ter 
sprake bracht van grote waarde geweest. 
Mijn kamergenoten door de jaren heen: Michiel Strijbos, Marieke de Graaf, Arjen de Jongste 
en Wendy Onstenk. Dank voor de gezellige en goede werkomgeving en ik wens jullie alle 
goeds met verdere carrière en promoties. Wendy, je bent de afgelopen maanden al begonnen 
om het CTC-werk over te nemen en voort te zetten. Ik heb met veel plezier maar vooral 
veel vertrouwen het werk over kunnen dragen; je enthousiasme en gedrevenheid hebben 
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en Raquel Moreno-Ramirez voor hun ondersteuning met het kweken en opwerken van 
materialen. Maxime Look en Marcel Smid wil ik graag bedanken voor hun hulp bij de analyses, 
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een aantal jaar bij jullie in de leer te mogen als fellow oncologie!
Ook de fellows en ANIOS die gedurende mijn promotietraject in de Daniel werkzaam zijn 
geweest wil ik bedanken voor het includeren van patiënten en voor de gezelligheid tijdens 
borrels, skireis etc.
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such a warm welcome during my stay in spring/summer 2010. You made me feel right at home 
and I have some great memories of that time!
 
Daarnaast ben ik veel dank verschuldigd aan alle patiënten en gezonde bloeddonoren die 
belangeloos hebben deelgenomen aan de CTC-studies. De inclusie in de verschillende studies 
was ook niet mogelijk geweest zonder de hulp van de oncologen in de perifere deelnemende 
centra: Jacqueline Stouthard in het Maasstad Ziekenhuis, Paul Hamberg en Dr. Zuetenhorst 
in het Sint Franciscus Gasthuis, Felix de Jongh en Dr. Baggen in het Ikazia, Dr. Kehrer in het 
IJsselland en Dr. Dirix in het Sint-Augustinus Ziekenhuis. Ook de researchverpleegkundigen 
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(Brenda van Prooijen, Janny Salomé, Anita van der Poel, Corry Leunis en Nicoline Schuur) en de 
laboratoriummedewerkers die de inclusie van die patiënten hebben gefaciliteerd wil ik graag 
hartelijk bedanken.
Mijn lieve paranimfen Jantine Posthuma de Boer en Daniëlla Oom: ik ben heel trots dat 
jullie naast me staan tijdens de verdediging van mijn proefschrift. Ik heb bewondering voor 
jullie beider uitzonderlijke prestaties, maar waardeer bovenal jullie vriendschap. Ontzettend 
bedankt dat jullie mijn paranimfen wilden zijn, ik voel me vereerd!
Ook mijn andere lieve vrienden wil ik bedanken voor hun humor, relativeringsvermogen, en 
optimisme. Een wijntje, etentje of even sporten, altijd goed voor nieuwe energie en ik ben 
heel blij dat ik zoveel bijzondere mensen om me heen heb! 
Marjolein, jou moet ik ook mijn grote dank betuigen voor je hulp bij het lay-out en drukproces, 
hadden destijds we niet kunnen voorzien in de Flintstone-tent! 
Allerliefste familie, de vader en de moeder, Li en Bart, ooms en tantes, nichten en neven; ik 
ben dankbaar voor mijn grote, hechte familie! In tijden van drukte en stress vind ik bij jullie 
rust en afleiding, en in tijden van verdriet of vreugde in de familie worden de zorgen van het 
onderzoek op gepaste wijze gerelativeerd. Ik mag niet zeggen dat het zonder jullie niet was 
gelukt om te promoveren, maar wellicht was ik er dan niet eens aan begonnen...
Martijn, ik doe je denk ik niets tekort als ik zeg dat je weinig hebt bijgedragen aan de 
totstandkoming van dit boekje, maar wél aan mijn geluk de afgelopen tijd. Ik ben oprecht blij 
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PHD TRAINING Year Workload
   (ECTS)
General academic skills
– Biomedical English writing and communication 2009 4.0
– Advanced imaging techniques for MDs 2009 0.2
– Photoshop and Illustrator CS5 workshop  2011 0.3 
– Integrity in Research 2011 2.0
Research skills
– Basic course regulations and organization for clinical 2009
 researchers (Basiscursus Regelgeving en Organisatie 
 voor Klinisch onderzoekers [BROK])
– Clinical farmacological research in oncology  2009
 (Klinisch geneesmiddelonderzoek in de Oncologie)
– Biostatistics for clinicians 2009 1.0
– Methodology of patient-involving research and 2009
  preparation of grant writing
– Biomedical Research Techniques 2009
– Introduction to clinical research 2010
In-depth courses
– Basic and Translational Oncology 2008 1.8
– Molecular Medicine 2008 1.9
– 1st European Breast cancer course at Institut Curie Paris 2008
– Oncogenesis and tumor biology 2008 1.5
– Molecular Diagnostics IV 2009 1.0
– Diagnostic Development Tutorial at the EORTC-NCI-ASCO    2011
   Annual meeting on “Molecular Markers in cancer”
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  Year Workload
   (ECTS)  
Presentations
– Oral presentation at Daniel Den Hoed Clinic for nurses 2008
– Bi-annual oral presentation at MTI Journal Club 2008 − 2011
– Oral presentation Junior Med School 2008 – 2009
– Oral presentation at the Medical Oncology Science Meeting  2009; 2011
– Annual oral presentation at the Scientific JNI Lab Meeting 2009 – 2011 0.9
– Oral presentation at 7th International symposium on  minimal  2009
 residual cancer, Athens, Greece
– Oral presentation at IKR-IKW Breast Cancer Meeting 2009
– Poster presentation at the annual Molecular Medicine Day 2009 0.3
– Oral presentation at 6th Clinical Course of the ESCCA “Cellular 2010
 biomarkers of cancer’, Valencia, Spain
– Oral presentation for TU Delft students doing a minor in 2011
 oncology
– Oral presentation at Diagnostic Development Tutorial at the 2011
 EORTC-NCI-ASCO Annual meeting on “Molecular markers in
 cancer”
– Oral presentation for Erasmus MC Internal Medicine residents 2012
 and attending
– Poster presentation at AACR Annual Meeting  2012
– Oral presentation at ASCO Annual Meeting  2012
International conferences
– 7th International symposium on Minimal Residual Cancer, 2009
 Athens, Greece
– Joint meeting of the Belgian Society for Analytical Cytology 2009
 and the Dutch Society for Cytometry
– 6th Clinical Course of the ESCCA ‘Cellular biomarker of cancer”, 2010
 Valencia, Spain
– 10th Euroconference of the ESCCA, Valencia, Spain 2010
– 2011 European Multidisciplinary Cancer Congress, Stockholm, 2011
 Sweden
– EORTC-NCI-ASCO Annual Meeting on “Molecular Markers in  2011
 Cancer”, Brussels, Belgium
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  Year Workload 
   (ECTS)
– AACR Annual Meeting, Chicago, Illinois, US 2012
– ASCO Annual Meeting, Chicago, Illinois, US 2012
Seminars and workshops
– Weekly MTI Journal Club 2008 – 2010
– Monthly JNI Oncology lectures 2008 – 2012 1.2
– Monthly Bridge Meetings Molecular Medicine 2008 – 2012
– Monthly Breast Cancer meeting Erasmus MC 2008 – 2012
– Annual Molecular Medicine Day Rotterdam 2009 0.3
– Cancer Genomics Centre Annual Scientific Meeting 2009 – 2011
– Monthly OMBO course Erasmus MC 2009 – 2012
– Borstkanker Behandeling Beter 2010 – 2011
TEACHING ACTIVITIES
Supervising students and bachelor’s thesis
– Junior Med School: supervising 3 high school students 2008
– Supervising 21-week research project for 4th year medical  2009
 student
– Junior Med School: supervising 2 high school students 2011
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zij op de ds J.J. Buskesschool te Rotterdam. In 2000 behaalde zij haar Gymnasium diploma 
cum laude aan het Comenius College te Capelle aan den IJssel. In datzelfde jaar begon zij aan 
de studie Geneeskunde aan de Erasmus Universiteit te Rotterdam. Tijdens haar studie was 
zij actief in de Medische Faculteits Vereniging Rotterdam (MFVR). Haar afstudeeronderzoek 
deed zij op de afdeling Congenitale Cardiologie van het Erasmus MC te Rotterdam, waar zij 
onderzoek deed naar het risico op complicaties tijdens de zwangerschap in vrouwen met een 
congenitale aortaklepstenose, onder supervisie van Prof.dr. J.W. Roos-Hesselink en Prof.dr. F.J. 
Meijboom. In september 2004 behaalde zij het Doctoraalexamen Geneeskunde.
Na haar afstudeeronderzoek en in de wachttijd voor aanvang van haar coschappen studeerde 
zij Griekse en Latijnse taal en cultuur aan de Universiteit van Leiden en volgde zij een minor 
Spaans aan Columbia University te New York City, NY, USA. In september 2005 begon zij met 
haar coschappen, en behaalde na een oudste coschap op de afdeling Hemato-Oncologie in het 
Hospital Universitario La Paz te Madrid, Spanje in september 2007 cum laude het artsexamen. 
Aansluitend werkte zij als ANIOS (assistent-geneeskundige-niet-in-opleiding-tot-specialist) op 
de afdeling Inwendige Geneeskunde van het Ikazia Ziekenhuis te Rotterdam (opleider Dr. A. 
Dees). In mei 2008 startte zij een promotie-onderzoek op de afdeling Interne Oncologie van 
het Erasmus MC te Rotterdam op de locatie Daniel den Hoed kliniek, onder supervisie van 
Prof.dr. J.A. Foekens, Prof.dr. S. Sleijfer en Dr. J.W. Gratama, met dit proefschrift als resultaat. 
Tijdens haar promotie-onderzoek was zij door het winnen van de Pieter de Mulder Award 
2009 in staat een onderzoeksstage te lopen bij Veridex LLC te Raritan, NJ, USA. In mei 2012 is 
zij begonnen met de opleiding Inwendige Geneeskunde van het Erasmus MC (opleider Prof.
dr. J.L.C.M. van Saase) in het Albert Schweitzer Ziekenhuis te Dordrecht (opleider Dr. E.F.H. van 
Bommel).
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